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Summary 
Malaria affects almost half of the world`s population causing more than 200 million clinical cases 
each year and thus, remains one of the major infectious diseases of mankind. The protozoan parasite 
Plasmodium falciparum transmitted by infected Anopheles mosquitoes is responsible for 99 % of 
deaths, of which most occur in African children. An effective vaccine is urgently required but not yet 
available. The malaria vaccine candidate Merozoite Surface Protein (MSP)-1 from P. falciparum is an 
essential and highly abundant protein on the surface of parasite blood stages, which has been 
associated with protection against malaria in various epidemiological and immunization studies and 
is currently tested in a clinical Phase I trial. The aim of this work is to characterize the human humoral 
and cellular immune response against the vaccine candidate PfMSP-1D in African adults with 
naturally acquired immunity against malaria and after experimental infection of malaria-naïve 
volunteers with Pf wildtype sporozoites.  
Antibodies against Plasmodium merozoites are considered as the main actors of naturally acquired 
immunity against malaria and can target the parasite via different immune mechanisms, such as 
direct growth inhibition or opsonization and recruitment of effector cells. By using sera from eleven 
semi-immune adults from Burkina Faso we show that a few sera were capable of directly inhibiting 
the growth of P. falciparum blood stages in vitro and MSP-1 specific antibodies partly contributed to 
this effect. Further antigens presumably responsible for the observed growth inhibitory activity were 
identified via western blot and mass spectrometry analysis. Furthermore, we demonstrate that 
serum antibodies from all African individuals could opsonize P. falciparum merozoites, recruit 
neutrophils and elicit antibody-dependent respiratory burst (ADRB). The antibody level against MSP-
1 correlated with ADRB activity and MSP-1 specific antibodies, obtained by affinity-purification, 
induced neutrophil respiratory burst. Opsonizing antibodies effective via ADRB appear to be mainly 
cross-reactive and – by affinity purification of specific antibodies and antigen-reversal ADRB – we 
identified MSP-1 and its largest subunit MSP-183 as important targets. Additionally, we show for the 
first time that opsonizing antibodies can be elicited in non-human primates by immunization with 
recombinant PfMSP-1D, suggesting that a MSP-1 based vaccine may function via the induction of 
ADRB-effective antibodies.  
Since MSP-1 is initially synthesized in Plasmodium infected hepatocytes at late liver stage, it can be a 
target of the cellular immune response. Cytotoxic CD8+ T-cells secreting IFNγ are supposed to be the 
key players eliminating infected hepatocytes. By stimulating PBMCs from semi-immune individuals 
from Burkina Faso and from malaria-naïve European controls with previously identified HLA-A0201 
restricted CD8+ T-cell epitopes within MSP-1D, MSP-1 specific IFNγ-secreting CD8+ T-cells were 
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detected in African adults via IFNγ ELISPOT assay. Aiming at a HLA-independent approach, potential 
CD8+ T-cell epitopes to frequent HLA-types were predicted within MSP-1D and the IFNγ ELISPOT 
assay was adapted for the use of full-length MSP-1D protein.  
Furthermore, the immune response of malaria-naïve volunteers experimentally infected once with 
cryopreserved P. falciparum wildtype sporozoites during the TUECHMI I study was investigated. 
Antibodies against MSP-1, MSP-6 and MSP-7 were induced by Pf sporozoite infection as well as CD8+ 
T-cells, which target the cross-stage antigen MSP-1 at comparable levels as the known pre-
erythrocytic antigens LSA-1 and CSP.  
Overall, this work provides a detailed characterization of different immune mechanisms targeting 
PfMSP-1D in humans with naturally acquired immunity against malaria or after single experimental 
infection with Pf sporozoites. Moreover, the established immunological assays can be employed to 
analyze the immune response induced by vaccination with PfMSP-1D during clinical trials.  
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Zusammenfassung 
Malaria betrifft fast die Hälfte der Weltbevölkerung, verursacht jährlich über 200 Millionen klinische 
Fälle und bleibt damit eine der bedeutendsten Infektionskrankheiten der Menschheit. Der einzellige 
Parasit Plasmodium falciparum, der von infizierten Anopheles Moskitos übertragen wird, ist für 99 % 
der Todesfälle verantwortlich, von denen die meisten in afrikanischen Kindern auftreten. Ein 
wirksamer Impfstoff wird dringend benötigt, ist aber zurzeit noch nicht verfügbar. Das Merozoiten-
Oberfächenprotein-1 (MSP-1) von P. falciparum - ein Impfstoffkandidat gegen Malaria -  ist ein 
lebenswichtiges und in hohem Maße vorhandenes Protein auf der Oberfläche der parasitären 
Blutstadien. Es wurde in verschiedenen epidemiologischen Untersuchungen und Immunisierungen 
mit Schutz vor Malaria assoziiert und wird derzeit in einer klinischen Phase I Studie getestet. Das Ziel 
dieser Arbeit besteht darin, die humane humorale und zelluläre Immunantwort gegen den 
Impfstoffkandidaten PfMSP-1D zu untersuchen, sowohl in afrikanischen Erwachsenen mit natürlich 
erworbener Immunität gegen Malaria als auch nach experimenteller Infektion von Freiwilligen ohne 
vorherige Malaria-Exposition mit P. falciparum Sporozoiten.  
Antikörper gegen Plasmodium Merozoiten gelten als die Hauptakteure bei natürlich erworbener 
Immunität gegen Malaria und können den Parasiten mittels verschiedener Immunmechanismen 
bekämpfen, z.B. durch direkte Wachstumshemmung oder Opsonisierung und Rekrutierung von 
Effektorzellen. Anhand von Seren von elf semi-immunen Erwachsenen von Burkina Faso wurde 
gezeigt, dass das Wachstum von P. falciparum Blutstadien in vitro durch Serum-Antikörper gehemmt 
werden kann und dass MSP-1 spezifische Antikörper teilweise daran beteiligt sind. Weitere Antigene, 
die vermutlich für die gemessene Wachstumshemmung verantwortlich waren, wurden mittels 
Western Blot und Massenspektrometrie identifiziert. Außerdem zeigen wir, dass Serum Antikörper 
von allen Afrikanern Merozoiten von P. falciparum opsonisieren, neutrophile Granulozyten 
rekrutieren sowie respiratorischen Burst (ADRB) auslösen konnten. Der Antikörpertiter gegen MSP-1 
korrelierte mit ADRB Aktivität und MSP-1 spezifische Antikörper, die mittels Affinitätsaufreinigung 
gewonnen wurden, erzeugten respiratorischen Burst von Neutrophilen. Opsonisierende Antikörper, 
die im ADRB wirksam waren, scheinen hauptsächlich gegen kreuzreaktive Regionen gerichtet zu sein 
und mittels Affinitätsaufreinigung spezifischer Antikörper sowie „antigen-reversal ADRB“ wurden 
MSP-1 und seine größte Untereinheit MSP-183 als wichtige Angriffsziele identifiziert. Zusätzlich zeigt 
diese Arbeit zum ersten Mal, dass opsonisierende Antikörper in Primaten durch Immunisierung mit 
rekombinantem PfMSP-1D erzeugt werden können. Dies deutet darauf hin, dass ein Impfstoff 
basierend auf MSP-1 über die Induktion von Antikörpern, die ADRB auslösen, wirken könnte.  
Zusammenfassung
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Da MSP-1 bereits in infizierten Hepatozyten im späten Leberstadium hergestellt wird, kann es auch 
von der zellulären Immunantwort angegriffen werden. Zytotoxischen CD8+ T-Zellen, die IFNγ 
produzieren, wird eine Schlüsselrolle bei der Eliminierung infizierter Hepatozyten zugeschrieben. 
Durch die Stimulierung von PBMCs von semi-immunen Personen aus Burkina Faso sowie malaria-
naiven Kontrollen aus Europa mit HLA-A0201 begrenzten CD8+ T-Zell Epitopen innerhalb von MSP-
1D, konnten wir mittels IFNγ ELISPOT Untersuchung MSP-1 spezifische CD8+ T-Zellen ausfindig 
machen, die IFNγ sekretieren. Um eine HLA-unabhängige Methode zu entwickeln, wurden 
potenzielle CD8+ T-Zell Epitope zu häufigen HLA-Typen vorausgesagt und die IFNγ ELISPOT 
Untersuchung wurde für die Nutzung des Gesamt-MSP-1D Proteins angepasst.  
Außerdem wurde die Immunantwort von malaria-naiven Freiwilligen erforscht, die innerhalb der 
TUECHMI I Studie experimentell einmal mit kryokonservierten P. falciparum Wildtyp-Sporozoiten 
infiziert wurden. Antikörper gegen MSP-1, MSP-6 und MSP-7 wurden durch die Injektion von Pf 
Sporozoiten erzeugt, ebenso wie CD8+ T-Zellen. Diese sind gegen das phasenübergreifende Antigen 
MSP-1 in vergleichbarer Höhe gerichtet wie gegen die bekannten Leberstadien-Antigene LSA-1 und 
CSP.  
Insgesamt liefert diese Arbeit eine detaillierte Untersuchung von verschiedenen Immun-
mechanismen, die gegen PfMSP-1D gerichtet sind, sowohl in Menschen mit natürlich erworbener 
Immunität gegen Malaria als auch nach einmaliger experimenteller Infektion mit Pf Sporozoiten. 
Insbesondere dienen die etablierten immunologischen Methoden als Grundlage für die 
Untersuchung der Immunantwort während der klinischen Studien mit rekombinantem MSP-1.  
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1.  Introduction 
1.1. Malaria  
Malaria remains one of the most important infectious diseases of mankind, affecting almost 50 % of 
the world`s population in 91 countries and territories, especially in the tropical and subtropical 
regions of Africa, Latin America and South-East Asia (WHO, 2016) (Figure 1.1). The World Health 
Organization estimates about 212 million malaria cases and 429 000 deaths in 2015; most of them 
occur in Africa. Children under the age of five in sub-Saharan Africa are mostly affected - in average 
every two minutes a child is killed by the disease. Furthermore, pregnant women in malaria endemic 
regions often suffer from placental malaria, which poses a serious problem for both mother and 
unborn child (WHO, 2016). 
Malaria is caused by unicellular parasites of the genus Plasmodium, a member of the phylum 
Apicomplexa (class: Sporozoa, family Plasmodiidae), and is transmitted through the bites of infected 
Anopheles mosquitoes. All apicomplexan parasites share common features like the specialized apical 
complex which plays an important role in the invasion process of host cells. More than 150 
Plasmodium species are known infecting various animals but only five are pathogenic to humans: 
Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, Plasmodium knowlesi and Plasmodium 
falciparum (Singh and Daneshvar, 2013). The latter causes the most severe form of the disease, 
malaria tropica, and is responsible for 99 % of deaths (WHO, 2016).  
Although the global malaria eradication campaign has eliminated malaria in some countries (Figure 
1.1) and the incidence rate of malaria has been reduced worldwide by 41 % since the year 2000 
(WHO, 2016), efforts to control the disease are challenging due to growing resistance of Plasmodium 
to antimalarial drugs and insecticide resistant mosquitoes (WHO, 2016). The best available treatment 
against malaria to date is the artemisinin-based combination therapy (ACT). However, resistance of 
P. falciparum against artemisinin has recently been detected in some Asian countries (WHO, 2016). 
Furthermore, the treatment with antimalarial drugs as well as the distribution of tools against 
malaria such as mosquito nets is often hampered by poverty and a poor infrastructure in the affected 
regions. Therefore, the development and delivery of an efficient malaria vaccine – which is currently 
not available - is considered as a key tool for sustainable malaria control, elimination or even possible 
eradication of the disease.  
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Figure 1.1: Malaria endemicity around the world. Countries endemic for malaria in 2016 are shown in blue; 17 
countries which have eliminated malaria within the last 16 years are depicted in green (WHO, 2016). 
 
1.1.1. Plasmodium life cycle 
Transmission of Plasmodium sporozoites into the vertebrate host occurs during a blood meal of an 
infected female Anopheles mosquito. About 400 Anopheles species (phylum: Arthropoda, class: 
Insecta, family: Culicidae) have been recorded worldwide but only 30 play an important role for 
malaria transmission, especially A. gambiae and A. funestus (Tuteja, 2007). The life cycle of 
Plasmodium is very complex and involves the Anopheles (primary) and vertebrate (secondary) host 
(Figure 1.2).  
Several stages of parasite development in different cell types and host tissues with sexual or asexual 
proliferation can be divided: Upon injection of Plasmodium sporozoites into the bloodstream of a 
human host – approximately 15 to 123 sporozoites are injected by the Anopheles mosquito 
(Frischknecht et al., 2004) - sporozoites migrate to the liver and invade hepatocytes. There, the 
parasite differentiates and replicates asexually for 5 to 15 days to yield a liver-stage schizont, which 
contains several thousand merozoites. These liver merozoites are released into the bloodstream and 
invade erythrocytes, thereby initiating the erythrocytic cycle (Figure 1.2). 
Inside the erythrocytes, merozoites replicate asexually and develop through ring, trophozoite and 
schizont-stages within approximately 48 hours. Upon burst of the infected red blood cell, 8 to 32 
daughter merozoites are released into the blood stream where they invade new RBCs and start 
another replication cycle. All clinical symptoms arise during the asexual blood stage of Plasmodium. 
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Some intraerythrocytic stages develop into sexual stages, macrogametocytes and microgametocytes, 
which are taken up during the next mosquito bite; inside the Anopheles vector they develop into 
gametes and form zygotes by fusion. After development of the zygote into an invasive ookinete and 
traversal of the midgut wall, the ookinete transforms into an oocyst, in which sporozoites arise. Upon 
release, these sporozoites migrate to the salivary gland of the Anopheles mosquito from where they 
are injected into a human host during the next blood meal and thus, the Plasmodium life cycle starts 
again (Figure 1.2). 
           
Figure 1.2: Life cycle of Plasmodium falciparum. The complex life cycle of the parasite occurs in two different 
species - the human host (left) and the Anopheles Mosquito (right). Details are given in the text. Picture from 
(Ménard, 2005). 
 
1.1.2. Erythrocyte invasion by Plasmodium merozoites 
Plasmodium merozoites are egg-shaped, approximately 1.5 µm long unicellular organisms (Figure 1.3 
A). Their invasion into erythrocytes is a rapid, efficient and highly regulated process which occurs 
within minutes and can be separated into distinct phases (Farrow et al., 2011; Gilson and Crabb, 
2009)(Figure 1.3 B): (1) primary contact between merozoite and host erythrocyte by low affinity and 
reversible interactions; (2) reorientation of the parasite towards its apical end; (3) formation of a 
tight junction complex between the parasite and erythrocyte membrane and invagination of the 
erythrocyte membrane during which the merozoite surface coat is removed and the parasitophorous 
vacuole (PV) is formed; (4) active invasion powered by the parasite actin-myosin motor (Baum, 2006) 
and sealing of the PV.  
 
Introduction
 
18 
 
Proteins involved in the erythrocyte invasion process are either localized at the merozoite surface 
such as MSP-1, MSP-2, MSP-6 and MSP-7 or they are present inside specialized organelles - rhoptries, 
micronemes and dense granules - at the apical end of the parasite. Merozoite surface proteins are 
attached to the membrane either via GPI-anchor, as integral membrane proteins or by peripheral 
interactions with proteins covalently bound to the membrane. For example, the peripheral proteins 
MSP-3, MSP-6, MSP-7, MSPDBL-1 and MSPDBL-2 use the GPI-anchored protein MSP-1 as a platform 
to bind to the merozoite surface (Lin et al., 2016). Proteins maintained in apical organelles, such as 
Apical Membrane Antigen 1 (AMA-1) or Erythrocyte Binding Antigen 175 (EBA-175), are secreted and 
transported to the merozoite surface prior to RBC invasion via different mechanisms. Some parasite 
proteins have to be proteolytically processed prior to erythrocyte invasion in order to be functionally 
active such as MSP-1 and AMA-1 (Cowman and Crabb, 2006).    
Kinetic studies of erythrocyte invasion in vitro show that 80 % of Plasmodium merozoites invade the 
RBC within 10 minutes while the remaining 20 % enter erythrocytes after longer time-periods post-
egress (Boyle et al., 2010b). The half-life of merozoite invasive capacity was estimated to 8 minutes 
at 37 °C and 15 minutes at RT (Boyle et al., 2010b). However, whether these kinetics are applicable 
for the in vivo situation is currently not known (Boyle et al., 2013). 
 
 
 
Figure 1.3: Erythrocyte invasion by Plasmodium merozoites. (A) Morphology of a Plasmodium merozoite. (B) 
Schematic outline of the different steps during RBC invasion by merozoites: (A) Primary attachment between 
merozoite and RBC, (B) Reorientation of the merozoite, (C) Formation of a tight junction between the apical end 
of the merozoite and the RBC and start of penetration, (D) During further invasion into the RBC via the actin-
myosin motor of the parasite, the merozoite surface coat is shed and a parasitophorous vacuole (PV)  is formed, 
(E) Completion of RBC invasion, the parasite is surrounded by the PV. Picture from (Cowman and Crabb, 2006). 
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1.1.3. Pathogenesis and symptomatology of malaria 
The first symptoms of malaria – fever, chills, headache and vomiting – usually appear 10-15 days 
after infection. If not treated, P. falciparum malaria can progress to severe disease including anemia, 
respiratory distress, hypoglycaemia, multi-organ failure or cerebral malaria (WHO, 2016).  
All clinical symptoms are a consequence of the asexual erythrocytic life cycle of Plasmodium. 
Different aspects of malaria pathology can be divided: (i) Rupture of infected red blood cells causes 
anemia and impairs oxygen transport resulting in respiratory distress. (ii) Adherence of infected red 
blood cells to the blood capillary endothelium after modification of the erythrocyte surface with 
parasite proteins such as Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-1) 
(Baruch et al., 1995) in order to escape parasite elimination in the spleen. This sequestration in 
combination with rosetting, the agglutination of infected and non-infected red blood cells, leads to 
blockage of blood vessels and thus, an undersupply of affected organs, possibly resulting in multi-
organ failure, cerebral malaria, coma and death. (iii) Stimulation of the host inflammatory immune 
response by parasite metabolites like hemozoin released during lysis of red blood cells. The 
overproduction of several cytokines such as tumor-necrosis-factor (TNF) α, interferon (IFN) γ or 
interleukin (IL)-1 is indirectly responsible for many symptoms of malaria (Clark, 1987). For instance, 
TNFα, whose release is triggered by malaria toxins of ruptured schizonts, is associated with severe 
malaria disease, especially with cerebral malaria (Clark, 1987).   
1.2. Immune response against malaria infection 
So far, the human immune response against malaria infection is still not entirely understood. We 
observe a protective, non-sterilizing immune response against the parasite in individuals who live in 
malaria highly endemic regions and thus, are continuously exposed to P. falciparum infections during 
the transmission season. After multiple survived infections those individuals develop a naturally 
acquired immunity (NAI) against malaria, which means that they can be infected by Plasmodium but 
usually do not show any disease symptoms (Marsh and Kinyanjui, 2006; Snow et al., 1997). 
Antibodies against parasite blood stages are supposed to be the key players in NAI-mediated 
protection (Cohen et al., 1961) (Figure 1.4).  
Sterile protection in humans can be induced by immunization with either radiation-attenuated 
sporozoites (RAS) (Clyde et al., 1973) or wildtype sporozoites under chemoprophylaxis (CPS) 
(Mordmuller et al., 2017; Roestenberg et al., 2009). Here, protection is mainly mediated by cellular 
immune mechanisms such as the elimination of infected hepatocytes by cytotoxic T-cells (Figure 1.4). 
A better understanding of protective immune mechanisms and the availability of suitable in vitro 
assays to measure them will be critical for the development of an effective vaccine. 
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1.2.1. Humoral immune response 
Individuals living in malaria-endemic regions naturally acquire immunity against the disease with 
increasing numbers of survived infections (Aponte et al., 2007; Gupta et al., 1999; Marsh and 
Kinyanjui, 2006; Snow et al., 1997). However, this protection is short-lived and requires frequent 
Plasmodium infections in order to persist (Früh et al., 1991; Hoffman et al., 1987). It appears largely 
mediated by serum antibodies controlling levels of blood stage parasites (Cohen et al., 1961).  
Merozoites are key targets of naturally acquired antibodies (Crompton et al., 2010a; Osier et al., 
2008; Richards et al., 2013) and an association between antibody levels and protective human 
immunity has been reported for several merozoite antigens (Beeson et al., 2016; Fowkes et al., 2010; 
Osier et al., 2014b; Richards et al., 2013). Antibodies targeting the merozoite can function via 
different pathways such as direct growth inhibition or recruitment of immune effector cells 
(reviewed in (Teo et al., 2016)). However, it remains elusive which antibody mechanisms determine 
protection against malaria. The direct growth inhibition assay (GIA) of Plasmodium blood stages still 
remains the most commonly used functional assay for blood stage vaccine candidates and merozoite 
antigens (Crompton et al., 2010b; Duncan et al., 2012) although it is controversial whether direct 
growth inhibitory activity in vitro correlates with protection against clinical malaria (Duncan et al., 
2012).  
Increasing evidence points towards an important role of opsonizing antibodies, which bind to 
merozoites and recruit effector cells such as monocytes (Bouharoun-Tayoun et al., 1990; Osier et al., 
2014a) or neutrophils (Joos et al., 2010) via their Fc receptors. These eliminate the parasite, either by 
phagocytosis (Osier et al., 2014a) or by secretion of reactive oxygen species (Joos et al., 2010). 
Indeed, merozoites are mainly targeted by the cytophilic antibodies IgG1 and IgG3 (Reiling et al., 
2010; Richards et al., 2010; Stanisic et al., 2009), which can bind to the Fc receptor of immune cells 
(Osier et al., 2014a) or fix complement factors (Boyle et al., 2015). The acquisition of opsonizing 
antibodies increases with age and malaria exposition (Osier et al., 2014a) and correlates with 
protection (Joos et al., 2010; Osier et al., 2014a). Four functional assays have been developed to 
measure opsonizing antibodies in vitro: (i) the antibody-dependent cellular inhibition assay (ADCI) 
(Bouharoun-Tayoun et al., 1990), (ii) the opsonic phagocytosis assay (OPA) (Hill et al., 2013; Osier et 
al., 2014a), (iii) the antibody-dependent complement inhibition (Ab-C) assay (Boyle et al., 2015) and 
(iv) the antibody-dependent respiratory burst (ADRB) assay (Joos et al., 2010). Importantly, several 
studies using these assays show a correlation between opsonizing antibodies and protection against 
malaria (Boyle et al., 2015; Chiu et al., 2015; Hill et al., 2013; Hill et al., 2016; Joos et al., 2010; Osier 
et al., 2014a; Tiendrebeogo et al., 2015).  
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A number of merozoite antigens have been identified which elicit opsonizing antibodies such as MSP-
119 (Boyle et al., 2015; Joos et al., 2015), MSP-1block2 (Galamo et al., 2009), MSP-2 (Boyle et al., 2015; 
Osier et al., 2014a), MSP-3 (Druilhe et al., 2005; Lundquist et al., 2006; Osier et al., 2014a), MSP-5 
(Perraut et al., 2014), MSP-6 (Singh et al., 2005), MSPDBL-1/-2 (Chiu et al., 2015; Singh et al., 2009) 
and GLURP (Theisen et al., 2000). However, the antigenic targets of antibodies inducing complement 
fixation, opsonic phagocytosis or neutrophil respiratory burst might differ. So far, only MSP-119, the 
small conserved C-terminal part of MSP-1, has been identified as antigenic target which contributes 
to neutrophil respiratory burst activity (Joos et al., 2015).  
 
 Figure 1.4: Immune mechanisms against the various developmental stages of P. falciparum. Pf sporozoites 
are injected into the human skin by an infected Anopheles mosquito and move via the blood-stream to the liver 
where they invade hepatocytes. Infected hepatocytes are targeted by T-cells, especially cytotoxic CD8+ T-cells 
which kill the intracellular parasite by secretion of the cytokine IFNγ. Parasites which escape the immune system 
develop in the liver and – upon burst of the liver schizont – several thousand merozoites enter the blood-stream 
and invade erythrocytes. Parasite blood stages are mainly controlled by antibodies via different mechanisms.  
Picture from (Richie and Saul, 2002). 
 
1.2.2. Cellular immune response 
Since erythrocytes cannot process and present parasite-derived antigens due to the lack of a nucleus 
and an antigen processing machinery, the T-cell response against malaria is mostly limited to the 
Plasmodium liver stages. While in a natural malaria infection some parasites are able to escape the 
cellular immune response in the liver and progress to blood stages, immunization of humans with P. 
falciparum RAS (Clyde et al., 1973) or CPS (Mordmuller et al., 2017) induces sterile protection against 
malaria mediated by T-cells (Doolan and Hoffman, 2000). T-cell priming in the liver presumably 
Introduction
 
22 
 
happens by recognition of malaria-specific antigens presented via HLA (=MHC)-I receptors on the 
surface of liver-resident dendritic cells (Cockburn and Zavala, 2016; Jobe et al., 2009) or infected 
hepatocytes (Balam et al., 2012; Cockburn et al., 2014; Frevert and Krzych, 2015).   
According to many studies performed within the last 30 years (reviewed e.g. in (Krzych et al., 2014)) 
cytotoxic CD8+ T-cells play the most important role in eliminating infected hepatocytes and thus, 
mediating protection. For example, RAS-induced sterile protection against sporozoite challenge is 
prevented in mice (Schofield et al., 1987; Weiss et al., 1988) and rhesus monkeys (Weiss and Jiang, 
2012) following depletion of CD8+ but not CD4+ T-cells in vivo. CD8+ T-cells recognize Plasmodium 
antigens presented by infected hepatocytes (Balam et al., 2012; Cockburn et al., 2014) or other liver-
resident cells via their HLA-1 receptor and eliminate the parasite either via cytolytic processes or by 
release of the cytokine IFNγ. The latter activates the nitric-oxide- synthase gene resulting in Nitric-
oxide production, which kills the parasite inside the infected hepatocyte. The major role of CD8+ T-
cells against Plasmodium appears to be their IFNγ production which constitutes a crucial component 
for protection against malaria (Ferreira et al., 1986; Imai et al., 2010; Mellouk et al., 1987; Schofield 
et al., 1987). Importantly, IFNγ-secreting CD8+ T-cells are also induced by immunizations of mice, 
monkeys and humans with radiation-attenuated sporozoites (Epstein et al., 2011; Lyke et al., 2017; 
Nganou-Makamdop et al., 2012; Weiss and Jiang, 2012), genetically-attenuated sporozoites (Jobe et 
al., 2007; Mueller et al., 2007; Tarun et al., 2007) and wildtype sporozoites under chemoprophylaxis 
(Brando et al., 2014; Nganou-Makamdop et al., 2012; Roestenberg et al., 2009; Roestenberg et al., 
2011) and are crucial for protection against malaria (e.g. (Fernandez-Ruiz et al., 2016)). Interestingly, 
the application of IFNγ alone strongly inhibits the development of Plasmodium liver stages in mice 
infected with P. berghei and decreases the parasitemia in P. vivax infected chimpanzees (Ferreira et 
al., 1986).  
In protected individuals immunized with RAS, T-cells have been detected which recognize epitopes 
from several P. falciparum proteins e.g. CSP or LSA-1 (Krzych et al., 1995) and these epitopes could 
induce a CD8+ T-cell response in individuals with naturally acquired immunity (Doolan et al., 1996). 
However, Plasmodium specific CD8+ T-cells show a low frequency in comparison to viral infections 
such as HIV (Lalvani et al., 1996; Plebanski et al., 1997). The antigenic epitopes presented to T-cells 
depend strongly on the HLA-subtype of each individual (Barouch et al., 1995).  
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1.3. Malaria vaccines 
Although malaria incidence and mortality rates have been remarkably reduced within the last 15 
years (Figure 1.1) by malaria control programs - such as vector control or chemoprevention (WHO, 
2016) - the emergence of insecticide resistant Anopheles mosquitoes and multi-drug resistant 
parasites underline the urgent need for an effective malaria vaccine. Despite high international 
efforts over the last decades, a safe and efficient vaccine against P. falciparum malaria is still not 
available (Halbroth and Draper, 2015). The target population for a malaria vaccine would consist of: 
(i) infants and children living in regions with malaria transmission, especially sub-Saharan Africa, (ii) 
pregnant women, (iii) individuals migrating to malaria-endemic areas, (iv) travelers and military 
(Hollingdale and Sedegah, 2017). The WHO sets the requirement for vaccine efficacy against clinical 
disease to 75 % (Moorthy et al., 2013), the US military even to 80 % against Plasmodium parasites 
(Teneza-Mora et al., 2015).  
The Plasmodium life cycle offers several targets for vaccine development: sporozoites, liver stages as 
well as sexual and asexual blood stages. Thus, four different types of malaria vaccines can be divided, 
respectively (reviewed in (Matuschewski, 2017)): (i) anti-sporozoite vaccines aim to induce 
antibodies inhibiting sporozoite invasion of the liver, (ii) whole parasite vaccine approaches which 
elicit mainly cytotoxic T-cell responses against Plasmodium liver stages, (iii) transmission blocking 
vaccines which aim to reduce malaria transmission by induction of antibodies against parasite sexual 
stages, (iv) erythrocytic vaccines which target the asexual blood stages, mostly by antibodies against 
merozoites.  
Typical approaches are either subunit vaccines, such as recombinant antigens or viral vectors which 
block Plasmodium development and life cycle progression, or whole sporozoite vaccines aiming to 
induce sterile immunity against disease. It is likely that a malaria vaccine consisting of several 
components and acting against different Plasmodium life cycle stages will be most effective.  
1.3.1. Anti-sporozoite subunit vaccines 
Anti-sporozoite vaccines intend to decrease the initial parasite load by the induction of antibodies 
which inhibit sporozoite invasion of the liver. However, these antibody responses have to be long-
lived (Dups et al., 2014). The RTS.S/AS01 vaccine consists of the repeat region and the 
thrombospondin domain from the circumsporozoite protein (CSP) - the most abundant protein on P. 
falciparum sporozoites - fused to the surface antigen S from hepatitis B virus (Cohen et al., 2010). 
Although RTS.S/AS01 is the most advanced vaccine candidate so far, recent results from Phase III 
clinical trials in African children were disappointing showing no efficacy over a 7 year period (Olotu et 
al., 2016). Another potential vaccine candidate on the surface of sporozoites is the Thrombospondin-
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related adhesive protein (TRAP). However, a recent phase II clinical study in adults from Senegal 
demonstrated no efficacy against P. falciparum malaria (Mensah et al., 2016).  
1.3.2. Whole sporozoite vaccines 
Whole parasite vaccinations pursue the goal of sterile immunity elicited by T-cell mediated immunity 
against Plasmodium liver stages. Three approaches can be differentiated depending on the mode of 
developmental arrest (Figure 1.5): (i) radiation attenuated sporozoites (RAS): Pf sporozoites are 
exposed to γ-irradiation which induces multiple random DNA double-strand breaks and leads to an 
early arrest in liver stage development (Hoffman et al., 2002), (ii) genetically attenuated parasites 
(GAP): genes crucial for liver stage development are removed and thus, the parasite can only 
progress to a defined developmental stage in the liver (Mueller et al., 2005b), (iii) wildtype 
sporozoites are injected under simultaneous chemoprophylaxis (CPS) using different drugs such as 
chloroquine or azithromycin which block further parasite life cycle progression (Borrmann and 
Matuschewski, 2011). 
 
Figure 1.5: Whole sporozoite vaccination approaches and their developmental arrest. Sporozoites attenuated 
by radiation (irradiated spz) and some genetically attenuated parasites (GAPs) arrest early in liver stage 
development. Immunization with late-arresting GAPs or chemoprophylaxis with infectious sporozoites (CPS) 
leads to late liver stage arrest or arrest in early blood stage and thus, a different antigenic repertoire can be 
presented to T-cells. Picture from (Epstein and Richie, 2013). 
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Immunizations with RAS elicit a sterile immunity in rodents (Nussenzweig et al., 1967) and humans 
(Clyde et al., 1973) when administered by mosquito bite and also by intravenous application of 
cryopreserved attenuated PfSpz (Lyke et al., 2017; Seder et al., 2013). However, very high PfSpz 
doses were necessary for complete protection by intravenous injection, namely five times 135 000 
PfSpz (Seder et al., 2013). Furthermore, the irradiated sporozoites show a high batch-to-batch 
variation and – since they arrest early in liver stage development – immunity against RAS is restricted 
to early LS antigens (Borrmann and Matuschewski, 2011).  
These restrictions were partly overcome by defined knock-out of Plasmodium genes important for LS 
development such as uis3 (Mueller et al., 2005b), uis4 (Mueller et al., 2005a) or sap1 (Aly et al., 
2008). In mice, immunizations with late-arresting GAPs induced superior protection in comparison to 
RAS or early-arresting GAPs (Butler et al., 2011) and could even protect against blood stage challenge 
likely due to cross-stage antigens (Sack et al., 2015). Recently, safety and immunogenicity of a triple 
knockout line (Pf p52-/p36-/sap1-) was assessed in 10 human volunteers and the results were 
encouraging (Kublin et al., 2017). Another approach is the administration of wildtype P. falciparum 
sporozoites under drug cover with chloroquine (Belnoue et al., 2004; Mordmuller et al., 2017; 
Roestenberg et al., 2011), azithromycin (Friesen et al., 2010) or primaquine (Putrianti et al., 2009). 
Depending on the used drug, the parasite arrest at late liver stage (azithromycin) or early blood stage 
(Chloroquine) (Figure 1.5). Importantly, CPS immunization induces sterile protection in mice (Belnoue 
et al., 2004) and in humans - by administration via mosquito bite (Roestenberg et al., 2009; 
Roestenberg et al., 2011) as well as by intravenous injection of cryopreserved P. falciparum wildtype 
sporozoites (Mordmuller et al., 2017).  
However, several major obstacles have to be tackled before whole sporozoite vaccines could be 
possibly realized in malaria-endemic regions: (i) the labor-intense production and purification of 
Plasmodium sporozoites from Anopheles mosquitoes have to be automated by developing 
sporozoite in vitro culture systems; (ii) protection against heterologous P. falciparum strains is a 
requirement for all malaria vaccines; so far it is incomplete after immunization with CPS (Schats et 
al., 2015) or RAS (Epstein et al., 2017); (iii) the vaccine should also protect when administered by 
intramuscular or subcutaneous routes since intravenous injection is not an acceptable delivery route; 
up to date about 23-times more Pf sporozoites are required for injection via the intramuscular route 
compared to intravenous (Gomez-Perez et al., 2015); (iv) since the parasites need to be stored in 
liquid nitrogen or dry ice, vaccine delivery in remote areas of Africa seems very visionary and poses 
an immense logistical challenge.      
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1.3.3. Transmission-blocking vaccines 
Transmission-blocking vaccines aim to reduce Plasmodium transmission by targeting the sexual 
forms of the parasite – gametocytes, the zygote and ookinete (reviewed in (Wu et al., 2015)). 
Antibodies against surface antigens of gametes and ookinetes are induced, taken up by the 
Anopheles mosquito during their blood meal and inhibit Plasmodium development in the mosquito 
midgut. Up to date, the sexual stage antigens s25 and s230 are the best available candidates but 
require further investigation (Kapulu et al., 2015). However, transmission-blocking vaccines will not 
immediately benefit the immunized individual but could prevent new parasite infections in a certain 
area and thus, help to eliminate malaria (Wu et al., 2015). Ideally, this vaccine should be combined 
with a malaria vaccine targeting the erythrocytic and/or pre-erythrocytic stages. 
1.3.4. Blood stage vaccines 
Blood stage (BS) vaccines either target the Plasmodium merozoite or the infected erythrocyte, mostly 
by antibodies, which play a crucial role against parasite blood stage infection and form the basis of 
naturally acquired immunity (Cohen et al., 1961). The objective of a BS vaccine is to reduce 
parasitemia and prevent clinical disease.  
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) – a target of naturally acquired 
immunity - is transported to the surface of infected erythrocytes by the parasite and binds to 
endothelial cells via CD36 or to the placenta via chondroitin sulfate A (CSA) in order to escape splenic 
clearance. This cytoadhesion is mainly responsible for the pathology of severe malaria (Haldar et al., 
2007) and placental malaria in primigravidae (Fried and Duffy, 2015) and thus, PfEMP-1 an 
interesting vaccine target (reviewed in (Bull and Abdi, 2016)). However, the extreme diversity of this 
protein, which is encoded by over 60 var genes, pose a high obstacle to vaccine design. So far, the 
most advanced PfEMP-1 vaccine candidate PAMVAC, based on VAR2CSA, has not entered the clinical 
stage (Gbedande et al., 2017).  
Up to date, seven vaccine candidates targeting P. falciparum merozoites have been tested in clinical 
trials (reviewed in (Beeson et al., 2016)): apical membrane antigen 1 (AMA-1), erythrocyte binding 
antigen 175 (EBA-175), serine repeat antigen 5 (SERA-5), glutamate-rich protein (GLURP), and the 
merozoite surface proteins MSP-1, MSP-2 and MSP-3. Most of these candidates have been assessed 
in Phase I clinical trials as recombinant proteins in combination with adjuvant; some also used the 
viral vectors ChAd63 and MVA as vaccine delivery systems (Beeson et al., 2016).  
AMA-1 represents the best studied BS candidate so far in 23 clinical trials and additional 9 in 
combination with other vaccine candidates (Beeson et al., 2016). The protein is localized within the 
micronemes of the parasite and – following proteolytic processing – it relocates to the merozoite 
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surface and plays an important role for erythrocyte invasion (Beeson et al., 2016; Yap et al., 2014). In 
clinical trials AMA-1 shows a good safety and immunogenicity profile with Alhydrogel as adjuvant 
(Dicko et al., 2008; Malkin et al., 2005) but no efficacy against malaria in a Phase IIb study in Malian 
children (Ouattara et al., 2010). Also a 3-4-fold increase in antibody titers by adding the adjuvant 
CPG7909 (Mullen et al., 2008) did not protect malaria-naïve individuals against Pf sporozoite 
challenge (Duncan et al., 2011). Supposedly, the high polymorphism of AMA-1 poses a major barrier 
to vaccine efficacy.  
EBA-175, a microneme protein which localizes to the merozoite surface and interacts with RBCs via 
glycophorin A (Sim et al., 1994), has been tested in phase 1 trials. Antibodies were induced at high 
levels but demonstrated only modest growth inhibitory activity in vitro. SERA-5 is a peripherally-
associated MSP which supposedly acts as protease and may be important for merozoite egress 
(Beeson et al., 2016). A Phase Ib trial in Uganda detected lower incidence rates of high parasitemia in 
vaccinated volunteers (Palacpac et al., 2013).  
GLURP, a protein on the merozoite surface with unknown function (Beeson et al., 2016) has been 
assessed in vaccine trials in combination with MSP-3 (GMZ2 vaccine). Although three Phase I trials 
were successful showing good safety and immunogenicity levels in malaria-naïve individuals and 
malaria-exposed individuals from Gabon (Beeson et al., 2016) and even the induction of ADCI-active 
antibodies (Jepsen et al., 2013), a Phase IIb trial of GMZ2 in almost 2000 African children 
demonstrated no protective efficacy (Sirima et al., 2016). However, a vaccine based on the conserved 
part of MSP-3 elicited antibodies active in ADCI (Druilhe et al., 2005) and showed protective efficacy 
against malaria in children from Burkina Faso (Sirima et al., 2011).  
The Combination B vaccine – consisting of MSP-2 (3d7 strain), the N-terminal part of MSP-1 and a 
part from RESA – has been tested in a Phase II clinical study in children from PNG; it could reduce 
parasitemia significantly (Genton et al., 2003; Genton et al., 2002). A combination of MSP-1 and 
AMA-1 and delivery via the viral vectors ChAd63-MVA in a prime-boost regiment induced high 
antibody levels against both proteins but protected only one out of 38 volunteers against mosquito 
bite challenge (Biswas et al., 2014; Sheehy et al., 2012). MSP-142 / ASO2A showed no protective 
efficacy in a Phase IIb study in 400 children from Kenya (Ogutu et al., 2009) despite the induction of 
high antibody levels and GIA activity in vitro (Beeson et al., 2016). Additionally, MSP-142 delivered via 
ChAd63-MVA did not protect three vaccinated volunteers against P. falciparum mosquito bite 
challenge although strong T-cell responses were detected (Sheehy et al., 2012). However, so far full-
length MSP-1 has not been assessed in clinical trials.  
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1.4. Merozoite surface protein 1 (MSP-1)     
1.4.1. MSP-1 complex & processing  
MSP-1 (synonyms MSA-1, merozoite surface antigen 1; gp190) is the most abundant protein on the 
surface of Plasmodium merozoites (Gilson et al., 2006; Holder and Freeman, 1981) and is present in 
all Plasmodium species described so far. The protein - encoded by a gene on chromosome 9 with 
roughly 5000 bp - is initially synthesized in infected hepatocytes at late liver-stage (Haussig et al., 
2011; Szarfman et al., 1988). Within the infected erythrocyte, MSP-1 is expressed as an 
approximately 190 kDa precursor protein in late trophozoite and schizont stages and deposited at 
the merozoite surface via glycosylphosphatidylinositol (GPI) anchor (Holder and Freeman, 1982) 
(Figure 1.6 A). 
 
       
 
             
Figure 1.6: MSP-1 complex and proteolytic processing. (A) The MSP-1 complex consisting of four major 
subunits - MSP-183, MSP-130, MSP-138, MSP-142 – is the major protein component at the merozoite surface and is 
anchored via GPI. (B) The approximately 190 kDa MSP-1 precursor is proteolytically cleaved by PfSUB1 during 
merozoite maturation into four major subunits: MSP-183, MSP-130, MSP-138 and MSP-142. Secondary processing 
prior to erythrocyte invasion is mediated by PfSub2 which cleaves MSP-142 into MSP-133and the GPI anchored 
MSP-119. The latter remains on the merozoite surface during erythrocyte invasion while all other fragments are 
shed.  
MSP-1 complex                Merozoite  Blood stages of P. falciparum 
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During merozoite maturation the MSP-1 precursor is cleaved into four major subunits - MSP-183, 
MSP-130, MSP-138, MSP-142 (Holder et al., 1985) - which remain non-covalently associated to the 
surface and interact with the processed forms of the peripheral surface proteins MSP-6 and MSP-7 
(Kauth et al., 2006; Pachebat et al., 2007; Stafford et al., 1996; Trucco et al., 2001) as well as with 
MSP-3, MSPDBL-1 and MSPDBL-2 (Lin et al., 2016). The processing step is mediated by the subtilisin-
like serine protease PfSUB1 which is released by merozoite exonemes just prior to egress of daughter 
merozoites from the infected host cell (Koussis et al., 2009; Yeoh et al., 2007). By inhibition of PfSUB1 
several merozoite proteins such as MSP-1, MSP-6 and MSP-7 cannot be processed and RBC invasion 
is reduced, suggesting that PfSUB1-mediated processing may be essential for the release of 
merozoites after schizont rupture and the preparation of merozoites for reinvading new RBCs 
(Koussis et al., 2009). Indeed, this processing step plays a crucial role for RBC rupture and parasite 
egress since it enables MSP-1 to bind to heparin and spectrin on the erythrocyte membrane (Das et 
al., 2015).  
Erythrocyte invasion requires a secondary proteolytic step mediated by the membrane-bound 
protease PfSUB2 which is released from micronemes shortly prior or during RBC invasion and cleaves 
MSP-142 into MSP-133 and the GPI-anchored MSP-119 (Blackman and Holder, 1992). This processing 
eventually results in shedding of the entire MSP-1/6/7 complex from the surface of Plasmodium 
falciparum except MSP-119 which is carried into the newly infected red blood cell (Blackman et al., 
1990) (Figure 1.6 B).  
 
1.4.2. MSP-1 structure  
According to primary structure analyses of MSP-1 from different P. falciparum isolates, the protein 
structure is divided into 17 blocks corresponding to the different levels of conservation (Tanabe et 
al., 1987)(Figure 1.7.): While some regions are highly conserved there are two short areas of higher 
sequence variation (block 2 and 4). However, as the major part of MSP-1 appears dimorphic (block 5-
16), all strains can be classified to one of the two allelic variants, termed K1 and MAD20 according to 
two representative isolates from PNG and Thailand (Tanabe et al., 1987). For instance, the laboratory 
strain 3d7 represents the MAD20 allele while Fcb1 is assigned as K1.  
The best studied part of MSP-1 is the C-terminal MSP-119 fragment (block 17) which is generated 
during secondary proteolytic cleavage and whose sequence is highly conserved within different P. 
falciparum isolates (Holder, 2009; Miller et al., 1993). As shown by NMR spectroscopy analysis MSP-
119 consists of two epidermal-growth factor (EGF)-like domains stabilized by disulfide bonds (Morgan 
et al., 1999).  
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The three-dimensional structure of the residual approximately 95 % of MSP-1 is currently not known 
- the large size of MSP-1 makes crystallization very challenging - but a structural model about the 
arrangements of MSP-1 subunits (Kauth et al., 2003) as well as their interaction with MSP-6 and MSP-
7 (Kauth et al., 2006) has been proposed.  
 
Figure 1.7: Structure of MSP-1. The 190 kDa precursor protein consists of 1720 amino acids including a signal 
peptide (SP) and a GPI anchor (GA). The arrows indicate sites of primary processing of the MSP-1 precursor into 
the subunits MSP-183, MSP-130, MSP-138 and MSP-142. During invasion, PfSub2 cleaves MSP-142 into MSP-133 and 
MSP-119. Black, grey and white boxes represent conserved, dimorphic and oligomorphic regions, respectively.   
 
 
1.4.3. MSP-1 function 
Several studies suggest that MSP-1 is essentially involved in the parasite´s life cycle and that it plays a 
crucial role for erythrocyte invasion and merozoite egress. Thus, attempts to knock out the msp1 
gene in P. falciparum blood stages by homologous recombination failed, whereas the C-terminal 
fragment MSP-119 can be replaced by the corresponding sequence of the distantly related 
Plasmodium species, P. chabaudi (O'Donnell et al., 2001). Different interaction partners of MSP-1 
have been proposed on the erythrocyte surface and the erythrocyte cytoskeleton, suggesting a role 
of MSP-1 for the initial attachment to erythrocytes: Sialic acid (Perkins and Rocco, 1988), spectrin 
(Herrera et al., 1993), heparin-like proteoglycans (Boyle et al., 2010a), band 3 (Goel et al., 2003), 
glycophorin A, B and C (Hafalla et al., 2011) as well as complement receptor 1 (Hafalla et al., 2011). 
Interestingly, binding of the N-terminal part of MSP-183 to glycophorin A on erythrocytes plays a 
crucial role for RBC invasion (Baldwin et al., 2015). Furthermore, processing by PfSUB1 enables MSP-
1 to bind to heparin and spectrin, leading to RBC rupture and parasite egress (Das et al., 2015). 
Interestingly, it was reported recently that several peripheral merozoite proteins – MSP-3, MSP-6, 
MSP-7, MSPDBL-1 and MSPDBL-2 – bind to MSP-1 independently of each other and thus, generate 
different MSP-1 dependent complexes on the merozoite surface with overlapping functions; 
complexes containing MSP-6, MSPDBL-1 or MSPDBL-2 are able to bind to human erythrocytes (Lin et 
al., 2016). MSP-183 seems to be the crucial component of all these complexes since by antibody-
mediated inhibition of this subunit MSP-1 complexes cannot form and parasite growth in vitro is 
reduced (Lin et al., 2016).   
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Furthermore, several monoclonal antibodies targeting MSP-119 efficiently inhibit the invasion of red 
blood cells in vitro (Blackman et al., 1990) and prevent the secondary cleavage of MSP-142 by PfSUB2 
during erythrocyte invasion (Blackman et al., 1994). Thus, this proteolytic step resulting in the 
generation of the MSP-119 fragment appears to play a crucial role in RBC invasion. However, 
antibodies raised in immunized rabbits against all MSP-1 subunits (Woehlbier et al., 2006) as well as 
against epitopes located throughout the MSP-1, MSP-6, MSP-7 complex (Woehlbier et al., 2010) 
efficiently inhibit secondary processing and interfere with erythrocyte invasion and the intracellular 
growth of the parasite. All these studies emphasize the essential role of MSP-1 for the erythrocyte 
invasion process of the parasite suggesting MSP-1 as a promising candidate for malaria vaccine 
development.  
 
1.4.4. MSP-1 as malaria vaccine candidate  
 
(i) MSP-1 specific humoral immune response  
Several epidemiological studies in malaria endemic regions report a positive correlation between 
acquired clinical immunity against malaria and serum antibody levels to different parts of MSP-1 
suggesting a protective potential of this protein. Antibodies directed against a dimorphic region 
within the MSP-183 subunit are associated with protection against P. falciparum malaria in 
adolescents from Mali (Tolle et al., 1993). Furthermore, antibody titers to MSP-142 and MSP-119 have 
been correlated with clinical immunity against malaria in children from West Africa and Papua New 
Guinea (al-Yaman et al., 1996; Egan et al., 1996). Moreover, antibodies directed to the oligomorphic 
block 2 of MSP-1 strongly correlate with protection against P. falciparum disease in 337 children from 
Gambia (Conway et al., 2000) as well as in 280 children from Ghana (Cavanagh et al., 2004).  
Interestingly, MSP-1 specific antibodies can target the parasite via several immune mechanisms: 
Direct growth inhibitory activity of P. falciparum blood stages in vitro has been reported for 
antibodies directed against MSP-119 (Blackman et al., 1990; Egan et al., 1999; O'Donnell et al., 2001), 
MSP-183 (Woehlbier et al., 2006) and the complete MSP-1 protein (Woehlbier et al., 2006). 
Additionally, MSP-119-specific antibodies inhibit the parasite in vitro in cooperation with complement 
factors (Boyle et al., 2015) and by recruitment of neutrophils via antibody-dependent respiratory 
burst (Joos et al., 2015). Antibodies to MSP-1block2 have been reported to inhibit parasite growth in 
vitro by activation of monocytes in the antibody-dependent cellular inhibition assay (Galamo et al., 
2009). 
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(ii) MSP-1 specific T-cell response  
Since MSP-1 is initially synthesized in infected hepatocytes at late liver-stage (Haussig et al., 2011; 
Szarfman et al., 1988) it may also induce a protective cellular immune response in the liver. Indeed, 
human T-lymphocytes from 3 out of 4 volunteers who have been vaccinated with radiation 
attenuated P. falciparum sporozoites recognize not only the pre-erythrocytic antigens CSP and LSA-1 
but also the blood stage antigens SERA-1, MSP-2 and MSP-1 (Krzych et al., 1995). Moreover, CD4+ 
and CD8+ T-cells could be induced in mice by vaccination with MSP-142 using the viral vectors AdHu5 
and MVA. Immunized mice were better protected against Plasmodium sporozoite challenge, 
probably due to enhanced IFNγ levels which were detected in the serum and associate with a lower 
liver stage parasite burden (Draper et al., 2009).  
Importantly, CD8+ T-cell epitopes restricted to the HLA-A0201 receptor have been identified within 
MSP-1D by mass spectrometry and via tetramer technology (details in chapter 5.3.1)(Carralot et al., 
2008; Idler, 2004), suggesting that MSP-1 induces also a cellular immune response in humans based 
on the activation of CD8+ cytotoxic T-cells.  
(iii) Protective potential of MSP-1 in immunization experiments 
Several immunization studies in mice and monkeys have been performed with native MSP-1 or 
recombinant MSP-1 subunits. Mice immunized with purified P. yoelii MSP-1 (Holder and Freeman, 
1981) or with recombinant MSP-119 or MSP-142 produced in E.coli (Daly and Long, 1995; Tian et al., 
1997) or S. cerevisiae (Hirunpetcharat et al., 1997) are protected against subsequent P. yoelii 
infection. Furthermore, immunization of Saimiri and Aotus monkeys with native PfMSP-1 purified 
from parasite cultures results in complete protection against a lethal infection with P. falciparum 
(Etlinger et al., 1991; Perrin et al., 1984; Siddiqui et al., 1987). Monkeys immunized with recombinant 
PfMSP-1 fragments produced in E. coli or S. cerevisiae are partially protected against malaria 
(Cavanagh et al., 2014; Etlinger et al., 1991; Herrera et al., 1990; Kumar et al., 1995; Singh et al., 
2006). Partial protection of Aotus monkeys has also been reported after immunization with 
recombinant MSP-142 purified from baculovirus cultures (Chang et al., 1996).  
Clinical vaccine trials performed with MSP-1 in humans are summarized in chapter 1.3.4 (Blood stage 
vaccines). Importantly, protective efficacy of MSP-1 vaccination has only been assessed in two clinical 
studies so far; both used the conserved C-terminal part MSP-142 for immunization and were 
unsuccessful in conferring protection against malaria (Ogutu et al., 2009; Sheehy et al., 2012). 
However, several studies indicate the importance of the dimorphic and oligomorphic regions of MSP-
1 for protection (Früh et al., 1991; Galamo et al., 2009; Müller et al., 1989; Siddiqui et al., 1987). 
Thus, full-length MSP-1 is considered as a promising vaccine candidate.  
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(iv) Production of recombinant MSP-1 under GMP conditions 
A major obstacle for a good immunological characterization of full-length MSP-1 and its use in 
immunization trials has been the difficulty of obtaining this protein in sufficient quantity and quality. 
The large size (nearly 5000 bp) and high AT content (~80 %) of the msp-1 gene makes stable cloning 
and heterologous expression of MSP-1 very challenging. Thus, most of the immunization studies have 
been based on the C-terminal MSP-1 fragments MSP-142 or MSP-119. However, a re-design of the full 
msp-1 gene using the human codon frequency and thereby reducing the AT content to 55 % has 
solved the problem (Pan et al., 1999). Due to the dimorphism of MSP-1 two different versions were 
synthesized (Pan et al., 1999): While the MSP-1F construct from the Fcb1 strain largely represents 
the K1 prototype, the MSP-1D construct from the 3d7 strain corresponds to MAD20.  
By using these constructs, sufficient amounts of full-length MSP-1 and its processing products have 
been synthesized in E. coli, purified by a three-step affinity chromatography (Epp et al., 2003; Kauth 
et al., 2003) and used for interaction- or immunological analysis. The MSP-1 complex can be 
reassembled in vitro from the recombinant MSP-1 processing products suggesting that the 
conformation of all recombinant proteins is very similar to their native one (Kauth et al., 2003). 
Furthermore, antibodies raised against the recombinant MSP-1 subunits recognize MSP-1 on the 
parasite surface (Epp et al., 2003) and can inhibit parasite growth in vitro (Woehlbier et al., 2006).  
For efficient production of MSP-1 a strategy has been developed, in which the two halves of MSP-1, 
MSP-183/30 (102kDa) and MSP-138/42 (90kDa), are (i) expressed separately in E.coli W3110-Z1, (ii) 
recovered as inclusion bodies, (iii) renatured and assembled to the MSP-1 heterodimer in vitro and 
(iv) purified as complete MSP-1 protein by sequential chromatography using ion-exchange matrices. 
Recently, recombinant full-length MSP-1D from the P. falciparum strain 3d7 has been successfully 
produced under Good Manufacturing Practice (GMP) conditions and is available for clinical studies. A 
Phase I trial assessing safety and immunogenicity in malaria-naïve volunteers from Germany is 
currently ongoing in Heidelberg. Throughout this work, recombinant full-length MSP-1 (191 kDa) 
from P. falciparum (3d7) was used, henceforth named MSP-1D.  
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1.5. Aim of the study 
The malaria vaccine candidate MSP-1D from P. falciparum (3d7) has just reached clinical trials, thus it 
is important to accurately characterize the immune mechanisms which are elicited by the protein in 
humans and possibly contribute to protection against malaria. The overall aim of this work is to 
investigate the human humoral and cellular immune response against the vaccine candidate PfMSP-
1D in individuals with naturally acquired immunity against malaria and in malaria-naïve volunteers 
experimentally infected with Pf sporozoites.  
MSP-1 specific antibodies, acquired by natural exposure to P. falciparum in eleven young adults from 
Nouna, Burkina Faso, will be analyzed for their capability to (i) directly inhibit the growth of P. 
falciparum blood stages in vitro and (ii) to induce neutrophil respiratory burst by opsonization of 
Plasmodium merozoites. Thus, the growth inhibition assay (GIA) and antibody-dependent respiratory 
burst (ADRB) assay will be applied, respectively. Antibody levels will be correlated with functional 
activity and the MSP-1 specific antibodies – purified by their affinity to recombinant MSP-1D – will be 
studied in vitro for their ability to directly inhibit parasite growth and also to opsonize merozoites 
and recruit neutrophils. Additionally, we aim to measure the contribution of defined antigens to GIA 
and ADRB activity by pre-incubation of total antibodies with recombinant proteins prior to 
performing the functional assays. Potentially unknown P. falciparum proteins present in blood stage 
schizonts which may mediate growth inhibitory activity in vitro in individuals with naturally acquired 
immunity, shall be identified via western blot and mass spectrometry analysis. Furthermore, purified 
IgG from rhesus monkeys immunized with recombinant MSP-1D will be analyzed for their potential 
to opsonize P. falciparum merozoites and elicit neutrophil respiratory burst.      
The MSP-1 specific cytotoxic CD8+ T-cell response will be investigated in individuals with naturally 
acquired immunity and in malaria-naïve volunteers experiencing a single Pf infection by experimental 
sporozoite challenge. HLA-A0201 restricted CD8+ T-cell epitopes have been identified previously 
within MSP-1D (Carralot et al., 2008; Idler, 2004). Using these peptides semi-immune adults from 
Nouna and malaria-naïve controls – all have the HLA haplotype A0201 - shall be studied for their 
MSP-1 specific CD8+ T-cell response via IFNγ ELISPOT assay. Furthermore, HLA independent methods 
such as the use of comprehensive peptide pools or recombinant MSP-1 protein for ELISPOT analysis 
will be investigated. A HLA-independent approach is the prerequisite to examine large cohorts of 
individuals for a potential correlation between MSP-1 specific T-cell response and protection against 
malaria.  
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Besides naturally acquired immunity, we also aim to study the immune response elicited by a single 
P. falciparum wildtype infection. We will use blood samples from a controlled human malaria 
infection study performed in Tübingen (TUECHMI I), in which 30 malaria-naïve volunteers received 
different doses of cryopreserved Pf sporozoites by intravenous or intradermal injection (Mordmuller 
et al., 2015). The antibody response to the merozoite surface proteins MSP-1, MSP-6 and MSP-7 will 
be investigated as well as the cytotoxic CD8+ T-cell response against LSA-1, CSP and MSP-1. Overall, 
we examine a possible contribution of MSP-1 specific immune responses to protection against 
malaria.   
 
 
Figure 1.8: Human immune mechanisms against Plasmodium infection analyzed in this study. A MSP-1 
specific CD8+ cytotoxic T-cell response against Plasmodium liver stages will be studied in semi-immune African 
adults and in malaria-naïve volunteers after single Pf sporozoite infection. Plasmodium blood stages can be 
targeted by neutralizing antibodies, which directly inhibit Plasmodium erythrocyte invasion and/or intra-
erythrocytic growth of the parasite, or opsonizing antibodies which recruit effector cells like monocytes or 
neutrophil granulocytes. Both mechanisms will be examined in African adults with naturally acquired immunity 
against malaria using the in vitro assays GIA and ADRB. Picture modified from (Cowman and Crabb, 2006).  
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2.  Abbreviations & Definitions 
2.1. Abbreviations 
α       Anti 
aa       Amino acid 
ACT       Artemisinin-based combination therapy 
ADCI       Antibody-dependent cellular inhibition 
ADRB       Antibody-dependent respiratory burst 
AMA-1       Apical membrane antigen 1 
AP       Alkaline phosphatase 
APC       Antigen presenting cell 
APS       Ammonium persulfate 
BCIP       5-Bromo-4-chloro-3-indolyl phosphate 
BSA       Bovine serum albumin 
°C       Degree Celsius 
ChAd63      Chimpanzee adenovirus 63 
CSA       Chondroitin sulphate A 
CSP       Circumsporozoite protein 
C-terminus      Carboxy-terminus  
CTL       Cytotoxic T-lymphocytes 
CV       Column volumes 
Da       Dalton 
DBL       Duffy-binding like 
ddH2O       double distilled water 
DMSO       Dimethylsulfoxide 
DNA       Deoxyribonucleic acid 
DTT       Dithiothreitol 
EBA       Erythrocyte binding antigen 
E.coli       Escherichia coli 
e.g.       For example (latin: exempli gratia) 
EGF       Epidermal growth factor 
ELISA       Enzyme-linked immunosorbent assay 
ELISPOT      Enzyme-linked immunospot assay 
FCS       Fetal calf serum 
FSC       Forward scatter 
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GIA       Growth inhibition assay 
GLURP       Glutamate rich protein 
GMP       Good manufacturing practice 
G6PD       Glucose-6-phosphate dehydrogenase 
GPI       Glycosylphosphatidylinositol 
H       Histidine (His)-tag 
HCl       Hydrochloric acid 
HLA       Human leukocyte antigen 
HRP       Horseradish peroxidase 
IB       Inclusion body 
IFN       Interferon 
Ig       Immunoglobulin 
IL       Interleukin 
LSA-1       Liverstage antigen-1 
MHC       Major histocompatibility complex 
MS       Mass spectrometry 
MSP       Merozoite surface protein 
MVA       Modified vaccinia Ankara virus 
MW       Molecular weight 
N2       Liquid nitrogen 
NA-pool      IgG pool (n=11) from African adults  
NaCl       Sodium chloride 
NaOH       Sodium hydroxide 
NBT       Nitro blue tetrazolium chloride 
N-terminus      Amino-terminus 
O2       Oxygen 
OD       Optical density 
ON       Overnight 
OPA       Opsonic phagocytosis assay 
PAA       Polyacrylamide 
PAGE       Polyacrylamide gel electrophoresis 
PBMC       Peripheral blood mononuclear cell 
PBS       Phosphate-buffered saline 
PCR       Polymerase chain reaction 
Pf       Plasmodium falciparum 
PfSUB       P. falciparum subtilisin-like protease 
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pH       Potentia hydrogenii 
pI       Isoelectric point 
PMN       Polymorphonuclear neutrophil 
PV       Parasitophorous vacuole 
r       Recombinant 
RBC       Red blood cell 
ROS       Reactive oxygen species 
RPMI       Roswell Park Memorial Institute medium 
RT       Room temperature 
SERA       Serine repeat antigen 
SDS       Sodium dodecyl sulfate 
SP       Signal peptide 
SPAM       Secreted polymorphic antigen associated 
       with merozoites    
SSC       Side scatter 
TBS       Tris-buffered saline 
TBST       Tris-buffered saline + Tween 20 
TEMED       Tetramethylethylenediamine 
TNFα       Tumour necrosis factor α 
TRAP       Thrombospondin related adhesive protein 
UV       Ultraviolet 
v/v       Volume to volume 
Vol       Volume 
WHO       World Health Organization 
wt       Wildtype 
ZMBH       Zentrum für Molekulare Biologie  
       der Universität Heidelberg 
 
2.2. Units of measurement 
A       Ampere 
bp       base pairs 
g       gram 
h       hour 
kDa       kilo Dalton 
l       liter 
M       molar (mol/l) 
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min       minutes 
rpm       rounds per minute 
U       unit  
V       Volt 
2.3.  Unit prefixes 
k       kilo  103 
m       milli  10-3 
µ       mikro  10-6 
n       nano  10-9 
 
2.4.  Bases 
A       Adenin 
C       Cytosin 
G       Guanin  
T       Thymin 
U       Uracil 
 
2.5.  Nomenclature of amino acids (IUPAC) 
Ala A Alanin     Leu L Leucin 
Arg R Arginin     Lys K Lysin 
Asn N Asparagin    Met M Methionin 
Asp D Aspartic acid    Phe F Phenylalanin 
Cys C Cystein     Pro P Prolin 
Gln Q Glutamin    Ser S Serin 
Glu E Glutamic acid    Thr T Threonin 
Gly G Glycin     Trp W Tryptophan 
His H Histidin     Tyr T Tyrosin 
Ile I Isoleucin    Val V Valin  
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3.  Material 
3.1.  Laboratory equipment  
Autoclaves 2540 EL & 5075ELV Systec GmbH, Göttingen 
Centrifuge Thermo Scientific, USA 
Centrifuge, Megafuge 1.0R  Heraeus Instruments, Hanau 
Centrifuge, Megafuge 2.0R     Heraeus Instruments, Hanau  
Centrifuge, Pico 17      Heraeus Instruments, Hanau 
Chromatography system: 
 Äkta Purifier 100 GE Healthcare, Freiburg  
Colum corpus & auxiliary equipment GE Healthcare, Freiburg 
Electrophoresis Power supply Consort EV243   Hoefer, USA 
ELISPOT reader AID AID Diagnostika GmbH, Straßberg 
FACS Calibur Becton Dickinson, Heidelberg 
FLUOstar OPTIMA microplate reader (ADRB) BMG Labtech GmbH, Ortenberg 
Freezer -20 °C comfort Liebherr International Deutschland 
GmbH, Biberach an der Riss 
Freezer -80 °C Thermo Fisher Scientific, Karlsruhe 
Fridge  Bosch, Stuttgart 
Heating block VWR International GmbH, Darmstadt 
Ice machine, AF30 Scotsman, Vernon Hills, IL, USA 
Incubator, Cell Star cytoperm 2 Heraeus Instruments, Hanau 
Incubator CO2, BBD6620 Heraeus Instruments, Hanau 
Laminar Flow Cell culture hood, Hera safe Heraeus Instruments, Hanau 
Light microscope, Axiolab Zeiss, Jena 
Magnetic stirrer  VWR International GmbH, Darmstadt 
Microplate reader, Multiscan FC (ELISA, GIA) Thermo Fisher Scientific, Karlsruhe 
Microwave Zanussi, Nuremberg 
Multi-channel pipette, 12-channel, 200 µl Eppendorf AG, Hamburg 
PAA gel system, MiniVE GE Healthcare, Freiburg 
pH meter, Five Easy Mettler-Toledo GmbH, Gießen 
Photometer plus Eppendorf AG, Hamburg 
Pipetman Gilson P2, P10, P20, P200, P1000 Gilson International, Bad Camberg 
Pipettus® akku Hirschmann Labortechnik, Eberstadt 
Printer hp LaserJet 1300 Hewlett Packard, Heidelberg 
Protein electrophoresis system, Mighty Small II Hoefer Inc., Holliston, MA, USA 
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Shaker (flatbed) VWR International GmbH, Darmstadt 
Vortex VWR International GmbH, Darmstadt 
Waterbath precitherm PFV Labora Mannheim GmbH, Mannheim 
Western Blot aperture, XCell SureLock, Mini Cell Invitrogen, Karlsruhe 
3.2.  Software 
Adobe Photoshop C5      Adobe systems Inc., USA 
AID ELISPOT version 4.0     AID Diagnostika GmbH, Straßberg 
Cell Quest Pro (FACS)      Becton Dickinson, Heidelberg 
EndNote X7.7.1       Thomson Reuters, Philadelphia, USA 
OPTIMA Data Analysis (ADRB)     BMG Labtech GmbH, Ortenberg 
Microsoft Office 2010      Microsoft Corporation, WA, USA 
PlasmoDB       The EuPathDB Project Team, USA 
Sigma Plot 12.3       Systat Software GmbH, USA 
UniCorn 5.2 (Äkta)      GE Healthcare, Freiburg 
3.3.   Consumables 
1.5 ml tubes       Sarstedt AG & Co., Nümbrecht 
15 ml tubes        Greiner Bio-One, Frickenhausen 
50 ml tubes       Greiner Bio-One, Frickenhausen 
5 ml polypropylene columns     Thermo Fisher Scientific, MA, USA 
96-well plates, Nunc F96 Maxisorp (ELISA)   Thermo Fisher Scientific, MA, USA 
96-well sterile F-bottom plates (GIA)    Greiner Bio-One, Frickenhausen 
96-well white LUMITRAC plates, F-bottom, sterile (ADRB) Greiner Bio-One, Frickenhausen 
96-well multiscreen-IP filter plates, sterile (ELISPOT)  Merck Millipore GmbH, Schwalbach 
24-well plates, Cellstar (ELISPOT)    Greiner Bio-One, Frickenhausen 
Amicon Ultra Centrifugal Filters , 30K    Merck Millipore GmbH, Schwalbach 
Cover glasses       Roth, Karlsruhe 
Cuvettes       Sarstedt AG & Co, Nümbrecht 
Dialysis membrane, Spectra/Por Roth, Karlsruhe 
Glass slides       Paul Marienfeld GmbH, Lauda 
Gloves Latex       VWR, USA 
Immobilon-P PVDF Membrane (0.45 µM)   Millipore Corp., MA, USA 
NuPAGE Bis-Tris Mini gels (4-12 %)    Thermo Fisher Scientific, MA, USA 
Parafilm  Pechiney Plastic Packaging, IL, USA 
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Pasteur pipettes, sterile & disposable Roth, Karlsruhe 
Petri dishes  Greiner Bio-One, Frickenhausen 
Pipette tips, Diamond (10 µl, 200 µl,1000 µl) Gilson International, Bad Camberg 
Plastic pipettes (1 ml, 2 ml, 5 ml, 10 ml, 25 ml) Greiner Bio-One, Frickenhausen 
S-Monovette Lithium-Heparin, 7.5 ml (ADRB) Sarstedt AG & Co, Nümbrecht 
Sterile filters, Rotilabo® (0.2 µM; 0.45 µM) Roth, Karlsruhe 
Whatman TM 3MM paper GE Healthcare, Freiburg 
3.4.  Chemicals 
Acetic acid       Sigma-Aldrich, Taufkirchen 
Acyrylamide, 30%      Carl Roth, Karlsruhe 
Ammoniumdihydrogenphosphate    Carl Roth, Karlsruhe 
Ammoniumsulfate      Sigma-Aldrich, USA 
3-Acetylpyridine adenine dinucleotide (APAD), 90%   Sigma-Aldrich, USA 
BCIP/NBT tablets (GIA & WB)     Sigma-Aldrich, USA 
BCIP/NBT-plus substrate (ELISPOT)    Mabtech, Sweden 
Bradford reagent      BioRad, München 
Coomassie Brilliant Blue R250      Merck, Darmstadt 
Dextran       Carl Roth, Karlsruhe 
Diethanolamin       Carl Roth, Karlsruhe 
Dimethylsulfoxid (DMSO)     Merck, Darmstadt 
DL-1.4-Dithiothreitol (DTT)     Carl Roth, Karlsruhe 
EDTA        AppliChem, Darmstadt 
Ethanolamine       Carl Roth, Karlsruhe 
Ethanol        VWR International GmbH, Darmstadt 
FBS, heat inactivated      Invitrogen, Karlsruhe 
Ficoll-Histopaque      Sigma-Aldrich, Taufkirchen 
Gentamycin       Gibco, Karlsruhe 
Giemsa stain       Carl Roth, Karlsruhe 
Glycine        Sigma-Aldrich, Taufkirchen 
HBSS         Thermo Fisher Scientific, MA, USA 
Hydrochloric acid      Sigma-Aldrich, Taufkirchen 
Hypoxanthin 10 mM      CC pro GmbH, Oberdorla 
Imidazol       Merck, Darmstadt 
Immersion oil (518 C)      Waldeck GmbH & Co KG, Münster 
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Isoluminol (4-Aminophthalhydrazide)    Santa Cruz Biotechnology, Dallas, USA 
Isopropanol       Sigma-Aldrich, Taufkirchen 
Kalium chloride       AppliChem, Darmstadt 
L-Glutamine, 200 mM      Invitrogen, Karlsruhe 
Methanol, 99.8 %      Sigma-Aldrich, Taufkirchen 
Milk powder        Carl Roth, Karlsruhe 
PBS         Invitrogen, Karlsruhe 
Penicillin-Streptomycin, 10 000 U/ml    Invitrogen, Karlsruhe 
Paraformaldehyd (PFA)      AppliChem, Darmstadt 
p-Nitrophenylphosphate (pNPP) tablets (ELISA)   Sigma-Aldrich, Taufkirchen 
Propidium iodide      Life Technologies, Darmstadt 
Protein-A agarose (20334, Pierce)    Thermo Fisher Scientific, MA, USA 
Protein-A, IgG Binding buffer (Pierce)    Thermo Fisher Scientific, MA, USA 
Protein-G agarose (20399, Pierce)     Thermo Fisher Scientific, MA, USA 
Protein-G, IgG Binding buffer (Pierce)    Thermo Fisher Scientific, MA, USA 
RPMI 1640-Medium (Gibco)     Thermo Fisher Scientific, MA, USA 
Saponin       Sigma-Aldrich, Taufkirchen 
Sodium acetate       Merck, Darmstadt 
Sodium azide       Sigma-Aldrich, Taufkirchen 
Sodium chloride      Sigma-Aldrich, Taufkirchen 
Sodium dodecyl sulfate (SDS)     Carl Roth, Karlsruhe 
Sodium L-lactate      Sigma-Aldrich, Taufkirchen 
Sorbitol, D-Sorbit      Carl Roth, Karlsruhe 
Tetramethylethylendiamine (TEMED)    Carl Roth, Karlsruhe 
Tris        Carl Roth, Karlsruhe 
Triton X-100       Merck, Darmstadt 
Trypan Blue       Carl Roth, Karlsruhe 
Tween20        Merck, Darmstadt 
UltraLink Biosupport      Thermo Fisher Scientific, MA, USA 
 
3.5.  Kits 
Human IFNγ ELISPOTPlus kit (3420-2AW-10)   Mabtech, Sweden 
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3.6.  Enzymes 
Benzonase, 10 ku, purity > 99 % (ELISPOT)   Merck Millipore GmbH, Schwalbach                                                                                                        
Diaphorase from Clostridium kluyveri (GIA)   Sigma-Aldrich, Taufkirchen 
Interleukin 2, 100 000 U/ml (ELISPOT)    Kindly provided by AG Watzel 
Streptavidin-Alkaline Phosphatase (ELISPOT)   Mabtech, Sweden 
3.7.  Antibodies 
Rabbit α-AMA-1, BG98 (GIA standard, DiCo)   Dr. E. Remarque, BPRC, Rijswijk, NL 
Rabbit α-MSP-1D (GIA & WB)     Confarma France SARL, Hombourg 
Rabbit α-MSP-1Dp19 (mAB 5.2) (WB)    Prof. H. Bujard, ZMBH, Heidelberg 
Rabbit α-gMSP-6 (3d7) (WB)     Prof. H. Bujard, ZMBH, Heidelberg 
Rabbit α-gMSP-7 (3d7) (WB)     Prof. H. Bujard, ZMBH, Heidelberg 
Rhesus monkey α-MSP-1D (ADRB)    Dr. E. Remarque, BPRC, Rijswijk, NL 
Mouse α-human CD4-PerCP (FACS)    BD Bioscience, Heidelberg 
Mouse α-human CD8-PE (FACS)    BD Bioscience, Heidelberg 
Goat α-human IgG – AP conjugate (ELISA & WB)  Sigma-Aldrich, St. Louis, MO, USA 
α-rabbit IgG – AP conjugate (ELISA & WB)   Sigma-Aldrich, St. Louis, MO, USA 
α-human IFNγ 1D1K (ELISPOT, coating)    Mabtech, Sweden 
α-human IFNγ 7-B6-1 (ELISPOT, detection)   Mabtech, Sweden 
 
α-malaria human serum (n=11) from Nouna, BF  Dr. B. Coulibaly, Nouna, Burkina Faso 
α-malaria human serum from Kisumu, Kenya (WHO)  NIBSC code: 10/198 (Bryan D, 2014) 
malaria-naïve human serum (2x n=4) from Germany  Blood bank, Heidelberg 
         
3.8  Recombinant proteins 
PfMSP-1D (full-length protein, 3d7 strain, E.coli)  BIOMEVA GmbH, Heidelberg 
PfMSP-1F (full-length protein, FCB1 strain, E.coli)  Prof. H. Bujard, ZMBH, Heidelberg 
PfMSP-1 p83 (3d7 strain, E.coli)     Prof. H. Bujard, ZMBH, Heidelberg 
PfMSP-1 p42 (3d7 strain, E.coli)     Prof. H. Bujard, ZMBH, Heidelberg 
PfMSP-1 p38 (3d7 strain, E.coli)     Prof. H. Bujard, ZMBH, Heidelberg 
PfMSP-1 p30 (3d7 strain, E.coli)     Prof. H. Bujard, ZMBH, Heidelberg 
 
PfMSP-6 p36 (3d7 strain, E.coli)     Prof. H. Bujard, ZMBH, Heidelberg 
PfMSP-7 p22 (3d7 strain, E.coli)     Prof. H. Bujard, ZMBH, Heidelberg 
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PfMSP-3 (PfSub1 processed form, 3d7, 35.6 kDa, E.coli)  Dr. C. Lin / Prof. A. Cowman, Australia 
PfMSP-9 (PfSub1 processed form, 3d7, 52.1 kDa, E.coli)  Dr. C. Lin / Prof. A. Cowman, Australia 
PfMSPDBL-1 (PfSub1 processed form, 3d7, 71.7 kDa, E.coli) Dr. C. Lin / Prof. A. Cowman, Australia 
Bovine serum albumin (BSA, 66 kDa)    Sigma-Aldrich, Taufkirchen 
 
3.9. Stimuli for ELISPOT 
Human anti-CD3 mAb      Mabtech, Sweden 
CEF Peptide pool (3615-1)     Mabtech, Sweden   
MSP-1 based peptides       Peptide Speciality Laboratories 
        GmbH, Heidelberg 
CSP based peptides      Dr. K.Heiss / Dr.AK Müller, Heidelberg 
LSA-1 based peptides      Dr. K.Heiss / Dr.AK Müller, Heidelberg 
PfMSP-1D (full-length protein, 3d7 strain, E.coli)  BIOMEVA GmbH, Heidelberg 
 
3.10. Protein marker 
Color Plus Protein ladder, 10-230 kDa (prestained)  New England Biolabs, Schwalbach 
Protein ladder, 10-250 kDa (unstained)    New England Biolabs, Schwalbach 
 
 3.11. Parasite strains 
Plasmodium falciparum 3d7  Prof. M. Lanzer, Center for Infectious 
Diseases - Parasitology, Heidelberg  
Plasmodium falciparum FCB1 Prof. M. Lanzer, Center for Infectious 
Diseases - Parasitology, Heidelberg  
 
3.12.  Buffers, solutions and media 
Common buffers 
10x PBS       1.4 M NaCl   
        27 mM KCl   
        100 mM Na2HPO4  
        18 mM KH2PO4   
        pH 7.4 
1x PBS        100 ml 10x PBS   
        ad 1 L ddH2O 
Material
 
46 
 
1x TBS         150 mM NaCl   
        10 mM Tris/HCl    
        pH 8.0 
Biochemical Methods 
4x Upper Tris       500 mM Tris/HCl   
        0.4 % SDS, pH 6.8 
4 x Lower Tris       1.5 M Tris/HCl    
        0.4 % SDS, pH 8.8 
Stacking gel, 4 % (10 ml)     330 µl PAA (30 %)  
        625 µl upper Tris  
        1.55 ml ddH2O   
        5 µl Temed   
        25 µl APS (10 %) 
Separation gel, 10 % (10 ml)     1.65 ml PAA (30 %)  
        1.25 ml lower Tris  
        2.1 ml ddH2O   
        10 µl Temed   
        40 µl APS (10 %) 
SDS-PAGE running buffer     250 mM Glycine  
        0.1 % SDS   
        25 mM Tris/HCl, pH 8.3 
SDS-PAGE sample buffer (4x)      8 % SDS   
        50 % Upper Tris  
        40 % Glycerol   
        0.08 % Bromphenolblue 
TBST buffer       0.2 % Tween 20 in TBS 
Blocking buffer       2 % Skim milk powder in TBS 
Western Blot transfer buffer      0.01 % SDS    
        25 mM Tris/HCl   
        192 mM Glycin    
        20 % methanol or ethanol 
Stripping buffer      62.5 mM Tris/HCl, pH 6.8 
        2 % SDS   
        100 mM β-mercaptoethanol 
Coomassie staining solution     50 % EtOH   
        10 % Acetic acid  
        40 % ddH2O   
        0.25 % Serva Blue R   
Coupling of rMSP-1D to the Ultra Link Biosupport 
Coupling buffer       0.1 M NaH2PO4   
        0.6 M C6H5Na3O7 x 2 H2O 
        pH 7.5 
Quench solution      3 M Ethanolamin, pH 9 
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Wash solution       1 M NaCl 
Storage solution      0.02 % NaN3 in PBS 
Immune affinity chromatography (α-MSP-1) 
Elution buffer 1 (Glycin)     75 mM Glycin   
        0.5 M NaCl, pH 2.8 
Elution buffer 2 (NaCl)      1 M NaCl in PBS, pH 7.4 
Neutralization buffer      1 M Tris, pH 8.0 
Immune affinity chromatography (Protein-G) 
IgG Binding buffer (Pierce)     Thermo Fisher Scientific, USA 
Elution buffer        0.1 M Glycine, pH 2.5 
Neutralization buffer       1 M Tris, pH 8.0 
ELISA 
Coating buffer       34 mM Na2CO3    
        16 mM NaHCO3   
        pH 10.6 
TBST buffer       0.05 % Tween 20 in TBS 
Blocking buffer       1 % skim milk powder in TBST 
Substrate buffer      Diethanolamine (9.6 ml)  
        2 M MgCl2 (500 µl)  
        pH 9.5    
        ad 1 L ddH2O   
Substrate p-Nitrophenylphosphate (pNPP) 
tablet (Sigma-Aldrich) dissolved in 20 
ml substrate buffer (1 mg/ml) 
Stopping solution      0.2 M NaOH 
 
Cell culture of Plasmodium falciparum 
Human erythrocytes, blood group 0+    Blood bank, Heidelberg 
Human serum, blood group A+ (heat inactivated)  Blood bank, Heidelberg 
Parasite culture medium     RPMI 1640 (500 ml)  
        + L-Glutamine   
        + 25 mM HEPES  
        0.1 mM hypoxanthin  
        20 µg/ml gentamycin  
        10 % (v/v) human serum 
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Freezing solution      56 % (v/v) Glycerol  
        3 % (v/v) Sorbitol  
        0.65 % (w/v) NaCl  
Thawing solutions      1) 12 % NaCl in ddH2O  
        2) 1.6 % NaCl in ddH2O  
        3) 0.9 % NaCl + 0.2 % Glucose  
Saponin solution, 1 % (10x)     0.1 g saponin in 1 ml ddH2O 
RIPA buffer       Sigma-Aldrich, Taufkirchen 
1x SSC buffer       7.5 mM NaCl   
        0.25 mM sodium citrate 
        pH 7.0 
GIA (pLDH assay) 
GIA medium       RPMI 1640 (500 ml)  
        + L-Glutamine   
        + 25 mM HEPES  
        0.2 mM hypoxanthin  
        40 µg/ml gentamycin  
        20 % (v/v) human serum 
      
LDH buffer       10 % (v/v) 1 M Tris/HCL, pH 8.0 
        2.8 g Sodium – L-Lactate 
        0.25 % (v/v) Triton X-100 
        Ad 500 ml ddH2O 
LDH substrate buffer      1 NBT tablet dissolved in 50 ml  
        LDH buffer (in the dark) 
APAD solution       10 mg/ml stock in ddH2O 
        store 50 µl aliquots at -20 °C 
Diaphorase solution       50 units /ml in ddH2O  
        store 200 µl aliquots at -20 °C  
ADRB assay  
Dextran solution      3 % (w/v) Dextran in 0.9 % NaCl 
        sterile filtered 
Isoluminol stock      4 mg/ml in DMSO 
NaCl solutions       1) 0.9 % NaCl (w/v) in ddH2O 
        2) 1.8 % NaCl (w/v) in ddH2O 
        sterile filtered    
      
ELISPOT assay 
PBMC medium       RPMI 1640    
        10 % (v/v) FCS or FBS  
        200 mM L-Glutamin   
        1 % Pen/Strep  
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Peptide stocks       20 mg/ml peptide in   
        90 % DMSO 
Wash buffer       PBS    
        0.05 % Tween 20 
Coating Ab α-human IFNγ 1D1K     10 µg/ml in sterile PBS 
Detection Ab α-human IFNγ 7-B6-1     1 µg/ml in PBS   
        0.5 % FCS  
Streptavidin-Alkaline Phosphatase    1:1000 in PBS   
        0.5 % FCS 
Substrate solution BCIP/NCB     Ready to use (Mabtech, Sweden)
        sterile filtered 
Stop solution       ddH2O 
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4.  Methods 
4.1. Animal immunizations with recombinant MSP-1D 
4.1.1. Rhesus monkey immunizations 
Rhesus immunizations and antibody preparation were carried out at the Biomedical Primate 
Research Centre (BPRC), Rijswijk, Netherlands in 2010. The BPRC is AAALAC accredited and compliant 
with recommendations of the Weatherall report on the use of non-human primates in research 
(Weatherall, 2006). The study was approved by an independent ethics committee at BPRC, 
constituted in accordance with Dutch law (DEC598) and European Acts (directive 2010/63/EU) on 
animal experimentation. To minimize discomfort to animals, immunization and blood sampling were 
all done under ketamine sedation. Animals were assigned in a manner that ensured that age, weight 
and sex were similar amongst groups, and treatments were randomly assigned to groups.  
Captive-bred Rhesus macaques (n = 5, 2x female & 3x male, age: 4.6 – 12.5 years) were immunized 3 
times intramuscularly (day 0, 28 and 56) with 100 µg MSP-1D per dose formulated with CoVaccine HT 
(Cowan et al., 2011; Mahdi Abdel Hamid et al., 2011) in 500 µl volume. From each animal 29 ml blood 
was collected by venous puncture at day 0, 28, 56, 70, 126 and 182. IgG from sera were purified by 
Protein G affinity purification and stored at -80 °C. 
4.1.2. Rabbit immunizations 
Rabbit immunizations were performed at Confarma France SARL, F-68490 Hombourg, in compliance 
with legal animal health regulations and according to EC-GMP and c-GMP guidelines. New Zealand 
white rabbits (n=6) were immunized intramuscularly with lyophilized full-length PfMSP-1D (50 µg) 
and adjuvant IDRI-SE + GLA (100 µg) in a total volume of 500 µl on day 0, 28 and 56. Two weeks after 
the last immunization (d70) blood was sampled by heart puncture and serum was prepared and 
transported to Heidelberg. There, IgG were purified from serum via Protein A affinity 
chromatography and tested for growth inhibitory activity. 
 
4.2. Production of recombinant P. falciparum merozoite antigens 
4.2.1. MSP-1 
Recombinant PfMSP-1D (from 3d7 strain; 191.7 kDa) was produced in E.coli and purified under GMP 
compatible conditions by BIOMEVA GmbH, Heidelberg. In brief, the two halves of the PfMSP-1 
complex – p83/30 and p38/42  - were expressed separately in E.coli W3110-Z1, recovered as 
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inclusion bodies and reconstituted to the MSP-1 heterodimer in vitro followed by a three step 
purification via affinity chromatography. Recombinant MSP-1F (from FCB1 strain; 183.4 kDa) was 
produced similarly, according to a protocol developed by Kauth et al. (Kauth et al., 2003). MSP-183 
(from 3d7 strain; 81.8 kDa) was expressed and purified as published previously (Kauth et al., 2006). 
All proteins except MSP-1D contain a N-terminal hexa-histidine tag. 
4.2.2. MSP-3/-9/-DBL1 
The PfSub1 processed forms of PfMSP-3 (35.6 kDa), PfMSP-9 (52.1 kDa) and PfMSPDBL-1 (71.7 kDa) 
were kindly provided by Dr. C. Lin and Prof. A. Cowman from the Walter and Eliza Hall Institute of 
Medical Research in Melbourne, Australia. The recombinant proteins were expressed in E.coli and 
contain a N-terminal hexa-histidine tag (Lin et al., 2016).  
 
4.3. Biochemical methods 
4.3.1. Discontinuous, denaturizing polyacrylamide gel electrophoresis  
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, is a widely used technique to 
separate proteins in an electric field according to their molecular weight. As the charge-mass ratio of 
proteins is not constant due to their different amino acid compositions, the proteins are denatured 
by heat and their own charge is covered by binding of the ionic detergent sodium dodecyl sulfate 
(SDS). Additionally, disulfide bridges may be reduced by treatment with DTT. Therefore, negatively 
charged SDS-protein complexes with a constant charge to mass ratio are generated.   
Gel electrophoresis is performed using a double-stage polyacrylamide gel, which is characterized by a 
pH step from the large-pored stacking gel (4 %, pH 6.8) to the narrow-pored separation gel (8-15 %, 
pH 8.8). Both gels are generated by radical polymerisation of acrylamide and bisacrylamide using the 
radical formers APS and TEMED. In the polymerized meshwork, the electrophoretic mobility of 
proteins decreases proportional to their size. In this thesis, the Lämmli system with a Tris-Glycine 
buffer was used. 
o Cast polyacrylamide gel with appropriate percentage (10 %)  
o Mix samples with SDS-sample buffer and boil for 10 minutes at 80°C. The reducing agent DTT 
(50 mM) was added sometimes in order to reduce disulfide bridges  
o Pipette samples in wells of the gel (12 µl) 
o Apply a voltage of 125 V in the stacking gel and 200 V in the separation gel  
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Alternatively, NuPAGE Bis-Tris gradient mini gels (4-12 %) were used according to the manufacturer 
instructions (Thermo Fisher Scientific).  
4.3.2. Coomassie protein staining 
After electrophoretic separation in a polyacrylamide gel, protein bands can be easily stained using 
Coomassie brilliant blue R-250. However, the sensitivity is only moderate with a detection limit of 
about 200 ng protein per band. For detection of proteins, the separation gel is incubated in 
coomassie staining solution for 30 minutes at RT with slight shaking. Then, the gel is unstained by 
boiling 5 to 6 times in fresh water.  
4.3.3. Western Blot 
Proteins on a polyacrylamide gel can be transferred via electrical current onto a PVDF membrane 
where they are accessible to immunodetection with specific antibodies.  
Protein transfer:  
o Activate PVDF membrane by incubation in 99 % ethanol for 1 min 
o Soak polyacrylamide gel, PVDF membrane, whatman filter papers and blotting pads in WB 
transfer buffer 
o Assemble all components in the transfer chamber according to the picture below (Figure 
4.1.); remove air bubbles carefully 
o Fill the chamber with transfer buffer (→ wet blot) 
o Transfer proteins at 125 mA for 2 h (self-made polyacrylamide gels) or 3 h (NuPAGE gels) 
 
 
Figure 4.1: Schematic outline of the Western blot sandwich. Proteins on the polyacrylamide gel are transferred 
to the PVDF membrane in the electric field. 
 
 
 
Methods
 
53 
 
Immunodetection of proteins:  
o Block the PVDF membrane with blocking buffer for 1 h at RT or ON at 4 °C 
o Add primary antibody in blocking buffer. Incubate 1.5 h at RT or ON at 4 °C 
o Wash with TBST three times (5-10 min each) 
o Incubate with secondary antibody in blocking buffer for 1 h at RT (goat α-human IgG – AP 
conjugate; dilution 1: 30 000)  
o Wash with TBST three times (5-10 min each) 
o Add substrate (BCIP/NBT tablet dissolved in ddH2O) to membrane, stop color reaction by 
washing with ddH2O 
4.3.4. Mass Spectrometry (MS) 
MS analysis was performed at the ZMBH in Heidelberg. Proteins from Pf schizont lysate were 
separated on a NuPAGE Bis-Tris gradient gel, stained with Coomassie blue and protein bands of 
interest were cut out and digested with trypsin. The digested fragments were compared to the Swiss- 
Prot protein sequence database (from July 2015).     
4.3.5. Bradford assay 
In order to determine the concentration of protein solutions, the Bradford assay (Bradford, 1976) is a 
commonly used method because it is fast, easy to perform and rather unsusceptible to interference 
by different chemicals except SDS. However, the specificity can vary between different proteins as 
the dye favors alkaline and aromatic amino acids.  
The test is based on binding of the acidic dye Coomassie brilliant blue G-250 to proteins resulting in a 
shift of the absorbance maximum from 465 nm to 595 nm. Therefore, the protein concentration can 
be quantified by measuring the optical density at a wavelength of 595 nm and comparing the value 
with a calibration curve of the protein standard BSA. The test is suitable for protein concentrations 
from 0.1 to 1.5 mg/ml.  
o Reaction mix: 1 ml Bio-Rad reagent (diluted 1:5 in ddH2O) + 20 µl protein sample (at 
appropriate dilution) 
o 15 min incubation at RT 
o Determine absorbance at 595 nm (OD595) 
o Calculate the protein concentration using a BSA calibration curve 
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4.4. Cell Culture of Plasmodium falciparum  
4.4.1. Culturing of Plasmodium falciparum  
P.falciparum asexual blood stages can be cultured in vitro in petri dishes under the following 
conditions:  Culture volume: 10 – 12 ml (small dishes) / 36 ml (large dishes)   
  Hematocrit:     4 % (human erythrocytes, type A)    
  Parasitemia:     < 5 %        
  Atmosphere:     37°C, 5 % CO2, 3 % O2, 92 % N2, 95 % air humidity  
  Medium:     RPMI 1640 supplemented with 10 % human serum, 0.1 mM  
          hypoxanthine, 20 µg/ml gentamycin 
Under these conditions a parasite multiplication rate of 7 – 10 per cycle is achieved. Culture medium 
is replaced at least every second day. Cells are split appropriately to avoid a parasitemia of > 5 %.  
4.4.2. Giemsa staining of blood smears 
In order to determine parasitemia and parasite stage, blood smears are stained with Giemsa and 
analyzed microscopically.  
o A drop of the parasite culture from the petri dish bottom is placed on a glass slide 
o The blood drop is distributed to a thin smear using a second glass slide 
o The smear is air dried and briefly fixed in 100 % methanol 
o The smear is dried and incubated in Giemsa solution for 10 min 
o The slide is dried and examined microscopically (100 x magnification) 
4.4.3. Parasite synchronization with sorbitol 
Synchronization of P. falciparum cultures can be achieved with sorbitol treatment since the 
membrane permeability of erythrocytes infected with trophozoite or schizont stages is remarkably 
different. Therefore, only uninfected or ring-stage infected erythrocytes survive the sorbitol 
treatment while the other cells burst due to osmotic processes.  
o The culture is centrifuged for 2 min at 1900 rpm. The supernatant is discarded 
o The pellet is resuspended in 5 ml D-Sorbitol (5 %) and incubated for 5 min at 37°C 
o Centrifugation for 2 min at 1900 rpm 
o The erythrocyte cell pellet is resuspended in the original volume of the culture medium and 
the culture is plated out in a new petri dish  
o To achieve complete synchrony, sorbitol treatment has to be repeated either 3-6 h after first 
synchronization or during the next cycles when parasites are in ring stage  
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4.4.4. Purification of P. falciparum merozoites 
Merozoite extracts are prepared from synchronized schizont-stage cultures of about 5 % parasitemia.  
Schizonts are ruptured by mechanical force (pipetting) and centrifuged twice at 400 g for 20 min to 
remove erythrocytes (pellet). Merozoites are recovered from the supernatant by centrifugation for 
15 min at 1500 g. The merozoite pellet is resuspended in RPMI (200 µl per 36 ml culture) and stored 
at -20 °C. The quality of the merozoite preparation is assessed via Giemsa-stained smears and 
merozoite numbers are estimated by FACS measurement. Prior to use, all merozoite preparations are 
tested in parallel in the ADRB assay with the NA pool and their concentration is adjusted to show the 
same ADRB activity. 
4.4.5. Preparation of P. falciparum schizont extract  
Proteins are extracted from a highly synchronous culture of P. falciparum (3d7) at late schizont-stage 
and with a parasitemia > 3 % in order to use them for ELISA and WB analysis.  
o Centrifuge 36 ml P. falciparum schizont-stage culture at 800 g for 2 min 
o Resuspend the pellet in 36 ml SSC buffer with 0.2 % saponin (RBC lysis) 
o Incubate on ice for 15 min, invert sometimes 
o Centrifuge at 2200 g for 8 min and 4 °C 
o Wash pellet 3x with ice-cold PBS 
o Resuspend pellet in 90 µl RIPA buffer + 1 mM DTT  
o Incubate on ice for 20 min (complete lysis of parasites & protein solubilization) 
o Store protein extract at -80 °C 
 
4.5. Purification of antibodies from human sera 
4.5.1. Total IgG purification by affinity chromatography (Protein A or G) 
Most immunoglobulins can be purified from serum via Protein A or Protein G affinity 
chromatography with high specificity. Protein A, a bacterial cell wall component from Staphylococcus 
aureus, is used for affinity purification of immunoglobulins from rabbits; it binds strongly to rabbit 
total IgG. Human immunoglobulins are affinity purified via Protein G, a cell wall protein of group G 
Streptococci; Protein G binds with strong affinity and specificity to all human IgG subtypes (IgG 1-4) 
but not to IgA, IgD or IgM.  
o Column preparation: Protein A or Protein G immobilized to agarose is mixed 1:1 with storage 
buffer and 5 ml each are poured into a polystyrene column  
o Buffer preparation: sterile filtration 
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o Serum preparation: 5 ml heat inactivated serum (30 min at 56 °C) is diluted with 10 ml 
binding buffer and incubated ON at 4°C. Then, the sample is centrifuged at 2400 g and 4°C 
for 10 min. The supernatant is transferred into a new falcon and used for chromatography  
o Equilibration of the columns with 2 CV (10 ml) binding buffer  
o Serum application (Supernatant) 
o Washing with 2 CV (10 ml) binding buffer 
o Washing with 10 CV (50 ml) PBS 
o Elution with 3 CV (15 ml) elution buffer. The pH is checked using a pH strip and as soon as it 
turns acidic, 13 ml eluate fractions are collected 
o Immediate neutralization of the eluate with 1.5 ml neutralization buffer  
o The Protein A or Protein G columns are washed with 3 CV PBS (15 ml) and 1 CV PBS + 0.02 % 
NaN3 at 4°C. They are stored upright at 4°C and can be re-used several times 
4.5.2. MSP-1 specific antibody purification by affinity chromatography (MSP-1D) 
Prior to the chromatographic affinity purification of α-MSP-1D antibodies, recombinant MSP-1D was 
covalently coupled to a pre-activated resin (Ultra Link Biosupport). Details to the protocol can be 
found in my master thesis (Jäschke, 2012) or in the manufacturer`s instructions (Thermo Scientific). A 
total of 44 mg MSP-1D and 625 mg dry beads were used resulting in 5 ml resin. MSP-1 specific 
antibodies were affinity purified from human serum using this resin and the “Äkta Purifier 100” 
system at 4°C allowing a computer based real time-monitoring of OD280, pH, conductivity, pressure 
and flow rate. 
o Column preparation: 5 ml Ultra Link Biosupport resin coupled to MSP-1D is poured into a 
column  
o Buffer preparation: sterile filtration and outgassing using a vacuum pump 
o Serum preparation: 20 ml human serum is mixed 1:1 with PBS and incubated ON at 4°C. After 
centrifugation the following day at 2400 g for 10 min, the supernatant is transferred to a new 
falcon and used for chromatography  
o Äkta preparation: Washing with (i) Ethanol, (ii) ddH2O and (iii) 1x PBS. Settings: Alarm 
pressure 0.5 MPa, Auto Zero UV, End-timer disabled, Record on  
o Connection of the column to the “Äkta Purifier 100” without air bubbles 
o Washing of the column with 6 CV PBS (1 ml/min) to remove NaN3 
o Serum application (0.5 ml/min) using either a syringe or a superloop. The flow-through is 
collected and used for further analysis  
o Washing with 6-8 CV PBS (1 ml/min) to remove all serum components except the α-MSP-1D 
antibodies bound to the matrix  
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o Elution using an acidic buffer (75 mM Glycin, 0.5 M NaCl, pH 2.8) (1 ml/min). The eluate is 
neutralized immediately with 0.1 volumes 1 M Tris, pH 8 
o Additional elution by high salt concentration (1 M NaCl in PBS, pH 7.4). Since this step is 
unnecessary, it is skipped the following times  
o Washing of the column with 6 CV PBS (1 ml/min) 
o Disconnection of the column from the Äkta system. Transfer of the matrix in a falcon. 
Addition of 0.02 % NaN3 and storage at 4°C. The matrix can be re-used 
o Cleaning of the Äkta system with (i) ddH2O and (ii) ethanol 
4.5.3. Concentration and dialysis of purified antibodies 
Total IgG preparations purified via Protein A or Protein G affinity chromatography from human serum 
as well as the α-MSP-1D eluate from MSP-1 specific affinity chromatography are concentrated to 
roughly 500 µl and dialyzed into RPMI using Amicon Ultra Centrifugal filters.  
o The Amicon filters are filled with RPMI and centrifuged at 1900 g for 10 min. Discard RPMI 
o Each eluate is transferred to the Amicon filter. Centrifugation at 1900 g for 15 – 40 min at 
4°C. The flow-through is discarded  
o RPMI is added to the concentrated eluate to the maximal volume. Centrifugation at 1900 g 
for 15 – 40 min at 4°C. The flow-through is discarded. These steps are repeated at least twice  
o Sterile filtration of the dialyzed IgG using a 0.22 µM filter 
o The protein concentration is determined via Bradford test and – for total IgG - adjusted to 30 
mg/ml (for GIA) or 10 mg/ml (for ADRB) by addition of RPMI. 150 µl aliquots of each sample 
are stored at -20°C  
 
4.6. Enzyme-linked immunosorbent assay (ELISA) 
4.6.1. ELISA - Principle 
ELISA is an immunological method for the qualitative and quantitative detection of antibodies 
binding to their antigen. Following immobilization of a certain antigen on a solid phase (Polystyrol), 
sera containing the antigen-specific antibodies are added in different dilutions. The antibodies 
binding to the immobilized antigen are then recognized by added secondary antibodies which are 
coupled to an enzyme enabling the visualization of the complex e.g. alkaline phosphatase. The 
amount of bound secondary antibody determines the strength of the signal measured at a certain OD 
and is used to calculate the antibody titer.  
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4.6.2. ELISA using recombinant proteins 
o Recombinant protein is diluted in coating buffer to a concentration of 100 nM. Each well is 
coated with 100 µl and the plates are incubated at 4°C overnight 
o Protein which has not bound to the plate is removed by two wash steps, each with 200 µl / 
well wash buffer (1x TBST) 
o In order to prevent unspecific binding of antibodies, the plates are blocked with 100 µl 
blocking buffer (1 % milk powder in TBST) per well for 1 h at RT 
o Wells are washed twice with 1x TBST 
o 100 µl of blocking buffer is added to all wells. 100 µl of sera or purified IgG are added to the 
first row. Each sample is tested in duplicates. Sera or purified IgG and blocking buffer are 
mixed in row 1 using a multichannel pipette and 100 µl are transferred to the next row and 
so on. Thereby, two-fold dilutions are made from top to bottom rows with 100 µl volume in 
each well. One well of the plate serves as reference value for equilibration (no first antibody) 
o Plates are incubated for 2 h at RT  
o Wells are washed four times with 1x TBST (200 µl/well) 
o Secondary antibody (goat α-human IgG-AP conjugate) was diluted 1:30 000 in blocking buffer 
and 100 µl are added to each well. The plates are incubated for 1 h at RT  
o Wells are washed twice with 1x TBST and twice with Substrate buffer (200 µl/well) 
o Substrate (pNPP, 1 mg/ml, 100 µl/well) is added and incubated for 1 h at RT in the dark 
o Reaction is stopped by addition of 0.2 M NaOH (100 µl/well) 
o Absorption is read at 405 nm by the microplate reader 
o In order to determine the antibody titer, a linear trendline is generated using OD values of 
the serial dilutions in the linear range (0.01-0.2). By using the equation of the trendline, the 
antibody endpoint titers are determined; they represent the antibody dilution at OD405 = 0.2  
4.6.3. ELISA using P. falciparum merozoites or schizont lysate 
o P. falciparum merozoites or schizont lysate are adjusted to 5 µg/ml with 1x PBS and 100 
µl/well are added to the 96 well plate. Incubation at 4°C overnight 
o The following procedure is performed as described above (4.6.2.). Exception: Sera or purified 
IgG are not added in serial 2-fold dilutions, but with a single appropriate dilution (1:700 for Pf 
schizont lysate; 1:350 for Pf merozoites) resulting in OD values in the linear range 
o The linear range is defined by a standard curve created with serial dilutions of IgG from 
malaria-exposed Kenyan individuals (WHO Standard, NIBSC 10/198 (Bryan D, 2014)) 
o Appropriate single-point OD values correlate well with antibody endpoint titers (Drakeley et 
al., 2005; Tongren et al., 2006) and thus, can represent antibody levels 
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4.7. Growth inhibition assay (GIA) of P. falciparum blood stages 
4.7.1. GIA - Principle 
The inhibition of both erythrocyte invasion and intraerythrocytic development of P. falciparum 
parasites by purified IgG can be measured via the activity of Plasmodium Lactate DeHydrogenase 
(pLDH). The latter is a soluble glycolytic enzyme expressed at high levels in blood-stage parasites and 
can convert 3-Acetylpyridine Adenine Dinucleotide (APAD) and Lactate to APADH and Pyruvate. 
APADH then reduces the chromogenic substrate Nitro Blue Tetrazolium (NBT) using the enzyme 
diaphorase. This results in the formation of Nitro Blue Formazan (NBF), a deep purple stain that can 
be measured at a wavelength of 650 nm.  
4.7.2. Standard GIA  
o The parasitemia and parasite stage of the P.falciparum (3d7) culture is determined 
microscopically by counting 1000 erythrocytes of a Giemsa-stained blood smear. All parasites 
have to be in schizont stage 
o Half of the parasite culture (6 ml) is centrifuged at 1900 rpm for 2 min. The supernatant is 
discarded. The pellet is resuspended in 6 ml GIA medium 
o The culture is diluted to a parasitemia of 0.6 % using 4 % hematocrit 
o The purified, concentrated and RPMI-dialyzed IgG preparations (stock 30 mg/ml) are 
pipetted into a 96-well plate in different IgG concentrations and a final volume of 25 µl; RPMI 
1640 is used for dilution. Triplicate measurements  
o 25 µl parasites (0.6 %) are added in each well 
o Controls: (i) 25 µl RPMI and 25 µl parasites (parasite growth control), (ii) 25 µl culture 
medium and 25 µl 4 % hematocrit (erythrocyte control), (iii) rabbit α-AMA-1 antibodies (GIA 
standard BG98) at a concentration of 25 % and 12.5 % in RPMI and 25 µl parasites (positive 
control), (iv) 25 µl pooled IgG from four malaria-naïve individuals and 25 µl parasites 
(negative control) 
o Incubation at 37°C for one parasite cycle (40 h)  
o Each well of the 96-well plate is filled with 200 µl sterile, cold PBS and resuspended 
o Centrifugation at 1300 g for 10 min. The supernatant is carefully discarded 
o In order to kill the parasites, the plate is frozen at -20°C for at least 45 min and thawed at RT 
for 45 min 
o Preparation of the substrate solution: 0.2 mg/ml NBT + 0.01 mg/ml APAD + 0.2 U/ml 
Diaphorase from C. kluyveri in LDH buffer; 10 ml are needed per plate 
o 100 µl of the solution are added rapidly in each well and the pellets are resuspended 
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o Centrifugation at 1800 g for 10 sec to remove potential air bubbles 
o Shaking of the plate for 20-30 min in the dark  
o OD values are determined at a wave length of 650 nm using the microplate reader 
o Data analysis in Excel and calculation of the inhibition: 
Inhibition [%] = 100 % - (((OD650 IgG sample – OD650 erythrocyte control) / (OD650 parasite 
control – OD650 erythrocyte control)) x 100) 
4.7.3. Antigen-reversal GIA 
The growth inhibitory effect of antigen-specific antibodies can be determined by pre-incubation of 
total antibodies with competitor antigen such as MSP-1D prior to performance of the GIA.  
o 10 µl/well competitor antigen in RPMI (e.g. MSP-1D, 1 mg/ml) in two-fold dilutions ranging 
from 200 µg/ml to 12.5 µg/ml are pipetted in a 96-well plate  
o 15 µl purified IgG in RPMI (stock concentration: 40 mg/ml for human IgG & 20 mg/ml for 
rabbit IgG) are added per well. Triplicate measurements 
o Incubation for 1 h at 37 °C 
o P. falciparum schizont-stage parasites are counted and diluted to 0.6 % parasitemia as 
described above. 25 µl parasites are added to each well 
o Controls: (i) 25 µl RPMI and 25 µl parasites (parasite growth control) (ii) 25 µl culture medium 
and 25 µl 4 % h 
o ematocrit (erythrocyte control) (iii) rabbit α-AMA-1 antibodies (GIA standard BG98) at a 
concentration of 25 % and 12.5 % in RPMI and 25 µl parasites (positive control), (iv) 25 µl 
pooled IgG from four malaria-naïve individuals and 25 µl parasites (negative control), (v) 10 
µl competitor antigen at highest concentration (200 µg/ml), no IgG, 25 µl parasites 
(competitor control), (vi) no competitor, IgG, 25 µl parasites (IgG control) 
o Incubation at 37°C for one parasite cycle (40 h)  
o Development and analysis of the GIA as described above 
4.8. Antibody-dependent respiratory burst (ADRB) assay 
Antibodies can opsonize P. falciparum merozoites and induce neutrophil respiratory burst (Joos et 
al., 2010). The ADRB assay detects the production of reactive oxygen species by human neutrophils 
via chemiluminescence. Components of the assay are: (i) P. falciparum merozoites, (ii) Protein G 
purified IgG, (iii) freshly purified human polymorphonuclear neutrophils (PMNs), (iv) Isoluminol and 
(v) competitor antigen in PBS (for antigen-reversal ADRB). Two persons are needed to purify the 
PMNs and simultaneously perform the assay.  
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4.8.1. PMN purification 
Whole blood samples from malaria-naïve healthy adults were collected in Lithium-Heparin tubes. 
Written informed consent was obtained from all participants and ethical approval was granted by the 
Ethical Committee of the Medical Faculty, University of Heidelberg.  
Blood from 3 donors (12 ml each) was pooled, mixed 1:1 with 3 % Dextran in 0.9 % NaCl, inverted 
approximately 10 times, and incubated for 18 min at RT to pellet RBCs. The supernatant was 
centrifuged (500 g, 4 °C, 10 min) and the thin white layer of PMNs (see Figure 4.2. A) was 
resuspended in 0.9 % NaCl (10 ml). This suspension was layered carefully on top of Ficoll-Histopaque 
(3 ml) and centrifuged at 400 g, RT, for 35 min without break. The thin PMN layer above erythrocytes 
(see Figure 4.2. B) was resuspended in ice-cold ddH2O (600 µl), incubated for 30 seconds to lyse 
remaining erythrocytes and neutralized with equal volume of 1.8 % NaCl. After centrifugation (500 g, 
5 min, 4 °C) the pellet was washed with HBSS (800 µl), centrifuged (500 g, 5 min, 4 °C), and the PMN 
pellet resuspended in cold PBS (700 µl). The quality of the preparation and PMN number were 
determined in a hemacytometer after trypanblue staining (1:10 dilution). The following formula is 
used: Cells/ml = counted cell number / counted square number x dilution x 104. The PMN 
concentration was adjusted to 1.3 x 107/ml (ADRB) or 2.5 x 107/ml (antigen-reversal ADRB) with 
sterile PBS; purity and viability of the cells was > 95 %. PMNs were stored at 4 °C and used for ADRB 
within < 1 h after isolation. 
 
Figure 4.2: Purification of PMNs from whole blood. (A) Schematic outline of the different blood layers after 
Dextran sedimentation and first centrifugation. (B) Schematic outline of the different layers after second 
centrifugation with Ficoll.  
 
4.8.2. ADRB assay protocol 
o 10 µl Protein G purified IgG (stock: 10 mg/ml) are pipetted to each well of an opaque white 
96 well LUMITRAC microplate. To facilitate rapid handling, less than 60 wells are used. 
Duplicate measurements 
o 40 µl P. falciparum merozoites (about 2.5 x 105) are added per well 
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o Controls: (i) IgG from malaria-naïve individuals (negative control), (ii) IgG from semi-immune 
individuals from Nouna, Burkina Faso (NA-Pool, positive control and reference), (iii) IgG from 
malaria-exposed individuals from Kenya (WHO 10/198 Standard (Bryan D, 2014), positive 
control), (iv) no IgG, no merozoites (PMN & Isoluminol control) 
o Incubation for 1 h at 37 °C 
o 100 µl/well freshly purified human PMNs in PBS (1.3 x 107/ml) are added rapidly 
o 100 µl/well Isoluminol (4 mg/ml stock in DMSO; 1:100 dilution in PBS) are added rapidly 
using a multichannel pipette 
o Immediate chemiluminescence detection with the FLUOstar OPTIMA microplate reader (150 
min, measurements for 1 second every minute, Gain 4095)  
4.8.3. Antigen-reversal ADRB assay 
The contribution of antigen-specific antibodies to ADRB activity was quantified by pre-incubation of 
total IgG with competitor antigens such as MSP-1 prior to the ADRB assay.    
o 50 µl sterile filtered competitor antigen in PBS (0.5 µM/well; 2.5 µM stock) or 50 µl PBS per 
well is pipetted to an opaque white 96 well LUMITRAC microplate. Duplicate measurements  
o 10 µl Protein G purified IgG (human IgG: 5 mg/ml; rhesus IgG: 1.25 mg/ml) are added 
o Incubation for 1.5 h at 37 °C 
o 40 µl P. falciparum merozoites are added per well 
o Controls additionally to the ones described above: (i) Competitor antigen, no IgG, no 
merozoites (competitor control), (ii) Competitor antigen and IgG (NA-Pool), no merozoites 
(competitor and antibody control) 
o Incubation for 1.5 h at 37 °C 
o 50 µl/well freshly purified human PMNs in PBS (2.5 x 107/ml) are added rapidly 
o 100 µl/well Isoluminol (4 mg/ml stock in DMSO; 1:100 dilution in PBS) are added rapidly 
using a multichannel pipette 
o Immediate chemiluminescence detection with the FLUOstar OPTIMA microplate reader (150 
min, measurements for 1 second every minute, Gain 4095)  
4.8.4. ADRB data analysis 
o Transfer the chemiluminescence data for all time points in one Excel table, calculate the 
mean of duplicate measurements and create curves showing the raw chemiluminescence 
activity [Light Units (LU)] over time  
o Determine the peak of each curve within the first 30 min 
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o Normalize the chemiluminescence activity of a sample to the chemiluminescence activity of a 
reference (NA-Pool: IgG pool from eleven semi-immune individuals from Nouna). Thus, 
calculate the ADRB Index for each sample 
o ADRB Index = (LU maximum sample / LU maximum NA-pool) x 1000 
 
4.9. Thawing of cryopreserved human PBMCs 
PBMCs are stored in liquid nitrogen (-196°C) and should be thawed quickly under sterile conditions. 
In order to prevent the formation of cell clumps resulting from dying cells, it could be beneficial to 
include benzonase in the thawing procedure.   
4.9.1. Thawing of human PBMCs (without benzonase) 
o Transfer the cryotubes from liquid nitrogen to ice and immediately into a 37 °C water bath. 
Hold the tube at the water surface for about 1 min and – with a small chunk of ice remaining 
– transfer the tube to a biosafety hood 
o Pour the content of the cryotube into 30 ml pre-warmed PBMC medium in a 50 ml falcon 
tube; clean the cryotube with medium  
o Centrifuge at 1400 rpm for 5 min. Discard the supernatant 
o Wash the cell pellet with 12 ml PBMC medium, thereby transfer to 15 ml falcon tube 
o Resuspend the cell pellet in 5 ml PBMC medium and incubate for 1-2 h at 37 °C in an 
incubator (atmosphere: 5 % CO2, 3 % O2, 92 % N2, 95 % air humidity). The lids should be 
slightly opened for gas exchange 
o Centrifuge at 1400 rpm for 5 min. Discard the supernatant 
o Resuspend the cell pellet in 1 ml PBMC medium. Count the living cells (see 4.9.3.) 
4.9.2. Thawing of human PBMCs (with benzonase) 
o Transfer the cryotubes from liquid nitrogen to ice and immediately into a 37 °C water bath. 
Hold the tube at the water surface for about 1 min and – with a small chunk of ice remaining 
– transfer the tube to a biosafety hood 
o Pour the content of the cryotube into a 50 ml falcon tube. Add 2 ml pre-warmed PBMC 
medium with benzonase (50 U/ml) drop by drop, thereby sway falcon tube gently 
o Add PBMC medium to 10 ml 
o Centrifuge at 1400 rpm for 7 min. Discard the supernatant 
o Wash the cell pellet with 12 ml PBMC medium, thereby transfer to 15 ml falcon tube 
o Continue as described above (4.9.1.) 
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4.9.3. Counting of PBMCs using the Neubauer hemocytometer 
In order to determine the number of living cells/ml in the PBMC suspension, cells are stained with 
trypanblue prior to microscopic analysis. Since this dye is only absorbed by dead cells resulting in a 
blue color, dead (blue) and living (unstained) cells can be distinguished microscopically. Only 
unstained cells are counted using a Neubauer hemocytometer. This counting chamber contains a 
counting grid with four large squares, each divided into 16 small squares, and a depth of 0.1 mm.   
o Preparation of the counting chamber: After cleaning with ethanol the coverslip is placed over 
the counting area  
o 5 µl cells are mixed with 45 µl trypanblue (dilution 1:10) and pipetted under the coverslip. 
The area fills by capillary action 
o The number of living cells present in 2-4 large squares is determined microscopically  
o The number of cells per ml is calculated:  
Cells/ml = counted cell number/counted squares x dilution x 104 
 
4.10. Flow cytometry   
4.10.1. Principle of flow cytometry 
Flow cytometry allows the simultaneous detection of size, granularity and fluorescence of single cells 
in a suspension. The method is based upon stimulation of each cell with laser light (Argon-Laser and 
Helium-Neon-Laser) and measurement of the light scattering in different angles, thereby determining 
the cell size (forward scatter, FSC) and cell granularity (sideward scatter, SSC). Furthermore, 
fluorophors are transferred by laser light into an excited state and can be detected via the wave 
length of their emitted energy. Therefore, cells expressing certain antigens can be identified by 
specific fluorophor-coupled antibodies. For instance, CD8+ and CD4+ PBMCs can be detected by flow 
cytometry using α-human CD4-PerCP and α-human CD8-PE antibodies.  
4.10.2. Detection of CD4/CD8 positive PBMCs 
o After thawing, PBMCs are transferred into 2 ml Eppendorf tubes  
o Centrifugation at 1100 rpm for 5 min. The supernatant is discarded. The pellet is 
resuspended in 50 µl PBS / 2 % FCS for blocking. Incubation for 5 min on ice 
o The antibodies α-human CD4-PerCP and α-human CD8-PE are diluted 1:100 in PBS / 2 % FCS. 
50 µl are transferred into each tube/ well. Controls: (i) unstained (ii) stained with α-human 
CD4-PerCP (iii) stained with α-human CD8-PE  
o Incubation for 20-30 min on ice in the dark 
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o Washing with 1ml PBs. Centrifugation at 1100 rpm for 5 min. The supernatant is discarded 
and the washing step is repeated once  
o The cells are resuspended in PBS with 1 % PFA for fixation 
o Measurement using the FACS Calibur machine and the program Cell Quest Pro  
4.10.3. Analysis of PBMC viability with Propidium Iodide 
Propidium Iodide (PI) is a DNA binding dye which is excited at 488 nm and emits at 617 nm. Since it 
penetrates the cell membrane of dying or dead cells in contrast to viable cells, it can be used to 
determine the viability of cells. 
o After thawing, PBMCs are resuspended in PBS and transferred into Eppendorf tubes (100 µl) 
o Centrifuge at 1100 rpm for 5 min, discard the supernatant 
o Resuspend the cell pellet in 100 µl PI (1:100 dilution in PBS) or in 100 µl PBS (control) 
o Incubate for 20 min on ice in the dark 
o Add 1 ml PBS, centrifuge at 1100 rpm for 5 min, discard the supernatant 
o Wash a second time with 1 ml PBS 
o Resuspend cells in PBS and transfer them to FACS tubes 
o Analyze PI staining using the FACS Calibur machine and the program Cell Quest Pro  
 
4.11. ELISPOT assay 
4.11.1. ELISPOT Principle 
The Enzyme Linked Immunospot (ELISPOT) assay is an extremely sensitive cellular assay which allows 
the quantification of cytokine secreting T-cells in vitro at the single cell level. One activated T-cell may 
be detected in 100 000 cells. Due to its high sensitivity and relatively easy performance, ELISPOT 
assays are a widely used tool to investigate specific cellular immune responses in several diseases or 
to develop or monitor new vaccine candidates.  
One of the most common ELISPOT assays is based on the detection of IFNγ. In this thesis, the 
ELISPOTPlus kit for human IFNγ from Mabtech AB (Sweden) was used. Whereas in the ex vivo ELISPOT 
the PBMCs are directly transferred to the ELISPOT plate after thawing, a prior cultivation period of 9 
days or 24 h in presence of the stimuli of interest is required in the cultured or short-term cultured 
ELISPOT assay, respectively.     
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Figure 4.3: Procedure of a cytokine ELISPOT assay. T-cells are added to a 96-well ELISPOT plate coated with a 
cytokine specific monoclonal antibody. During the incubation period of 20-24h activated T-cells secrete certain 
cytokines e.g. IFNγ which bind to the capture antibody. After removal of the cells, the enzyme-coupled detection 
antibody is added which recognizes another epitope of the cytokine of interest. Following addition of substrate 
the enzymatic reaction visualizes the position of cytokine secreting T-cells as colored spots. The picture was 
taken from (Caulfield, 2004). 
 
4.11.2. Overview of the stimuli used for ELISPOT experiments 
Peptide stocks at a concentration of 20 mg/ml were prepared in 90 % DMSO and sterile filtrated. 
Aliquots containing 1 µl peptide(s) were stored at -80 °C until their use for PBMC stimulation. The 
used concentration (2x) for all peptides was 20 µg/ml, thus 1 ml PBMC medium was added to 1 µl 
peptide(s) (1:1000 dilution). Since stimuli and PBMCs are combined 1:1 in the ELISPOT assay, stimuli 
are always prepared with the 2-fold concentration.  
Protein stimuli: Full-length PfMSP-1D, produced under GMP-compatible conditions by BIOMEVA 
GmbH, Heidelberg, was available at a concentration of 1 mg/ml in PBS.  20 µl, 10 µl and 2 µl aliquots 
were prepared and stored at -80 °C until usage. Upon addition of 1 ml PBMC medium, used 
concentrations (2x) of 20 µg/ml, 10 µg/ml and 2 µg/ml were derived. 
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Controls:  Cells without stimulus served as negative controls. The α-CD3 mAb from Mabtech AB 
served as positive control (stock concentration 100 µg/ml; 2x used concentration 0.2 µg/ml). 
Epitope Aa Sequence From Protein Reference 
HLA 
restriction 
674  KLKEFIPKV PfMSP-1 
(Carralot et al., 
2008; Idler, 2004) 
A0201 
291 GLHHLITEL PfMSP-1 (Idler, 2004) A0201 
374 SLLTELQQV PfMSP-1 (Idler, 2004) A0201 
437 VIYLKPLAGV PfMSP-1 (Idler, 2004) A0201 
J ERRAKEKLQEQQRDLEQRKADTKK PfLSA-1 (Luty et al., 1999) N/D 
S6 KPIVQYDNF PfLSA-1 (Luty et al., 1999) N/D 
T1 LTMSNVKNVSQTNFKSLLRNLGVS PfLSA-1 (Krzych et al., 1995) N/D 
1 GLIMVLSFL PfCSP ? A02 
2 YLNKIQNSL PfCSP ? A2.1 
3 ILSVSSFLFV PfCSP ? A2.1 
CMV NLVPMVATV control  A0201 
Table 4.1: Overview of the peptide stimuli used for ELISPOT experiments 
 
4.11.3. Pre-cultivation of PBMCs & Coating of the ELISPOT plate (Day 1) 
o After thawing and counting of PBMCs (4.9.), the cell number is adjusted to 106 cells in 300 µl 
o Stimuli are prepared two-fold as described above (4.11.2.) 
o 300 µl PBMCs (106 cells) and 300 µl stimulus (2x) are combined in a 15 ml falcon tube 
o Incubation for approximately 24 h at 37 °C in a CO2 incubator (atmosphere: 5 % CO2, 3 % O2, 
92 % N2, 95 % air humidity). The falcons are placed diagonal into a rack and the lids are 
slightly opened for gas exchange 
 
o Coating of the ELISPOT 96-well filter plate: the coating antibody (IFNγ, 1-D1K) is diluted 1:100 
in sterile PBS (Invitrogen); for 1 plate 5 ml PBS and 50 µl antibody is needed. 50 µl (10 µg/ml) 
are added to each well using a multichannel pipette 
o Seal the plate with parafilm and store it ON at 4 °C 
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1 2 3 4 5 6 7 8 9 10 11 12
A CD3 CD3 CD3
B CD3 CD3 CD3
C CD3 CD3 CD3
D CD3 CD3 CD3
E CD3 CD3 CD3
F CD3 CD3 CD3
G
H
CSP peptide mix CSP peptide mix CSP peptide mix
MSP-1D protein (1 µg/ml) MSP-1D protein (1 µg/ml) MSP-1D protein (1 µg/ml)
LSA-1 peptide mix LSA-1 peptide mix LSA-1 peptide mix
MSP-1 peptide mix MSP-1 peptide mix MSP-1 peptide mix
MSP-1D protein (10 µg/ml) MSP-1D protein (10 µg/ml) MSP-1D protein (10 µg/ml)
Donor 1 Donor 2 Donor 3 
unstim unstim unstim
4.11.4. Transfer of Stimuli & PBMCs to the ELISPOT plate (Day 2) 
o Wash the ELISPOT plate 3x with 200 µl/well sterile PBS 
o Block the ELISPOT plate with PBMC medium (200 µl/well) for at least 1 h  
o Prepare a 96-well “masterplate” for restimulation of PBMCs allowing a fast and easy transfer 
of the stimuli to the ELISPOT plate with the multichannel pipette. For each condition (either 
unstimulated or one of the stimuli used for pre-cultivation) add each stimulus in triplicates 
and a fourth well with the α-CD3 mAb (positive control). The stimuli are prepared two-fold 
concentrated as described above (4.11.2.). If the same stimulus is needed for several donors 
or different time-points, multiply the stimuli volume accordingly (~70 µl per donor and time-
point are required) 
o Transfer the stimuli (50 µl/well) from the “masterplate” to the ELISPOT plate using a multi-
channel pipette. The ELISPOT plate must not dry out 
o Centrifuge the PBMCs in the 15 ml falcons for 5 min at 1400 rpm. Discard the supernatant 
and resuspend the pellet in 250 µl PBMC medium 
o Transfer the PBMCs to the ELISPOT plate (50 µl/well, estimated 150 000 - 200 000 cells) 
o Incubate the ELISPOT plate for 22 -24 h at 37 °C 
o Determine the exact number of living PBMCs transferred to the ELISPOT plate in each falcon 
tube: stain the cells with trypanblue (1:10 dilution) and count viable cells as described above 
(4.9.3.). This step is important since some of the PBMCs die during the pre-cultivation period 
or are lost during transfer  
 
  
Figure 4.4: Example of a pipetting plan for the ELISPOT assay. Each stimulus is added in triplicates and the 
fourth well contains the positive control α-CD3 mAb. An unstimulated control is used per donor and time point 
in triplicates. 
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4.11.5. Development of the ELISPOT assay 
o Dumping of the cells 
o Washing of the plates 5x with PBS / 0.05 % Tween 20 (200 µl/well)  
o 50 µl /well biotinylated detection antibody (1 µg/ml; 7-B6-1) in PBS / 0.5 % FCS is added. 
Incubation for 2 h at RT 
o Washing of the plates 5x with PBS / 0.05 % Tween 20 (200 µl/well) 
o Streptavidin-Alkaline Phosphatase is diluted 1:1000 in PBS / 0.5 % FCS and 50 µl are added 
per well. Incubation for 1 h at RT 
o Washing of the plates 5x with PBS / 0.05 % Tween 20 (200 µl/well) 
o Substrate solution BCIP/NBT-plus is sterile filtrated before use and stored in the dark. 50 µl 
are pipetted to each well  
o As soon as blue-colored spots are clearly visible (after 5 – 20 min) the reaction is stopped by 
dipping the ELISPOT plate 10x in ddH2O   
o The plate is air-dried and stored in the dark at RT 
4.11.6. Analysis of the ELISPOT assay 
o The ELISPOT plate is photographed and analyzed using the AID ELISPOT reader and the AID 
ELISPOT software version 4.0. The reader counts the spots in each well. All plates are 
analyzed with the same settings (Intensity: 20-255; Size: 50-5000; Gradient: 5-90) 
o The number of activated cells secreting IFNγ (spot forming units: SFU) per 106 PBMCs is 
calculated in Excel. The number of living cells transferred to the ELISPOT wells – as 
determined by cell counting of each falcon tube - is included in the calculations. For each 
condition, the spot number of the unstimulated wells is subtracted from the spot number of 
the stimulated wells 
o Net SFU/ 106 cells = (Øspots in stim. wells – Øspots in unstim. wells) / cells per well x 10
6  
  
4.12. Statistical analyses 
Sigma Plot version 12.3 (Systat Software) was used for data analysis. Antibody levels (ELISA), GIA 
levels and ADRB activity were compared by Spearman`s rank correlation. Paired data was analyzed 
for statistical significance using paired t-Test (for two samples) or One Way RM Anova (for > 2 
samples); unpaired data was examined by t-Test (for two samples) or One Way Anova (for > 2 
samples). Significances: P ≤ 0.05 (*), P ≤ 0.01 (**), P ≤ 0.001 (***). 
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5.  Results 
5.1. Overview of the semi-immune individuals from Burkina Faso  
Blood samples were obtained from eleven healthy young adults (18 – 31 years) from Nouna, an area 
with high seasonal malaria transmission in Burkina Faso, West Africa. Blood (10 ml) from 40 
individuals was taken who (i) had no fever episodes within the last 15 days (ii) were not vaccinated 
within the last month (iii) received no medication within the last two weeks and (iv) were HIV, HBV 
and VDRL negative. The HLA-type of each individual was determined in the Institute for Immunology, 
University of Heidelberg; the HLA-A0201 genotype - the most common allele in Africa (~30%) – was 
detected in 11 from 40 individuals. A further blood donation of 100 ml each was taken from these 11 
individuals with the HLA-A0201 haplotype at the end of the dry, non-malaria transmission season 
(March 2004). PBMCs and sera were prepared via Ficoll centrifugation and transported to 
Heidelberg. Additionally, PBMCs from malaria-naïve individuals from Heidelberg carrying the HLA-
A0201 allele were prepared as controls. This work was done by the laboratory of Prof. Hermann 
Bujard (ZMBH, Heidelberg) and Dr. Boubacar Coulibaly (Centre de Recherche en Santé de Nouna 
(CRSN), Burkina Faso). Ethical approval was granted by the Ethical Committee of the Medical Faculty, 
University of Heidelberg, and Prof. B. Kouyaté, former Director of the CRSN. 
 
Donor Age Sex HLA Location Sample date PIN 
1 28 M A 0201 Nouna March 04 549 
2 31 M A 0201 Nouna March 04 494 
3 18 F A 0201 Nouna March 04 501 
4 19 M A 0201 Nouna March 04 504 
5 20 F A 0201 Nouna March 04 513 
6 22 M A 0201 Nouna March 04 545 
7 17 M A 0201 Nouna March 04 528 
8 19 M A 0201 Nouna March 04 497 
9 19 M A 0201 Nouna March 04 534 
10 21 M A 0201 Nouna March 04 533 
11 22 M A 0201 Nouna March 04 548 
 
Table 5.1: Overview of the eleven semi-immune individuals from Nouna. Shown are their age, sex, HLA-
subtype and PIN for exact identification. All samples were taken in Nouna (Burkina Faso) in March 2004 by Dr. 
Boubacar Coulibaly (CRSN, Burkina Faso).   
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5.2. Humoral immune response against PfMSP-1 in individuals with 
naturally acquired immunity 
5.2.1. Antibody levels to PfMSP-1 and Pf blood stages in Nouna donors 
Sera from eleven healthy young adults from Nouna, Burkina Faso were analyzed for antibodies 
directed towards P. falciparum specific antigens. Sera from malaria-naïve Europeans and a WHO 
reference reagent for anti-malaria (P. falciparum) human serum, containing a serum pool from 
malaria-exposed individuals from Kisumu, Kenya (NIBSC code: 10/198; (Bryan D, 2014)), served as 
controls. There was a high correlation between antibody levels to MSP-1 and to P. falciparum 
schizont lysate or merozoites (Spearman`s correlation coefficients r=0.899 (***) and r=0.886 (***), 
respectively) (Figure 5.1).  
 
Figure 5.1: Antibody profiles of 11 semi-immune individuals from Burkina Faso. Antibody levels determined by 
ELISA against P. falciparum 3d7 schizont lysate (black), merozoites (grey) and MSP-1D (red). Spearman`s rank 
correlation coefficients between antibody levels to MSP-1 and to P. falciparum schizont lysate or merozoites 
were r=0.899 (***) and r=0.886 (***), respectively. Nouna Pool (n=11): IgG from eleven individuals from Nouna; 
WHO Pool: IgG from malaria-exposed Kenyan adults (NIBSC code: 10/198; (Bryan D, 2014)); Naïve Pool: IgG 
from malaria-naïve European individuals (n=4).  
 
Furthermore, antibody levels to each of the four processing fragments of MSP-1D - MSP-183, MSP-130, 
MSP-138 and MSP-142 - were determined in the eleven semi-immune individuals from Nouna. The 
MSP-183 and MSP-142 fragment showed the highest immunogenicity in all Nouna donors while much 
lower antibody titers were detected to MSP-130 and MSP-138 (Figure 5.2). 
Results
 
72 
 
 
Figure 5.2: MSP-1 specific antibody profile of 11 semi-immune individuals from Burkina Faso. Antibody levels 
were determined by ELISA against the four MSP-1 processing fragments p83, p30, p38 and p42; shown is the 
relative titer [%] of each MSP-1 subunit.   
 
5.2.2. Growth inhibitory potential of MSP-1 specific antibodies 
Sera from eleven healthy young adults from Nouna, Burkina Faso were analyzed for their potential to 
inhibit parasite growth in vitro. Antibodies from four semi-immune individuals directly inhibited the 
growth of P. falciparum blood stage parasites in vitro (Figure 5.3 A). In order to quantify the 
contribution of MSP-1 specific antibodies to growth inhibitory activity in vitro, an antigen-reversal 
GIA was established in which antigen-specific antibodies are bound to their respective antigen, such 
as MSP-1, prior to performance of the classical GIA assay.  
By this approach, the growth inhibitory activity of purified α-MSP-1 antibodies from rabbits 
immunized 3x with MSP-1D and adjuvant (IDRI-SE + GLA), could be gradually reduced with increasing 
concentrations of MSP-1D from about 45 % without antigen to 0 % in presence of 200 µM MSP-1D 
(Figure 5.3 B). Interestingly, GI activity of purified α-MSP-1 antibodies from immunized rabbits could 
also be reduced in presence of MSP-1F or MSP-142, albeit not as good as with MSP-1D (Figure 5.4). 
Thus, growth inhibitory MSP-1 specific antibodies in immunized rabbits mainly target cross-reactive 
regions within MSP-1 (~70 %) and these are partially localized in the MSP-142 subunit. 
Total IgG from the two Nouna donors with highest GI activity (Donor 6 & 8) were analyzed for the 
contribution of MSP-1D specific antibodies to growth inhibitory activity using the antigen-reversal 
GIA. While MSP-1D had no effect on IgG from donor 8, the growth inhibitory activity of IgG from 
donor 6 was diminished by about 50 % upon addition of 200 µM MSP-1D (Figure 5.3 B). Interestingly, 
donor 6 had the highest antibody titer to MSP-1D (Figure 5.1) suggesting that high antibody 
concentrations are required in GI assays. Thus, naturally acquired MSP-1 specific antibodies can 
contribute to growth inhibitory activity in vitro. 
Results
 
73 
 
 
Figure 5.3: Antibodies to MSP-1 partly contribute to growth inhibitory activity. (A) Growth inhibitory activity 
of Protein G purified IgG from 11 semi-immune donors from Nouna and from a malaria-naïve pool (n=4), 3 
independent experiments. (B) Antigen-Reversal GIA with increasing concentrations of MSP-1D. P. falciparum 
(3D7) parasites are cultured in presence of purified IgG and increasing concentrations of competitor antigen 
MSP-1D for one parasite cycle (40 h). Readout is the activity of Plasmodium Lactate Dehydrogenase (pLDH). 
Mean values are shown with standard deviations; statistical differences were calculated using paired t-Test 
(Donor 6, P=0.024). 
 
 
Figure 5.4: Antigen-Reversal GIA with α-MSP-1D antibodies from immunized rabbits. Protein A purified IgG 
from rabbits immunized 3x with recombinant PfMSP-1D and adjuvant were pre-incubated with increasing 
concentrations of competitor antigen MSP-1D, MSP-1F or MSP-142. P. falciparum (3d7) parasites were added 
and incubated for 40 h (one parasite cycle). Readout is the activity of Plasmodium Lactate Dehydrogenase 
(pLDH). Statistical differences were calculated using paired t-Test. 
A 
B 
GIA 
Antigen-Reversal GIA 
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5.2.3. Search for new malaria antigens responsible for growth inhibitory activity 
in semi-immune individuals by mass spectrometry 
The finding that antibodies from the semi-immune Nouna donors 2 and 8 show growth inhibitory 
activity of P. falciparum blood stages in vitro independent of MSP-1 specific antibodies (Figure 5.3 B  
and Figure 5.13 C) prompted us to search for the target antigens responsible for the observed growth 
inhibition. Thus, P. falciparum (3d7) schizont lysate was separated by SDS-PAGE, transferred to a 
nitrocellulose membrane and stained with the different fractions of purified IgG from Donor 2 and 8 
received via MSP-1 specific affinity purification (Figure 5.13 A and B). While we detected in the α-
MSP-1D eluate only bands from full-length MSP-1 and processing fragments thereof, several other 
bands were visible in the flow-through (FT) fractions of Donor 2 and 8 (Figure 5.5). Since these 
antigens might be responsible for the observed growth inhibitory activity of the FT fractions (Figure 
5.13 C), we aimed to identify them by Mass Spec analysis.      
 
 
Figure 5.5: Western blot of Pf schizont lysate with different IgG preparations from Nouna donors. Pf schizont 
lysate (3d7) was separated on a NuPage gradient gel, transferred to a nitrocellulose membrane and immuno-
stained with either Protein G purified complete IgG, flow-through IgG (complete IgG without α-MSP-1 
antibodies) or affinity purified α-MSP-1D antibodies from Donor 2 and 8; from Donor 6 only complete IgG is 
available. The location of full-length MSP-1D and MSP-119 – as identified using α-MSP-1D IgG from immunized 
rabbits – is indicated.  
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Another P. falciparum (3d7) schizont lysate preparation was separated via SDS-PAGE and either used 
for WB analysis using antibodies from Donor 2 (FT) and 8 (FT) or stained with coomassie blue. Six 
bands of interest were identified which were visible at the same location by both staining with 
coomassie and immuno-staining with antibodies from the two donors by WB (Figure 5.6 B). Mass 
spectrometry analysis of the 6 bands - performed at the MS facility in the ZMBH in Heidelberg – 
revealed two proteins from P. falciparum: MSP-9 (band 3 with 15 % sequence coverage) and MSP-2 
(band 5 and 6 with 28 and 12 % sequence coverage, respectively) (Figure 5.6 A). Strikingly, many 
proteins from human erythrocytes were detected, such as Spectrin α-chain (band 1, 61 % sequence 
coverage) and β-chain (band 2, 65 % sequence coverage), Flotillin (band 5, 60 % sequence coverage) 
or Erythrocyte band 7 protein (band 6, 55 % sequence coverage) (Appendix, Figure 7.3). However, in 
WB analysis using antibodies from donor 2 (FT) and 8 (FT) on lysed human erythrocytes (ery ghosts) 
no bands were detected (Figure 5.6 C). Thus, we can exclude the possibility that the two semi-
immune donors from Nouna might have antibodies against human erythrocytes.  
 
Figure 5.6: P. falciparum proteins identified by Mass Spec analysis. (A) Two P. falciparum proteins were 
identified by MS: PfMSP-9 (band 3, 15 % sequence coverage) and PfMSP-2 (band 5 & 6, 28 % and 12 % sequence 
coverage, respectively).  (B) Localization of the six bands analyzed by MS. P. falciparum schizont lysate (3d7) 
was separated on a gel via SDS-PAGE and stained with either Coomassie blue or transferred to a nitrocellulose 
membrane and immuno-stained with flow-through IgG (FT, no α-MSP-1 antibodies) from Donor 2 (dilution 1: 
11000) and 8 (dilution 1:5000). Six bands were detected by both approaches and potential proteins were 
identified by Mass Spec at the MS facility in the ZMBH (Heidelberg). (C) Lysed erythrocytes (Ery ghosts) were 
analyzed via Coomassie-staining following SDS-PAGE and western blot immuno-stained with IgG from Donor 8 
FT (dilution 1:5000).   
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5.2.4. Establishment of the ADRB assay in our laboratory 
Antibody-dependent cellular immunity was analyzed via respiratory burst (ADRB) assay (Joos et al., 
2010), based on killing of parasites by reactive oxygen species (ROS) from recruited neutrophils 
(Figure 5.7). The ADRB assay, in which oxygen radicals are measured by chemiluminescence using 
Isoluminol, was established in our lab. A clear chemiluminescence signal was only detected if all 
assay components - P. falciparum merozoites, purified IgG from malaria exposed individuals, freshly 
purified PMNs and Isoluminol - were present. Only background activity was obtained with IgG from 
malaria-naïve individuals (Figure 5.8). The ADRB Index was calculated as previously described (Joos et 
al., 2010; Joos et al., 2015; Perraut et al., 2014) using the chemiluminescence maximum of the curve. 
Interestingly, this readout correlated perfectly with the total area under curve within the first 60 min 
(Pearson correlation coefficient R = 0.996) (Figure 5.9). Furthermore, the ADRB assay showed a 
remarkable reproducibility even if different P. falciparum merozoite and PMN preparations were 
used (intra-assay CV < 6 %, inter-assay CV < 12 %; Figure 5.10). Similar results for ADRB activity were 
obtained with Protein A or Protein G affinity-purified human immunoglobulins (Figure 5.11 A).  
 
                                                             
Figure 5.7: Mechanism of the Antibody-dependent Respiratory Burst (ADRB). Antibodies opsonize merozoites, 
bind to the Fc receptors of neutrophils and cross-link them. Thereby, the neutrophil gets activated and its 
NADPH oxidase produces reactive oxygen species (ROS) by electron transfer to molecular oxygen. ROS can be 
measured via chemiluminescence. 
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Figure 5.8: Controls for the ADRB assay. (A) Chemiluminescence raw data of a semi-immune IgG pool 
opsonizing P. falciparum 3d7 merozoites (orange line) and different controls. Each dot represents the mean of 
duplicate measurements. (B) Calculation of the ADRB Index for all samples shown in A using the maximum value 
of the chemiluminescence curve within the first 30 min. ADRB Index = LU maximum sample / LU maximum semi-
immune IgG pool x 1000. Shown is the mean with SEM. LU: Light units; PMNs: Polymorphonuclear neutrophils; 
IgG naïve: Protein G purified IgG from a malaria-naïve pool (n=4); IgG immune: Protein G purified IgG from 
semi-immune individuals (n=11). 
 
 
 
 
Figure 5.9: Comparison of possible readouts of ADRB data. ADRB raw data are analyzed by either calculating 
the total area under curve (isoluminol as baseline, 0-60min) or by using the chemiluminescence maximum value 
(0-30min). As an example, the ADRB activity of a malaria-naïve IgG Pool (n=4) and a semi-immune IgG Pool 
(n=11, Nouna Pool) against different concentrations of P. falciparum 3d7 merozoites was analyzed using both 
methods; these show a very good correlation (Pearson correlation coefficient R = 0,996).  
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Figure 5.10: Precision of the ADRB assay. ADRB activity against P. falciparum 3d7 and FCB1 merozoites was 
determined in 5 (3d7) or 4 (FCB1) independent experiments with two different analysts. Intra-assay CV was < 6 
%, inter-assay CV was < 12%. Statistical differences were assessed by One Way Anova. Naïve: Protein G purified 
IgG from malaria-naïve individuals (n=4); Nouna: Protein G purified IgG from semi-immune individuals (n=11) 
from Burkina Faso; WHO: Protein G purified IgG from malaria-exposed Kenyan adults (NIBSC code: 10/198; 
(Bryan D, 2014)). 
 
 
Figure 5.11: ADRB activity of IgG purified by affinity chromatography via Protein A or G. (A) ADRB activity of 
IgG from a malaria-naïve European pool (n=4) and from a malaria-exposed African pool (Nouna Pool, n=11) was 
determined against P. falciparum 3d7 merozoites. IgG were affinity-purified either by Protein G (black bars) or 
Protein A (grey bars); no significant difference was determined between the purification methods. Shown is the 
mean of duplicate measurements with SEM. (B) Overview of human immunoglobulins isolated via Protein A or 
Protein G affinity purification and their importance for opsonization. Table from (Murphy, 2014).  
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5.2.5. Correlation of MSP-1 antibody titer with ADRB activity 
Purified IgG from all eleven semi-immune individuals from Burkina Faso can mediate the activation of 
neutrophils and release of ROS (Figure 5.12 A) and, remarkably, ADRB activity of these donors was 
higher than the activity measured with the WHO IgG Pool prepared from malaria-exposed Kenyan 
adults (NIBSC code: 10/198; (Bryan D, 2014); Figure 5.14 A). The level of ADRB activity correlated well 
with antibody levels to MSP-1D (Spearman`s rho r= 0.758, P=0.001) (Figure 5.12 B), MSP-1F (r=0.615, 
P=0.024) and also to P. falciparum schizont lysate (r=0.767, P<0.001) or merozoites (r=0.855, 
P<0.001) (Figure 5.12 C). Thus, MSP-1 specific antibodies may opsonize merozoites and activate 
neutrophils.    
 
 
Figure 5.12: Correlation of ADRB activity with MSP-1 antibody titer. (A) ADRB activity of 11 semi-immune 
individuals and a malaria-naïve pool (n=4) against P. falciparum 3d7 merozoites. Shown is the mean of 
duplicate measurements with SEM. (B) MSP-1 antibody titer in semi-immune sera correlates with ADRB activity 
(Spearman`s rank correlation coefficient r=0.758). (C) Antibody levels to P. falciparum 3d7 schizont lysate (α-
SZL) and merozoites correlate with ADRB activity (Spearman`s rank correlation coefficients r=0.767 and r=0.855, 
respectively). 
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5.2.6. Affinity-purified MSP-1 antibodies opsonize P. falciparum merozoites 
To further examine opsonizing MSP-1 specific antibodies, sera from two semi-immune individuals 
(Donor 2 & 8) were fractionated by antigen affinity purification with MSP-1D. A preparation of MSP-1 
specific antibodies was obtained (Figure 5.13 A and B) while the flow-through (FT) material was 
efficiently depleted, as shown by ELISA (Figure 5.13 B). Importantly, ADRB activity was reduced 
substantially in the FT fraction compared to total IgG and MSP-1 specific antibodies could opsonize 
merozoites and recruit neutrophils (Figure 5.13 D). Interestingly, the same eluate fractions containing 
MSP-1 specific antibodies were not active in the GI assay while MSP-1 depleted sera showed 
undiminished activity (Figure 5.13 C). Thus, MSP-1 specific antibodies from Donor 2 and 8 - though 
not active in the GI assay – were capable of activating neutrophils via opsonized merozoites.  
 
Figure 5.13: MSP-1 as target of opsonizing antibodies. Sera from two semi-immune individuals were 
fractionated by antigen affinity purification to MSP-1D. The fractions were analyzed by Coomassie staining (A) 
and ELISA (B). MSP-1 antibody titers are strongly reduced in MSP-1 depleted IgG (flow-through, FT) and 
enriched in the eluate fraction (E and E conc.). (C) Affinity-purified MSP-1 antibodies do not neutralize the 
parasite. Affinity purified MSP-1 antibodies (E) from donors 2 and 8 did not inhibit parasite growth in vitro while 
MSP-1 depleted sera (FT) showed undiminished activity similar to total IgG (L). (D) Affinity-purified MSP-1 
antibodies opsonize merozoites. ADRB activity is reduced in MSP-1 depleted IgG (FT) compared to the total IgG 
fraction (L). MSP-1 specific IgG (E) can recruit neutrophils. Statistical differences were assessed using One Way 
RM Anova.  
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5.2.7. Establishment of the antigen-reversal ADRB 
An antigen-reversal ADRB assay was established in order to (i) assess if MSP-1 specific antibodies play 
a role in opsonization in all eleven semi-immune individuals from Burkina Faso, (ii) examine potential 
cross-reactivity of the opsonizing antibodies between different P. falciparum strains and (iii) identify 
the MSP-1 processing fragments eliciting opsonizing antibodies. By pre-incubation of serum 
antibodies with recombinant antigens such as MSP-1 the contribution of antigen-specific antibodies 
to ADRB activity could be quantified. Prior to their use in antigen-reversal ADRB, all recombinant 
antigens were pre-tested for their chemiluminescence activity in presence of PMNs and isoluminol 
but in absence of merozoites; all competitors showed only background chemiluminescence activity 
(Figure 5.14 B). Furthermore, pre-incubation of human IgG from semi-immune individuals together 
with control proteins such as BSA did not reduce ADRB activity (Figure 5.14 A) indicating that a 
potential decrease of ADRB activity by pre-incubation of antibodies with MSPs is specific. After 
identifying an appropriate IgG concentration for the antigen-reversal ADRB assay (200 µg/ml for 
human IgG) (Figure 5.15), we determined an adequate competitor antigen concentration by pre-
incubation of IgG from semi-immune individuals with increasing concentrations of MSP-1D followed 
by ADRB. Neutrophil respiratory burst activity decreased substantially even at very low MSP-1D 
concentrations (2 nM) and followed a hyperbolic decay curve (Figure 5.16); to ensure that nearly all 
antigen-specific antibodies are removed, a competitor antigen concentration of 500 nM was chosen.  
 
Figure 5.14: Controls for Antigen-Reversal ADRB. (A) ADRB activity of IgG from 2 malaria-naïve European pools 
(each n=4) in comparison to malaria-exposed donors from Burkina Faso (Nouna Pool, n=11) and from Kenya 
(WHO pool, NIBSC code: 10/198; (Bryan D, 2014)) was determined against P. falciparum FCB1 merozoites. 
Presence of 500 nM BSA does not reduce ADRB activity of semi-immune donors (Nouna IgG Pool, black bars). 
(B) ADRB activity of the indicated competitor antigens (500 nM) alone and in combination with purified IgG 
from 11 semi-immune donors (Nouna pool) but in absence of merozoites was assessed; only background activity 
was detected. Mean values of duplicate measurements are shown; statistical differences were calculated using 
paired t-test.  
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Figure 5.15: Finding an appropriate IgG concentration for Antigen-Reversal ADRB. ADRB activity of Protein G 
purified IgG from 11 semi-immune individuals from Burkina Faso (A) and from rhesus monkeys (n=5) immunized 
3x with rMSP-1D and adjuvant (d70) (B) was analyzed against P. falciparum 3d7 merozoites using different IgG 
concentrations. For antigen-reversal ADRB we used the following IgG concentrations per well: 200 µg/ml for 
human IgG and 50 µg/ml for α-MSP-1D IgG from immunized rhesus monkeys. 
 
 
Figure 5.16: Antigen-Reversal ADRB with increasing concentrations of MSP-1D. Protein G purified IgG from 
two semi-immune donors and rhesus α-MSP-1D antibodies (d70) were tested against P. falciparum 3d7 
merozoites in presence of increasing concentrations of MSP-1D. ADRB activity strongly decreases even at low 
MSP-1D concentrations. The data points fit well (R > 0.9) to a hyperbolic decay curve with 3 parameters. 
 
5.2.8. MSP-1 and MSP-183 are major targets of opsonizing antibodies 
In presence of 500 nM MSP-1D antigen, ADRB activity was strongly reduced in all eleven semi-
immune donors from Burkina Faso. The mean reduction was 58.6 % using P. falciparum (3d7) 
merozoites and 51.7 % using P. falciparum (FCB1) merozoites (Figure 5.17 A and B), indicating a 
strong cross reactivity of MSP-1 specific opsonizing antibodies. Antibody levels to the partially 
conserved MSP-1D processing fragments MSP-183 and MSP-142 were comparable in the eleven 
individuals from Burkina Faso (Figure 5.2). Interestingly, pre-incubation of antibodies from the semi-
immune individuals with 500 nM MSP-183 highly reduced ADRB activity; the mean reduction was 50.2 
% (Figure 5.17 C). Thus, MSP-1 and especially its processing fragment MSP-183 is a major target of 
opsonizing antibodies in individuals with naturally acquired immunity.  
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Figure 5.17: MSP-1 as target of opsonizing antibodies (Antigen-Reversal ADRB) and importance of conserved 
regions. ADRB activity of Protein G purified IgG from 11 semi-immune donors was analyzed against P. 
falciparum 3d7 (A,C) and FCB-1 (B) merozoites in the absence and presence of MSP-1D (A,B) or its processing 
fragment MSP-183 (C). Mean values of duplicate measurements are shown as individual columns and as vertical 
point plot; statistical differences were calculated using paired t-test. Average reduction of mean in presence of 
competitor: 58.6% (MSP-1D, 3d7), 50.2% (MSP-183, 3d7), 51.7% (MSP-1D, FCB1). N: IgG from malaria naïve 
European donors (n=4). 
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5.2.9. Comparison of PfMSPs for their opsonizing activity 
Having established an important role for MSP-1 in eliciting opsonizing antibodies, we aimed to 
compare its contribution to ADRB activity with other merozoite surface antigens. We thankfully 
received the recombinant proteins MSP-3, MSP-9 and MSPDBL-1 from P. falciparum (3d7) produced 
in E.coli from our cooperation partners in Melbourne, Australia (Dr. Clara Lin & Prof. Alan Cowman). 
In absence of merozoites but presence of PMNs, isoluminol and the NA pool, these antigens showed 
only background chemiluminescence activity (Figure 5.14 B) and thus, can be used for antigen-
reversal ADRB experiments. 
Strikingly, ADRB activity against P. falciparum (3d7) merozoites was strongly reduced in all eleven 
semi-immune donors from Burkina Faso in presence of MSP-3 or MSPDBL-1 and – to a lower extent – 
also of MSP-9. The average reduction of mean in presence of 500 nM competitor antigen was 48.2 % 
for MSP-9, 83.8 % for MSP-3 and 89.2 % for MSPDBL-1 (Figure 5.18).  Thus, besides MSP-1 also other 
merozoite surface antigens such as MSP-3, MSP-9 and MSPDBL-1 elicit opsonizing antibodies which 
are able to activate neutrophils and cause respiratory burst.  
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Figure 5.18: Other MSPs as target of opsonizing antibodies (Antigen-Reversal ADRB). ADRB activity of Protein 
G purified IgG from 11 semi-immune donors was analyzed against P. falciparum 3d7 merozoites in the absence 
and presence of MSP-9 (A), MSP-3 (B) and MSPDBL-1 (C). Mean values of duplicate measurements are shown as 
individual columns and as vertical point plot; statistical differences were calculated using paired t-test. Average 
reduction of mean in presence of competitor: 48.2 % (MSP-9), 83.8 % (MSP-3), 89.2 % (MSPDBL-1). N: IgG from 
malaria naïve European donors (n=4). 
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5.2.10. Immunization with recombinant MSP-1D induces opsonizing antibodies in         
 rhesus monkeys 
Purified IgG from rhesus monkeys (n=5), immunized three times with recombinant MSP-1D and 
adjuvant (CoVaccine HT), were examined by antigen-reversal ADRB assay for opsonizing antibodies 
directed against MSP-1D and MSP-183. Sera were sampled two weeks (d70) and > 4 months (d182) 
after third immunization. Antibody levels against MSP-1D were comparable in immunized rhesus 
monkeys (d70) and the NA pool (Appendix, Figure 7.2). Interestingly, the observed high ADRB activity 
induced by immunization with MSP-1D was similar to the activity found for the NA pool (Figure 5.19) 
and was efficiently competed out by pre-incubating the IgG with 500 nM MSP-1D; a substantial 
decrease was also observed after pre-incubation with 500 nM MSP-183 (Figure 5.20). Comparable 
results were obtained with P. falciparum 3d7 or FCB1 strains. Remarkably, ADRB activities were 
similar at d70 and d182 (Figure 5.19) indicating that immunization of non-human primates with MSP-
1D apparently induces a long-lasting antibody response capable of opsonizing P. falciparum 
merozoites.  
In summary, both natural exposure against malaria and immunization of rhesus monkeys with 
recombinant MSP-1D elicits antibodies against MSP-1 and its processing fragment MSP-183, which are 
effective in merozoite opsonization and neutrophil activation.  
 
 
Figure 5.19: Immunization with MSP-1D elicits opsonizing antibodies in rhesus macaques. Rhesus monkeys 
(n=5) were immunized three times (d0, d28, d56) with recombinant MSP-1D and adjuvant (CoVaccine HT). Blood 
was sampled at d0, d70 and d182. ADRB activity of Protein G purified IgG from blood was analyzed against P. 
falciparum 3d7 (A) and FCB1 (B) merozoites. d0: pre-immune control IgG. Human IgG Pool: Protein G purified 
IgG from 11 semi-immune individuals from Burkina Faso. Statistical differences were assessed by One Way RM 
Anova. 
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Figure 5.20: Antigen-Reversal ADRB with rhesus MSP-1D antibodies and MSP-1 competitors. Protein G 
purified IgG from rhesus monkeys (n=5) immunized 3x with MSP-1D (d70) were analyzed for opsonizing activity 
to 3d7 (A) and FCB1 (B) merozoites in presence of 500nM MSP-1D or MSP-183. Shown are the means of two 
independent experiments, each with duplicate measurements. Statistical differences were assessed using One 
Way Anova. 
 
  
A B 
Results
 
88 
 
5.3. Cellular immune response against PfMSP-1D in individuals with 
naturally acquired immunity 
5.3.1. Identification of CD8+ T-cell epitopes within MSP-1D 
Since MSP-1 is initially synthesized in infected hepatocytes at late liver stage (Szarfman et al., 1988), 
it can be a target of the cellular immune response. HLA-A0201 restricted CD8+ T-cell epitopes have 
already been identified within MSP-1D in the laboratory of Prof. H. Bujard (Carralot et al., 2008; Idler, 
2004) (Table 5.2; Figure 5.21) using two different approaches: (i) In silico prediction of potential CD8+ 
T-cell epitopes within MSP-1D for the HLA haplotype A0201 by the computer program SYFPEITHI 
(Rammensee et al., 1999). The in vivo relevance of the predicted epitopes was analyzed in HHD mice 
which express the human HLA-A0201 receptor. These mice were vaccinated with MSP-1D and MSP-1 
specific CD8+ T cells were discovered via tetramer technology. The strongest response was detected 
for epitope 291 (Idler, 2004). (ii) MSP-1D was tetracyclin-inducible expressed in a cell line positive for 
HLA-A0201; the CD8+ T-cell epitopes presented under physiological conditions were eluted and 
identified by MS. Via this strategy epitope 674 was discovered (Carralot et al., 2008). CD8+ T-cell 
epitopes with a high binding score were synthesized and the most promising peptides - 291, 374, 437 
and 674 (according to (Idler, 2004; Jäschke, 2012) - were used in this thesis (Figure 5.21).  
 
Epitope Sequence Aa position Binding score MW [Da] Location 
182 Y YLLRAKLNDV 182 26 1204,7 p83/30 
313  KLLDKINEI 313 30 1085,3 p83/30 
162  YLIDGYEEI 162 27 1114,2 p83/30 
674  KLKEFIPKV 674 30 1101,7 p83/30 
291 GLHHLITEL 1180 28 1032,6 p38/42 
374 SLLTELQQV 1263 28 1030,6       p38/42 
437 VIYLKPLAGV 1326 27 1072,7 p38/42 
Table 5.2: Overview of MSP-1 specific CD8+ T-cell epitopes for the HLA haplotype A0201. The peptides were 
discovered previously (Carralot et al., 2008; Idler, 2004); four epitopes are located within MSP-183/30 (light grey) 
and three within MSP-138/42 (dark grey). The binding score was derived from SYFPEITHI.  
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Figure 5.21: Location of MSP-1 specific CD8+ T-cell epitopes for the HLA haplotype A0201. Schematic depiction 
of MSP-1 with subunits, processing sites (small arrows) and regions of different degree of conservation. HLA-
A0201 restricted CD8+ T-cell epitopes are indicated (large arrows), enframed peptides were used in this study.  
 
 
5.3.2. MSP-1 specific CD8+ T-cell response in semi-immune individuals 
The identified CD8+ T-cell epitopes within MSP-1D – 291, 374, 437 and 674 (Figure 5.21) – were used 
to examine the CD8+ T-cell response of the semi-immune individuals from Nouna via IFNγ ELISPOT 
assay. Additionally, PBMCs from malaria-naive European donors were analyzed as controls. All 
individuals have the same HLA haplotype A0201.  
Unfortunately, the quality of the cryopreserved PBMCs from the Nouna donors was quite bad: 60 % 
of the samples tested contained only dead cells, the apoptosis rate within 24 h after thawing was > 
50 % and PBMCs from three donors were contaminated with bacteria. Nevertheless, PBMCs from 
three donors (Donor 2, 7 and 8) were of sufficient quality and could be analyzed by IFNγ ELISPOT 
assay after stimulation with the respective MSP-1 specific peptides. Interestingly, all of them 
recognized the CD8+ T-cell epitopes from MSP-1 (Figure 5.22 A). Although one of four malaria-naïve 
individuals also reacted to peptide 291 (Figure 5.22 B), the overall MSP-1 specific CD8+ T-cell 
response of the semi-immune individuals from Nouna (n=3) was significantly higher compared to 
malaria-naive individuals (n=4) for the peptide pool 291+374+437 and for peptide 674 (P=0.023 and 
P=0.000135, respectively) (Figure 5.22 C and D). Thus, CD8+ T-cell epitopes within MSP-1D were 
recognized by individuals with naturally acquired immunity.  
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Figure 5.22: MSP-1 specific CD8+ T-cell response in semi-immune and malaria-naive individuals. CD8+ T-cell 
response of 3 semi-immune individuals (A) and 4 malaria-naive individuals (B) to the MSP-1 specific epitopes 
291, 374, 437 and 674; a monoclonal antibody against CD3 was used as positive control. Cryopreserved PBMCs 
from each individual were stimulated with MSP-1 derived peptides (10 µg/ml) and their activation was 
measured by 24h pre-cultered IFNγ-ELISPOT assay. The net number of Spot Forming Cells (SFCs) in one million 
PBMCs is shown +/- SEM. (C) Comparison of CD8+ T-cell activation between semi-immune (n=3) and malaria-
naïve (n=4) individuals following stimulation of PBMCs with the indicated MSP-1 specific peptides. Statistical 
analysis was performed via t-test. (D) Selected ELISPOT wells from 3 semi-immune and 2 malaria-naïve 
individuals showing the CD8+ T-cell response against MSP-1 derived peptides or the positive control CD3. Each 
blue spot represents a cell secreting IFNγ.  
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5.3.3. HLA-independent analysis of the MSP-1 specific T-cell response using 
peptide pools 
Since we aimed to examine the MSP-1 specific CD8+ T-cell response in larger cohorts which are not 
HLA-typed, HLA independent methods were investigated. One possibility is the use of MSP-1 specific 
peptide pools covering many important HLA-types. Thus, potential HLA binding epitopes within MSP-
1D were predicted to the most frequent HLA-types by the Artificial Neural Networks (ANN) algorithm 
(Honeyman et al., 1998). 161 CD8+ T-cell epitopes (nonamers) within MSP-1D were predicted to the 
most frequent HLA-types in Mali; their location is distributed quite equally throughout the whole 
MSP-1 molecule (Figure 5.23 A). No region with especially high prevalence of CD8+ T-cell epitopes 
could be detected – a disadvantage for creating peptide pools since considering the whole MSP-1 
protein for peptide synthesis would be very expansive.   
Furthermore, HLA-frequencies show a wide variety between different countries, such as Mali and 
Germany (Figure 5.23 B and C). Only two HLA haplotypes are present in both populations (HLA-A0201 
and C0401). Thus, separate peptide pools would have to be synthesized for individuals from different 
countries e.g. Germany and Mali. Since the approach with peptide pools covering full-length MSP-1 is 
expensive and time-consuming, the whole protein was tested via ELISPOT assay. 
 
 
Figure 5.23: Distribution of CD8+ T-cell epitopes within MSP-1D and HLA-frequencies. (A) MSP-1 specific CD8+ 
T-cell epitopes to the most frequent HLA-types in Mali: 161 strong  and weak  binding CD8+ T-cell epitopes 
(nonamers) within MSP-1D were predicted by the Artifical Neural Networks (ANN) algorithm. Their location 
within MSP-1 is indicated (black bars). (B) HLA allele frequencies in Mali and Germany. HLA allele frequencies 
were derived from the “allele frequency net” database which used the bone marrow registry (n ≈ 40 000) for 
Germany and an anthropology study (n = 138; (Cao et al., 2004)) for Mali. Only HLA-A0201 and C0401 are 
present in both populations. 
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5.3.4. HLA-independent analysis of the MSP-1 specific T-cell response using 
recombinant MSP-1D  
The use of recombinant proteins such as full-length MSP-1D for analysis of the MSP-1 specific T-cell 
response has several advantages: (i) it is independent from the HLA type of the blood donor, (ii) it is a 
much easier and cheaper approach compared to peptide pools and (iii) it is likely that the protocol 
can be easily adapted to other recombinant antigens such as MSP-1F, MSP-6 or MSP-7, if they are 
available in sufficient quality - e.g. without endotoxins - and quantity. 
 
 
Figure 5.24: T-cell response against recombinant MSP-1D protein. (A) Cryopreserved PBMCs of the cross-
reactive malaria-naïve donor were stimulated with the indicated peptides (10 µg/ml) or MSP-1D protein (1 
µg/ml, 5 µg/ml, 10 µg/ml) either with or without a 24h pre-incubation step in presence of the respective stimuli 
and following IFNγ ELISPOT assay. Positive control: mAb CD3. Selected ELISPOT wells are shown; each blue spot 
represents a cell secreting IFNγ.  (B) Diagram showing the net number of Spot Forming Cells (SFCs) in one million 
PBMCs +/- SEM. PBMCs were stimulated with either MSP-1 peptides or recombinant MSP-1D protein at the 
indicated concentrations and – partly following a 24h pre-incubation step in presence of the stimuli - analyzed 
via IFNγ ELISPOT assay. 
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I successfully adapted the IFNγ ELISPOT protocol for the use of full-length MSP-1D protein. PBMCs 
from the cross-reactive malaria-naïve donor were stimulated with either MSP-1 specific peptides 
(291, 374, 437 and 674; 10 µg/ml) or MSP-1D protein (1 µg/ml, 5 µg/ml or 10 µg/ml) and analyzed by 
IFNγ ELISPOT assay. Importantly, the approach with MSP-1D protein requires a pre-incubation step 
(24 h) in presence of MSP-1D prior to the ELISPOT assay while for MSP-1 specific peptides this step 
could be omitted (Figure 5.24). A strong response was detected with 5 µg/ml and 10 µg/ml MSP-1D if 
pre-incubated for 24 h.   
The other three malaria-naïve individuals were also tested with MSP-1 specific peptides and MSP-1D 
protein but - as expected – showed no reaction. Due to insufficient quality of PBMCs from the Nouna 
donors, which contain no antigen presenting cells like monocytes or dendritic cells in contrast to the 
malaria-naïve PBMC preparations (Appendix, Figure 7.4), MSP-1D protein could not be processed and 
presented to T-cells and thus, no IFNγ response was detected.      
 
5.3.5. Planned analysis of PBMCs from a large cohort in Mali  
In cooperation with Prof. O. Doumbo and Prof. B. Kouriba (MRTC, University of Bamako) we aimed to 
investigate the MSP-1 specific T-cell response in a cohort of 210 children (2-15 years) from Samako, a 
malaria-hyperendemic village with strong seasonal malaria transmission in Mali, West-Africa. From 
each study participant several blood samples were available taken before, during and after 
transmission season over a two year period (2011-2013). Since the volunteers differed in age and 
detailed health records were available, we wanted to study a possible connection between MSP-1 
specific immune response and acquired immunity against malaria.  
Unfortunately, the Mali cohort could not be employed for analysis of the cellular immune response 
since all cryopreserved PBMCs which arrived in Heidelberg (~1400 tubes) were unusable. Samples 
from all available time-points and from different donors were tested directly after thawing for their 
viability by light microscopy (trypanblue staining) and by flow cytometry (staining with propidium 
iodide) (Figure 5.25). From eleven samples tested, nine contained no viable cells and two less than 20 
%. In contrast, cryopreserved PBMCs from Heidelberg which were thawed in parallel and treated the 
same had a viability rate of about 99 % (Figure 5.25). Thus, so far a correlation between MSP-1 
specific T-cell responses and protection against malaria could not be analyzed since appropriate 
PBMC samples at sufficient quality were not available.  
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Figure 5.25: Viability of PBMCs from Mali determined by microscopy and flow cytometry. (A) Cryopreserved 
PBMCs from one malaria-naïve donor from Heidelberg and three donors from Mali were thawed, stained with 
trypanblue and analyzed by light microscopy. Viable (white) and dead (blue) cells were counted using a 
Neubauer hemocytometer and the viability rate was calculated. Representative images are shown (40x 
magnification, 3x camera zoom). (B/C) Cryopreserved PBMCs from one malaria-naïve donor from Heidelberg 
and two donors from Mali were thawed, stained with Propidiumiodide-PE for 20 min and analyzed by FACS. 
Percentages are calculated from total events. In the forward / side scatter cells are sorted according to their size 
and granularity; living cell populations could only be detected for the malaria-naïve donor. The respective 
Propidiumiodide-PE staining is shown under each image. Propidiumiodide stains only dead cells.    
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5.4. Immune response after controlled human malaria infection 
(TUECHMI I) 
TUECHMI I, a controlled human malaria infection study in Tübingen, was carried out in 2011/2012 in 
order to establish a standardized malaria infection of humans. 30 malaria-naïve adult volunteers (18 - 
55 years) were challenged with 50 to 3200 cryopreserved, GMP-graded PfSpz (NF54 strain) from 
Sanaria by either intravenous or intradermal injection (Figure 5.26 B). Blood was sampled at different 
time points and – upon detection of blood stage parasites by microscopy (thick blood smear) - 
volunteers were treated immediately with ACT (Lumefantrine-Artemether) (Figure 5.26 A). In total, 
22 out of 30 PfSpz infected volunteers developed malaria with a pre-patency time period of 10 – 15 
days while 6 non-infected individuals remained malaria-negative. 100 % of volunteers (9/9) in the 
highest dose group (3200 PfSpz i.v.) were malaria-positive (Figure 5.26 B) (Mordmuller et al., 2015).  
This standardized clinical study allowed us to investigate the human immune response induced by 
experimental P. falciparum wildtype sporozoite infection. In cooperation with Dr. Kirsten Heiss and 
Dr. Ann-Kristin Müller, we examined the CD8+ T-cell response to the liver stage antigens LSA-1 and 
CSP and the cross-stage antigen MSP-1 via IFNγ ELISPOT assay. Additionally, I analyzed the antibody 
levels to the merozoite surface antigens MSP-1, MSP-6 and MSP-7 via ELISA. Moreover, a cytokine 
profile was created via cytokine bead array by our cooperation partner in Munich (Dr. Michael 
Pritsch). The malaria antigens examined in this study and their expression throughout the 
Plasmodium life cycle are shown below (Figure 5.26 C).  
5.4.1. Antibody response after single Pf sporozoite infection 
Serum antibody titer against MSP-1, MSP-6 and MSP-7 were analyzed by ELISA at different time 
points after sporozoite infection. MSP-1 antibodies could be detected in 12 out of 19 malaria positive 
volunteers at day 28 post infection (Figure 5.27 A) and they were still present at day 84 and even at 
day 168 (Figure 5.27 A and E), thus the elicited MSP-1 antibodies were quite long-lived. However, 
compared to the MSP-1 antibody levels of the semi-immune individuals from Nouna, the antibody 
titer after single sporozoite infection is much lower (average titer of 6500 versus highest titer of 136, 
respectively). 
Antibody levels against MSP-6 and MSP-7 were measured in the 3200 PfSpz group (n=9) at the day 
before challenge (C-1), day 11 and day 28 post infection. Despite a “background titer” present 
already at C-1 for both MSP-6 and MSP-7 - probably due to cross-recognition of other antigens - 
there was a significant increase in antibody levels against both antigens at day 28 (Figure 5.27 B, C 
and D). Thus, a single infection with PfSpz elicits antibodies against MSP-1, MSP-6 and MSP-7 with 
MSP-1 being more immunogenic as MSP-6 and MSP-7 (Figure 5.27 D). 
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Figure 5.26: Study design of TUECHMI I and malaria antigen-specific immune responses investigated. (A) 30 
volunteers (18-55y) were challenged with cryopreserved P. falciparum NF54 sporozoites. Blood samples were 
taken one day prior infection (C-1) and on several time points after infection (d5 to d84). Upon detection of 
blood stage parasites by microscopy, volunteers were treated with Lumefantrine-Artemether. (B) Malaria-naïve 
volunteers received different doses of cryopreserved Pf NF54 sporozoites i.v. (50, 200, 800, 3200) or one dose 
i.d. (2500). The number of volunteers who showed blood stage parasites in the blood and their pre-patency time 
is indicated and depends on the Pf sporozoite dose. (C) Malaria antigens analyzed in this study and their 
expression in different stages of parasite infection. CSP is present on the surface of sporozoites and can be 
detected in early liver stages; the cross-stage antigen MSP-1 is expressed in late liver stages and blood stages. 
LSA-1 expression is restricted to liver stages. Using PBMCs and sera from the volunteers of this study, the 
cellular immune response against CSP, LSA-1 and MSP-1 as well as the humoral immune response against MSP-
1/-6/-7 was analyzed. Picture modified from (Michalakis and Renaud, 2009).  
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Figure 5.27: Antibody levels to MSP-1, -6 and -7 of TUECHMI volunteers (A) Anti-MSP-1 antibody titer 
determined by ELISA to recombinant MSP-1D for malaria positive TUECHMI volunteers (n=19) and malaria-
naïve controls (n=5) at four different time points. The individuals were grouped according to their Pf sporozoites 
dose received (naïve, 2500 id, 50 iv, 200 iv, 800 iv, 3200 iv) (B/C) Anti-MSP-6 and -7 antibody titer. The malaria-
positive 3200 sporozoite group (9 volunteers) was tested by ELISA to recombinant MSP-636 and MSP-722 at time 
point C-1 and d28. (D) Comparison of antibody titers to MSP-1/-6/-7 before (C-1) and after (d28) the Pf 
sporozoite injection in the 3200 sporozoite i.v. group (n=9). There was a significant increase in mean titers for all 
MSPs tested using paired t-test. (E) Development of the MSP-1 antibody titer over time from the day before 
challenge (C-1) until day 168 for one malaria-positive TUECHMI volunteer. The antibody titer peaks at day 28.  
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5.4.2. CD8+ T-cell response after single Pf sporozoite infection 
PBMCs from the malaria-positive 3200 PfSpz group (n=9) were analyzed at different time-points for 
the presence of CD8+ T-cells targeting MSP-1, LSA-1 and CSP via IFNγ ELISPOT assay. The antigen-
specific peptide pools used for this experiment are described in detail in the method section (chapter 
4.11.2.); for MSP-1 we used the HLA-A0201 restricted peptides 291, 374, 437 and 674.  
Antigen-specific CD8+ T-cells could be detected against MSP-1, CSP and LSA-1 in three out of nine 
individuals (Volunteer 5, 40 and 44; Figure 5.28). Importantly, MSP-1 shows a comparable CD8+ T-cell 
response as the known liver stage candidate antigens LSA-1 and CSP (Figure 5.28). However, the 
CD8+ T-cell response detected after single PfSpz infection was much lower compared to the response 
of the semi-immune individuals from Nouna (maximum 300 versus ~2200 net SFUs per 106 PBMCs, 
respectively). MSP-1 and LSA-1 specific stimulation of CD8+ T-cells occurs later than for CSP, 
according to their expression in late liver stages (highest response on day 10-12 versus day 7 post 
infection, respectively; Figure 5.28). Cytokine bead array analysis showed a balanced cytokine profile 
in the serum of volunteers infected with 3200 PfSpz (n=9). The concentration of the pro-
inflammatory cytokine IFNγ was below the detection limit (Appendix, Figure 7.5).  
 
 
Figure 5.28: Antigen-specific CD8+ T-cell response to LSA-1, CSP and MSP-1. Cryopreserved PBMCs from 9 
malaria-positive individuals who received 3200 PfSpz i.v. were stimulated with peptide pools derived from LSA-
1, CSP and MSP-1 and analyzed by 24h pre-cultured IFNγ ELISPOT assay. The net number of IFNγ-secreting cells 
(SFU: spot forming units) in 10
6
 PBMCs is shown for each individual at different time points (C-1, day 5/7/9/10-
12/28). For statistical analysis Mann-Whitney test was applied.  
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6.  Discussion 
Since around thirty years the merozoite surface protein MSP-1 has been under consideration as 
malaria vaccine candidate. Its essential role in Plasmodium blood stages (O'Donnell et al., 2001) for 
erythrocyte invasion (Baldwin et al., 2015; Blackman et al., 1990; Woehlbier et al., 2006) as well as 
erythrocyte rupture and merozoite egress (Das et al., 2015) support the candidacy of this protein. 
Furthermore, a protective potential of MSP-1 has been suggested by various epidemiological studies 
in malaria endemic regions (al-Yaman et al., 1996; Conway et al., 2000; Egan et al., 1996; Tolle et al., 
1993) as well as by immunization experiments in mice (Holder and Freeman, 1981) and monkeys 
(Etlinger et al., 1991; Kumar et al., 1995; Perrin et al., 1984; Siddiqui et al., 1987; Singh et al., 2006). 
Even though MSP-142 could not convince so far in clinical trials assessing protective efficacy of 
vaccination (Ogutu et al., 2009; Sheehy et al., 2012), several studies show that other regions within 
MSP-1 might be important for protection (Carralot et al., 2008; Cavanagh et al., 2004; Conway et al., 
2000; Früh et al., 1991; Galamo et al., 2009; Idler, 2004; Muller et al., 1991; Siddiqui et al., 1987; 
Tolle et al., 1993).  
The recent successful production of recombinant MSP-1D under GMP conditions allows us to study 
the potential of full-length MSP-1 as vaccine candidate against malaria. However, the epitopes within 
MSP-1 eliciting protective antibodies or T-cells and their immune mechanisms have not been clearly 
identified. For a vaccine candidate currently in clinical phase I trials, it is important to know how the 
protein is targeted by the human immune response and also to have suitable in vitro assays available 
to measure functional activity. Thus, the focus of this work was to analyze the human antibody and 
T-cell response against MSP-1D in individuals with naturally acquired immunity against malaria and in 
malaria-naïve volunteers experimentally infected with Pf wildtype sporozoites. Furthermore, 
appropriate functional in vitro assays have been established in our laboratory which can be used for 
immunological investigations during the clinical trials.   
6.1. Humoral immune response against MSP-1D 
The importance of antibodies for protection against malaria was already established in 1961 by 
passive transfer experiments of immunoglobulins (Cohen et al., 1961). However, their antigenic 
targets and protective mechanisms remain unclear but are urgently needed for malaria vaccine 
development. Correlations between direct growth inhibition of Plasmodium blood stages in vitro - as 
measured in the GIA – and protection against malaria have been weak and inconsistent (reviewed in 
(Duncan et al., 2012)), suggesting that protective antibodies may act via other functional 
mechanisms.  
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Indeed, recent studies strongly implicate the importance of opsonizing antibodies for naturally 
acquired immunity (Boyle et al., 2015; Chiu et al., 2015; Hill et al., 2013; Hill et al., 2016; Joos et al., 
2010; Osier et al., 2014a; Tiendrebeogo et al., 2015). In this work, serum antibodies of semi-immune 
adults from Nouna, Burkina Faso, were analyzed for their ability to directly inhibit the growth of P. 
falciparum blood stages in vitro and also to opsonize Plasmodium merozoites and elicit neutrophil 
respiratory burst. Additionally, the contribution of MSP-1 specific antibodies to GIA and ADRB activity 
was determined and compared to other merozoite surface proteins.  
6.1.1. Growth inhibitory potential of MSP-1 specific antibodies 
Most studies so far have analyzed the direct growth inhibitory potential of MSP-1 specific antibodies 
in vitro although a correlation between this mechanism and protective immunity remains elusive. 
Furthermore, it is controversial whether or under which circumstances MSP-1 contributes to direct 
growth inhibition of Plasmodium blood stages since some publications reported MSP-1 specific GI 
activity (Bergmann-Leitner et al., 2009; Bergmann-Leitner et al., 2006; Blackman et al., 1990; 
Blackman et al., 1994; Egan et al., 1999; O'Donnell et al., 2000; Singh et al., 2006; Woehlbier et al., 
2006) and others presented contradicting data (Bouharoun-Tayoun et al., 1990; Kumar et al., 1995; 
Malkin et al., 2007; McCallum et al., 2008; Wilson et al., 2011).  
In this study, serum antibodies from four out of eleven semi-immune African adults showed growth 
inhibitory activity in vitro but only for the individual with the highest MSP-1 antibody titer (Donor 6) a 
contribution of MSP-1 specific antibodies of about 50 % to total GI activity could be detected. 
Interestingly, affinity-purified antibodies against MSP-183 of the same individual efficiently inhibited 
growth of P. falciparum blood stages in vitro (Woehlbier et al., 2006) supporting my results gained 
via antigen-reversal GIA. The latter was established during this work in our laboratory as an effective 
and quite easy approach how to measure the contribution of antigen-specific antibodies to total 
growth inhibitory activity in vitro. Since only a small amount of serum and recombinant antigen is 
required, it could be used to examine also other merozoite surface proteins.  
The different outcomes regarding MSP-1 specific GI activity both in the previous studies as well as in 
this work could have several reasons: Firstly, there could be different IgG isotypes or affinities of 
antibodies targeting MSP-1 which partly inhibit parasite growth in vitro. Secondly, antibodies may 
target various MSP-1 epitopes and only some may have growth inhibitory potential. In rabbits 
immunized with MSP-1D it appears that about half of the antibodies active in the GIA are cross-
reactive and about 30 % target MSP-142 - as shown via antigen-reversal GIA. However, no remarkable 
differences could be detected between the semi-immune African donors regarding the relative 
distribution of their antibodies to the MSP-1 subunits. Thirdly, the MSP-1 antibody titer may be too 
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low for detectable GI activity in the in vitro assay. The latter is a very reasonable possibility since high 
antibody levels are necessary for direct growth inhibitory activity in vitro (Wilson et al., 2011), 
although this might not reflect the in vivo situation. However, a threshold level of antibodies 
targeting merozoite proteins is also required for clinical immunity against malaria (Murungi et al., 
2013).   
6.1.2. Search for new antigens eliciting growth inhibitory antibodies by MS 
Several merozoite proteins inducing growth inhibitory activity against P. falciparum blood stages in 
vitro are known so far, such as MSP-119 (Blackman et al., 1990; Egan et al., 1999; O'Donnell et al., 
2001), MSP-183 (Woehlbier et al., 2006), AMA-1 (Dutta et al., 2003), PfRh5 (Douglas et al., 2014), EBA-
175 (Badiane et al., 2013) GLURP (Pratt-Riccio et al., 2011), MSPDBL-1 (Chiu et al., 2015; Sakamoto et 
al., 2012) and MSPDBL-2 (Chiu et al., 2015). Most of these results were obtained using recombinant 
proteins and are thus restricted to certain antigens. An unbiased approach to identify potentially 
unknown antigenic targets of naturally acquired antibodies would include the separation of P. 
falciparum schizont lysate via SDS-PAGE, followed by western blot analysis using serum antibodies 
from semi-immune individuals and identification of recognized antigens by mass spectrometry 
(Eisenhut, 2007).  
Since the observed in vitro growth inhibitory activity of two semi-immune adults from Nouna (Donor 
2 & 8) was definitely independent from MSP-1 specific antibodies, we aimed to identify potentially 
unknown target antigens which might be responsible for the detected GI activity using the unbiased 
method described above. However, due to the presence of erythrocytes in the P. falciparum schizont 
lysate preparation, most of the proteins detected by MS belong to human RBCs e.g. spectrin, flotillin 
or band 3 anion transport protein. Although antibodies against the latter are naturally occurring and 
supposedly play a role in clearance of Plasmodium infected erythrocytes (Pantaleo et al., 2008), no 
bands were detected using lysed erythrocytes and the same antibody preparations from the two 
semi-immune donors. Thus, all human proteins detected by MS are not targeted by these antibodies. 
Instead, it is likely that Plasmodium proteins running at about the same position could not be 
detected by mass spectrometry since they were much less abundant compared to the erythrocyte 
proteins.   
However, two P. falciparum proteins were revealed by MS analysis as potential targets of growth 
inhibitory antibodies: MSP-2 and MSP-9. MSP-2 is an approximately 27 kDa GPI-anchored protein, 
which is highly abundant on the merozoite surface and essential for Plasmodium blood stages 
(Beeson et al., 2016). Antibodies against MSP-2 have been associated with naturally acquired 
protection (al-Yaman et al., 1994) and can act via opsonic phagocytosis (Osier et al., 2014a), ADCI 
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(McCarthy et al., 2011), in cooperation with complement factors (Boyle et al., 2015) and high 
antibody levels have also been associated with growth inhibitory activity in vitro (Courtin et al., 
2009). In a Phase IIb clinical trial in children from PNG in combination with MSP-1 and RESA 
(Combination B vaccine) it showed protective efficacy against the parasite, albeit only strain-specific 
(Genton et al., 2003; Genton et al., 2002). A major obstacle to MSP-2 based vaccine design appears 
to be its high polymorphism (Fenton et al., 1991). 
 MSP-9 (ABRA), a 101 kDa protein on the surface of merozoites and the parasitophorous vacuole, 
binds in a complex with MSP-142 (Li et al., 2004) to band 3 on human erythrocytes and is involved in 
RBC invasion (Beeson et al., 2016). Although MSP-9 is considered as vaccine candidate against 
malaria, no reports are available about growth inhibitory antibodies targeting this protein. 
Furthermore, there is no vaccine development at clinical stage for MSP-9 (Beeson et al., 2016).   
For future research, a better separation of the proteins from P. falciparum schizont lysate or 
merozoites using 2D electrophoresis would probably benefit the identification of Plasmodium 
proteins by MS. However, this step would also require more material (Plasmodium schizont lysate or 
merozoites) and special equipment. Furthermore, the erythrocytes present in the parasite schizont 
preparation should be completely removed in order to enable MS identification of low-abundant 
Plasmodium proteins.  
6.1.3. Correlation between neutrophil respiratory burst and protection 
Besides direct growth inhibition of Plasmodium blood stages we were interested whether MSP-1 
specific antibodies may be able to opsonize Plasmodium merozoites and recruit immune effector 
cells. Antibodies which opsonize P. falciparum merozoites and mediate the release of reactive 
oxygen species (ROS) from neutrophils can be measured in the antibody-dependent respiratory burst 
(ADRB) assay (Joos et al., 2010) (Figure 5.7). Oxidant damage mediated by ROS can kill the parasite 
(Allison and Eugui, 1983; Brown and Smalley, 1981; Clark and Hunt, 1983; Golenser et al., 1992; 
Gopalakrishnan and Kumar, 2015) and is associated with protection against malaria (Friedman, 1979; 
Greve et al., 1999; Joos et al., 2010). Interestingly, the antimalarial drugs mefloquine and artesunate 
cause parasite death by generation of ROS (Gopalakrishnan and Kumar, 2015; Gunjan et al., 2016) 
and ROS also protects against severe malaria in sickle and fetal erythrocytes (Cyrklaff et al., 2016) as 
well as in thalassemic and G6PD deficient red blood cells (Friedman, 1979). However, if high ROS 
secretion might also play a role in malaria complications such as anemia (Greve et al., 2000) requires 
further investigation.  
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ROS secretion from neutrophils can be induced by merozoite-specific antibodies (Joos et al., 2010; 
Kumaratilake et al., 1992; Salmon et al., 1986). Since neutrophils constitute the largest group of 
blood leukocytes in mammals and are highly mobile phagocytes, they represent possible immune 
effector cells. Furthermore, ROS production and release by neutrophils happens very fast – the peak 
of chemiluminescence activity measuring ROS was detected after approximately 2 minutes (Joos et 
al., 2010) – and thus, it is plausible that ROS can kill Plasmodium merozoites, which in vitro remain 
free after schizont rupture for several minutes before invading a new erythrocyte (Boyle et al., 
2010b). Additionally, reactive oxygen species can probably target Plasmodium parasites also inside 
erythrocytes (Allison and Eugui, 1983; Clark and Hunt, 1983; Greve et al., 1999).  
Interestingly, in malaria endemic regions higher age (Perraut et al., 2014) and a more diverse anti-
merozoite antibody repertoire (Murungi et al., 2016) promote ADRB activity suggesting that it plays a 
role in naturally acquired immunity. Indeed, ADRB activity correlates with protection from clinical 
malaria in meso- and holoendemic areas in Senegal (Joos et al., 2010) as well as with protection 
against severe malaria in Kenyan children within the first 6 month of life (Murungi et al., 2017). 
Furthermore, in 28 Kenyan volunteers experimentally infected with Pf sporozoites, only the 
individual showing the highest ADRB activity could remarkably reduce parasite multiplication and 
parasites were not detectable in the blood by microscopy up to day 21 (Hodgson et al., 2016). 
Despite a poor correlation between ADRB and GIA activity (Murungi et al., 2016; Osier et al., 2014a), 
total IgG active in both assays is associated with protection against severe malaria in Kenyan children 
(Murungi et al., 2016). Thus, protective immunity may result from a combination of antibody-
mediated mechanisms.  
6.1.4. Establishment of the ADRB and antigen-reversal ADRB assay 
In this work, the ADRB assay (Joos et al., 2010) was successfully established in our laboratory and a 
much higher activity was observed with serum antibodies derived from semi-immune African 
individuals compared to malaria-naïve volunteers. Furthermore, the assay showed a good 
reproducibility, even with different P. falciparum merozoite and neutrophil preparations. For 
detection of neutrophil respiratory burst we employed the chemiluminescent reagent isoluminol 
which particularly detects extracellular ROS (Dahlgren and Karlsson, 1999); the latter is considered to 
be especially toxic for Plasmodium parasites (Allison and Eugui, 1983; Clark and Hunt, 1983; Greve et 
al., 1999).  
Interestingly, remarkably lower antibody concentrations were required (about 40-fold) compared to 
the GIA assay. The antibody subtypes IgG1 and IgG3 are considered as the main actors against 
Plasmodium merozoites (Reiling et al., 2010; Richards et al., 2010) and - by interaction with the Fc 
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receptor of immune cells or with complement factors - they are supposed to be responsible for 
opsonic phagocytosis by monocytes (Osier et al., 2014a), complement-dependent inhibition (Boyle et 
al., 2015) and ADRB activity (Joos et al., 2010). However, comparable ADRB activity was obtained 
with Protein A or Protein G affinity-purified antibodies although human IgG3 is only purified via 
Protein G chromatography. Thus, IgG1 seems to be most important for ADRB activity. Alternatively, 
the opsonizing capacity of IgG3 might be replaced by the lower opsonizing potential of IgA and/or 
IgM for sera purified via Protein A (Figure 5.11 B). The induction of neutrophil respiratory burst by 
IgA has been reported (Shi et al., 2011).  
Limitations of the ADRB assay include: (i) Neutrophils are quite short-lived with a half-life of 6-8 
hours in vivo and thus, need to be purified freshly from human volunteers and used within one hour 
after purification for the ADRB assay. (ii) Since antibodies have to match human Fcγ receptors 
present on neutrophils, antibodies generated by immunization in most animals, such as mice or 
rabbits, cannot be tested. However, this work shows that antibodies from rhesus monkeys are 
compatible with human Fcγ receptors (details in 6.1.7). (iii) Neutrophil donors may vary in their 
expression of Fcγ RII A or B (= CD32) (Llewellyn et al., 2015), an important Fcγ receptor on human 
neutrophils responsible for respiratory burst and phagocytosis (Huizinga et al., 1989; Mitchell et al., 
1994). Interestingly, different polymorphisms in Fcγ RII A or B associate either with protection against 
malaria (Cherif et al., 2015; Ouma et al., 2012; Shi et al., 2001) or with an increased susceptibility to 
severe malaria (Cooke et al., 2003; Omi et al., 2002). In order to improve reproducibility of the ADRB 
assay performed with various neutrophil donors, we pooled the neutrophils from three donors for 
each assay and normalized the data to a standard, an IgG pool made from the eleven semi-immune 
African donors.  
Several approaches can be used in order to quantify the contribution of antigen-specific antibodies 
to opsonizing activity. Firstly, antibodies targeting the antigen of interest could be generated by 
immunization of animals and tested for their opsonizing capacity (Boyle et al., 2015). Secondly, 
transgenic parasites could be produced where the antigen of interest is either replaced (Joos et al., 
2015) or knocked out (Hill et al., 2016). And thirdly, affinity purified antibodies against merozoite 
antigens can be assessed for their opsonizing potential e.g. via ADCI (Oeuvray et al., 1994; Singh et 
al., 2009) or OPA (Chiu et al., 2015; Osier et al., 2014a). However, antigen-specific affinity purification 
of antibodies is quite time-consuming, requires special equipment for immuno-affinity 
chromatography and uses up a relatively large amount of serum and antigen. 
Here, two experimental approaches were employed to quantify the contribution of single antigens to 
ADRB activity, affinity purification of MSP-1 specific antibodies and antigen-reversal ADRB. In the 
latter, pre-incubation of serum antibodies with recombinant antigens allows us to quantify the 
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contribution of certain antigens to ADRB activity. Since this relatively easy approach requires only a 
small volume of serum and recombinant antigen it could be readily adapted to other merozoite 
antigens. Prior to their use in antigen-reversal ADRB experiments, all recombinant proteins were pre-
tested in absence of merozoites. Importantly, all showed only background chemiluminescence 
activity. Furthermore, the control protein BSA did not cause a reduction in ADRB activity, indicating 
that the results gained via antigen-reversal ADRB assay using merozoite surface proteins are 
probably specific. Remarkably, the antigen-reversal ADRB requires very low protein concentrations: a 
large decrease in ADRB activity was already observed with 2 nM recombinant MSP-1D using human 
IgG from semi-immune individuals; the minimum was reached at approximately 50 nM MSP-1D 
(Figure 5.16). An excess protein concentration of 500 nM was used for all experiments and thus, it 
can be assumed that all antigen-specific antibodies are bound to the respective protein.   
6.1.5. ADRB activity of MSP-1 specific antibodies in semi-immune individuals  
In this work, we provide further support for opsonizing antibodies mediating respiratory burst of 
neutrophils in individuals with naturally acquired immunity against malaria and identified PfMSP-183 
as major target antigen of ADRB activity. We show that the antibody titer to MSP-1D correlates with 
ADRB activity in the eleven semi-immune individuals from Burkina Faso. Furthermore, MSP-1 specific 
antibodies purified via affinity chromatography to recombinant MSP-1D from two African donors 
(Donor 2 and 8) are able to opsonize P. falciparum merozoites and elicit neutrophil respiratory burst 
while the removal of MSP-1 specific antibodies from total IgG causes a substantial decrease in ADRB 
activity. Interestingly, the same IgG fractions from the two African donors could not directly inhibit 
the growth of P. falciparum blood stages in vitro – as tested via GIA assay. Moreover, by using serum 
antibodies from the eleven African volunteers in the antigen-reversal ADRB and MSP-1D as 
competitor protein, ADRB activity observed against the heterologous strain P. falciparum (FCB1) was 
reduced almost as strongly as against the homologous strain (3d7). Thus, opsonizing antibodies 
eliciting neutrophil respiratory burst seem to be mainly cross-reactive. Importantly, we identified 
MSP-1 and especially its partially conserved subunit MSP-183 as an important target of opsonizing 
antibodies (the mean reductions observed in the antigen-reversal ADRB were 58.6 % and 50.2 %, 
respectively).  
So far, only one antigenic target of ADRB activity has been identified – the conserved C-terminal part 
of PfMSP-1, MSP-119 (Joos et al., 2015). Antibodies to MSP-119 were shown to contribute about 33 % 
to total neutrophil respiratory burst activity in two Senegalese villages using isogenic P. falciparum 
parasites with the non-cross-reactive MSP-119 orthologue from P. chabaudi and sera after removal of 
MSP-119 antibodies (Joos et al., 2015). Since we used alternative experimental approaches, an ADRB 
protocol, which differs in certain aspects such as the use of purified IgG instead of sera and 
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individuals from another African country, a direct comparison of our results with the previous study 
is not possible. However, we show that antibodies acquired by natural exposure to malaria opsonize 
P. falciparum merozoites of different strains equally well and ADRB activity against the P. falciparum 
FCB1 strain can be efficiently reduced with MSP-1 from the 3d7 strain (MSP-1D). Thus, cross-reactive 
regions within MSP-1 – present in both MSP-119 and MSP-183 - appear to be the main targets of 
opsonizing antibodies which elicit neutrophil respiratory burst.  
In contrast, it was reported that antibodies against MSP-1block2 - located within MSP-183 - show 
activity against P. falciparum by monocyte-dependent inhibition detected via ADCI (Galamo et al., 
2009) as well as by fixation of complement factors (Boyle et al., 2015). Due to the high cross-
reactivity observed in the ADRB assay it seems unlikely that antibodies targeting the oligomorphic 
region MSP-1block2 play a major role in neutrophil respiratory burst. Interestingly, opsonizing 
antibodies which recruit monocytes for merozoite phagocytosis - as measured in the OPA - are 
effective against 15 different parasite strains indicating a high strain-transcendence (Hill et al., 2016). 
Thus, opsonizing antibodies functional in ADRB or OPA seem to mainly target cross-reactive regions 
within merozoite antigens, which would be beneficial for vaccine development.      
6.1.6. Comparison of MSP-1 specific ADRB activity to other MSPs 
Having identified MSP-1 as important target of opsonizing antibodies eliciting neutrophil respiratory 
burst, we aimed to compare the contribution of MSP-1 to ADRB activity with other merozoite surface 
proteins. The recombinant proteins MSP-3, MSP-9 and MSPDBL-1 were kindly provided from Prof. A. 
Cowman & Dr. C. Lin (Walter and Eliza Hall Institute of Medical Research, Melbourne). All are 
peripheral MSPs which interact with MSP-1 on the merozoite surface and are shed following invasion 
(Li et al., 2004; Lin et al., 2016); for MSPDBL-1 also an interaction with erythrocytes has been 
reported (Lin et al., 2016; Sakamoto et al., 2012). Importantly, MSP-3 and MSPDBL-1 belong to the 
same protein family - the MSP-3 multigene family (MSP-3.1 – MSP-3.8) – and both contain the C-
terminal SPAM domain, which is conserved among different P. falciparum isolates and induces cross-
reactive antibodies with opsonizing activity (Oeuvray et al., 1994; Singh et al., 2009). Thus, both MSP-
3 and MSPDBL-1 have been described as targets of opsonizing antibodies effective via ADCI (Druilhe 
et al., 2005; Lundquist et al., 2006; Oeuvray et al., 1994; Singh et al., 2009) as well as via OPA (Chiu et 
al., 2015; Osier et al., 2014a). ADRB activity has not been reported so far for the two proteins. 
Interestingly, a correlation between antibody titers to MSP-3 (Osier et al., 2014a) and MSPDBL-1 
(Chiu et al., 2015; Tetteh et al., 2013) with protection against malaria has been reported. 
Furthermore, vaccination of children from Burkina Faso with the conserved part of MSP-3 not only 
induced antibodies active via ADCI (Druilhe et al., 2005) but also reduced malaria episodes 
significantly (Sirima et al., 2011).  
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Regarding MSP-9, which has not yet progressed to clinical trials, nothing has been reported yet about 
its ability to elicit opsonizing antibodies. In the antigen-reversal ADRB performed with the respective 
competitor proteins and antibodies from the eleven semi-immune African individuals, the average 
ADRB activity could be reduced almost 50 % using 500 nM recombinant MSP-9, around 60 % with 
MSP-1D and almost 90 % using MSP-3 or MSPDBL-1, respectively. For the latter two proteins, likely 
the same cross-reactive opsonizing antibodies, which target the conserved SPAM domain, are 
responsible for ADRB activity. Interestingly, the reductions observed with these four proteins add up 
to more than 100 %, even though antibodies to other merozoite proteins may also contribute to 
neutrophil respiratory burst activity. Thus, it seems that the results of the antigen-reversal ADRB 
assay should be interpreted in a qualitative rather than quantitative manner.   
Besides the complexity of the antigen-reversal ADRB assay which may make an exact quantification 
regarding the contribution of single antigens to ADRB activity impossible, other explanations may be 
possible: (i) there could be cross-reactive antibodies with opsonizing potential not only between 
MSP-3 and MSPDBL-1 but between all four proteins tested and thus, upon addition of one of these 
proteins in excess all antibodies will bind. However, a blast-p alignment between MSP-1, MSP-3, 
MSP-9 and MSPDBL-1 showed no conserved or similar regions except the SPAM domain present in 
MSP-3 and MSPDBL-1. (ii) Since MSP-3, MSP-9 and MSPDBL-1 can all bind to MSP-1 (Li et al., 2004; 
Lin et al., 2016) and we add one of these proteins in excess to the antigen-reversal ADRB, it might be 
possible that not all protein molecules are covered with antibodies and could bind to free MSP-1 on 
the merozoite surface. Thus, MSP-3/-9/DBL-1 may sterically hinder access of opsonizing antibodies, 
e.g. against MSP-1, to the merozoite surface and cause a higher reduction of neutrophil activation. 
(iii) Antibodies bound to the competitor protein might still be able to bind to the neutrophil via their 
Fc part. However, this might not result in cross-linking of neutrophil Fc receptors which is crucial for 
their activation but maybe spatially block the access for opsonized merozoites.  
In order to exclude the possibilities listed above which may disturb neutrophil respiratory burst 
activity in presence of the peripheral merozoite surface proteins MSP-3/-9/-DBL-1, ideally the 
protein-antibody complexes should be removed prior to performance of the ADRB. This approach 
was recently described for antibodies targeting MSP-119 (Joos et al., 2015): by using hexa-histidine-
tagged MSP-119, antigen-antibody complexes could be removed by binding of the his-tag to metal- 
chelate affinity resin and thus, sera were depleted from antigen-specific antibodies prior to ADRB 
experiments. Additionally, a Plasmodium non-merozoite surface protein - such as AMA-1 or an 
intracellular protein - could be included as further control for antigen-reversal ADRB experiments. In 
conclusion, the results indicate that antibodies to several merozoite surface proteins - including MSP-
1, MSP-3, MSP-9 and MSPDBL-1 - can opsonize merozoites and induce neutrophil respiratory burst.  
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6.1.7. Induction of ADRB activity in rhesus monkeys by immunization with MSP-1 
Importantly, opsonizing antibodies which cause neutrophil respiratory burst could be induced in 
rhesus monkeys by immunization with recombinant MSP-1D and adjuvant CoVaccine HT (Mahdi 
Abdel Hamid et al., 2011). Antibody titers against MSP-1D and ADRB activity were comparable 
between an IgG pool obtained from the eleven semi-immune African individuals and the immunized 
rhesus monkeys. This finding has several major implications. Firstly, we demonstrate here for the first 
time that antibodies raised in non-human primates are compatible with human Fcγ receptors on 
neutrophils. So far, this has been one of the major limitations of the ADRB assay since no animal 
species was known in which compatible antibodies can be generated and neutrophils from other 
species such as mice differ substantially from human neutrophils regarding their Fcγ receptor 
expression and binding abilities (Bruhns, 2012). Secondly, we show for the first time that antibodies 
functional in ADRB can be induced by immunization with a recombinant protein. In a recent study, 
ADRB effective antibodies could not be induced by vaccination of mice with AdHu5-PyMSP-142 but by 
primary infection with P. yoelii (Llewellyn et al., 2014). Furthermore, a single infection with 
cryopreserved radiation-attenuated Pf sporozoites did not elicit ADRB activity in malaria-naïve 
individuals (Hodgson et al., 2016). Opsonizing activity of antibodies raised in mice or rabbits by 
immunization with different merozoite antigens has been recently reported for opsonic phagocytosis 
(Quintana Mdel et al., 2016) and complement-dependent inhibition (Boyle et al., 2015). However, 
this is the first report on opsonizing antibodies induced in primates. Thirdly, we reveal that 
immunization with recombinant MSP-1D generates antibodies which are (i) long-lasting with 
undiminished ADRB activity more than four month after last immunization, (ii) mainly cross-reactive 
showing almost comparable activity against P. falciparum 3d7 and FCB1 parasites, (iii) targeting 
primarily conserved and dimorphic regions within MSP-183, and (iv) active via the same functional 
mechanisms as naturally acquired antibodies, thus supporting full-length MSP-1 as promising vaccine 
candidate.   
6.1.8. Antibodies targeting MSP-1 act via different mechanisms 
Besides direct growth inhibition of P. falciparum blood stages in vitro, MSP-1 also elicits opsonizing 
antibodies which can act at much lower antibody levels compared to GIA. MSP-119 (Blackman et al., 
1990; Egan et al., 1999; O'Donnell et al., 2001), MSP-183 (Woehlbier et al., 2006) and epitopes 
distributed within the complete MSP-1 protein (Woehlbier et al., 2006) have been described as 
targets of growth inhibitory antibodies. Interestingly, antibodies effective via direct growth inhibition 
in vitro seem to decline with increasing age in malaria highly endemic regions (Courtin et al., 2009; 
Dent et al., 2008; McCallum et al., 2008) suggesting that these antibodies may be involved in 
protection against severe malaria during childhood. In contrast, opsonizing antibodies active in ADCI 
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(Tiendrebeogo et al., 2015), OPA (Osier et al., 2014a), complement-dependent inhibition (Boyle et al., 
2015) and ADRB (Joos et al., 2010; Perraut et al., 2014) increase with age and thus, may be important 
for naturally acquired immunity against malaria. The activity of naturally acquired antibodies in both 
GIA and ADRB is weakly correlated (this work) or poorly correlated (Murungi et al., 2016), indicating 
that these functional mechanisms may be mediated by various antibody subsets.  
Additionally, for MSP-1 specific opsonizing antibodies also different immune mechanisms have been 
described: (i) the recruitment of monocytes by MSP-1block 2 antibodies measured via ADCI (Galamo et 
al., 2009), (ii) the fixation of complement factors by antibodies directed against MSP-119 and MSP-
1block 2 as detected via antibody-mediated complement dependent inhibition (Boyle et al., 2015), (iii) 
the induction of neutrophil respiratory burst analyzed via ADRB assay and reported for antibodies to 
MSP-119 (Joos et al., 2015) and MSP-183 (this work). However, MSP-119 antibodies did not seem to 
play a role in monocyte opsonic phagocytosis since the OPA response for transgenic P. falciparum 
merozoites with the MSP-119 orthologue from P. chabaudi did not differ from wildtype parasites (Hill 
et al., 2016). Furthermore, we observed a high cross-reactivity between different parasite strains in 
the ADRB suggesting that antibodies to the highly polymorphic block 2 of MSP-1 which is located 
within MSP-183 likely plays no role for neutrophil respiratory burst activity. Thus, opsonizing 
antibodies elicited by different regions within MSP-1 appear to act by various independent immune 
mechanisms. Interestingly, higher antibody levels and their action via multiple mechanisms is 
associated with naturally acquired immunity (Murungi et al., 2013; Rono et al., 2013) suggesting that 
several antibody-mediated mechanisms contribute to protection against malaria. Since the antigenic 
epitopes within MSP-1 are distributed over the whole protein and elicit a variety of immune 
responses, we propose full-length MSP-1 as malaria vaccine candidate.  
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6.2. Cellular immune response against MSP-1D 
Many studies within the last 30 years indicate the crucial role of cytotoxic CD8+ T-cells targeting 
Plasmodium liver stages in infected hepatocytes for protection against malaria (reviewed e.g. in 
(Frevert and Krzych, 2015)). Although CD8+ T-cells can kill intracellular parasites directly via cytolytic 
activity (White et al., 1996), their release of the cytokine IFNγ appears to be more important against 
Plasmodium. IFNγ released by certain immune cells such as CD4+ Th1 cells and CD8+ cytotoxic T-cells 
inhibits the development of pre-erythrocytic Plasmodium stages in hepatocytes and is absolutely 
required for sterile immunity to sporozoite challenge (Ferreira et al., 1986; Imai et al., 2010; Mellouk 
et al., 1987; Schofield et al., 1987). Importantly, in all whole sporozoite vaccination approaches – 
RAS, GAP and CPS – sterile protection appears mostly mediated by IFNγ-producing CD8+ T-cells 
(Brando et al., 2014; Epstein et al., 2011; Jobe et al., 2007; Lewis et al., 2015; Mueller et al., 2007; 
Nganou-Makamdop et al., 2012; Tarun et al., 2007; Weiss and Jiang, 2012).  
Priming of parasite-specific CD8+ T-cells can occur already in the lymph nodes by CD8α+ dendritic 
cells presenting antigens from migratory Plasmodium sporozoites via their HLA-I receptor (Cockburn 
and Zavala, 2016; Radtke et al., 2015). Furthermore, priming also takes place in the liver where it is 
mediated by CD8α+ dendritic cells (Cockburn and Zavala, 2016; Jobe et al., 2009) or infected 
hepatocytes (Balam et al., 2012; Cockburn et al., 2014; Frevert and Krzych, 2015). However, direct 
intravenous injection of Plasmodium sporozoites – as done currently in most whole parasite 
vaccination approaches – probably does not pass through the lymph nodes and thus, protective T-
cells may only be induced in the liver. Interestingly, imaging analysis have revealed that CD8+ T-cells 
cluster around infected hepatocytes which present parasite-derived antigens via their HLA-I 
receptors (Cockburn et al., 2013) and contribute to protection (Huang et al., 2015). Since MSP-1 is 
already expressed by Plasmodium late liver-stages in infected hepatocytes (Haussig et al., 2011; 
Szarfman et al., 1988) it potentially elicits a protective T-cell response in the liver. 
6.2.1. MSP-1 specific T-cell response: what is known so far? 
A MSP-1 specific T-cell proliferation has been observed in volunteers immunized with irradiated P. 
falciparum sporozoites (Krzych et al., 1995): three out of four vaccinated individuals recognized both 
pre-erythrocytic (CSP and LSA-1) and blood stage antigens (MSP-1, MSP-2, SERA-1) – as detected via 
proliferation assay using 3H-thymidine. Regarding MSP-1, four recombinant fragments from the Pf 
CAMP strain, which is very similar to the 3d7 strain, were used for stimulation of PBMCs.  
Up to date, several studies have analyzed the T-cell response against mostly MSP-119 or MSP-142 in 
African individuals with naturally acquired immunity against malaria, focusing on CD4+ T-cells. 
Lymphocyte preparations from African adults living in malaria-endemic regions recognize MSP-119 
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(Bisseye et al., 2011) and MSP-142 (Dent et al., 2009; Moormann et al., 2013) recombinant proteins or 
CD4+ T-cell epitopes thereof. Additionally, a response of African children to several recombinant 
MSP-1 derived fragments (Riley et al., 1992a) and to a CD4+ T-cell epitope located within MSP-183 (aa 
20-39) (Chelimo et al., 2003; Quakyi et al., 1994) has been reported. Importantly, lymphocytes from 
African individuals secrete IFNγ upon stimulation with MSP-119 (Bisseye et al., 2011) or MSP-142 
(Bowman et al., 2016; Chelimo et al., 2011; Dent et al., 2009; Moormann et al., 2013). Furthermore, 
MSP-1 specific IFNγ production increases with age in children from Kenya (Chelimo et al., 2011; 
Chelimo et al., 2003) and also in individuals from Gambia (Riley et al., 1992a). Importantly, a 
correlation with protection against malaria has been reported for the T-cell response against MSP-142 
in Kenyan children and adults (Bowman et al., 2016; Moormann et al., 2013).  
In contrast, the MSP-119 fragment is supposed to be a poor T-cell target due to its disulfide bridges 
hindering protein processing and presentation (Egan et al., 1997). Thus, MSP-119-based vaccinations - 
even via viral vectors (Douglas et al., 2010) - could not elicit a CD8+ T-cell response. Interestingly, in 
mice immunized with MSP-142 using viral vectors (AdHu5-MVA), CD4+ and CD8+ T-cells targeting 
MSP-133 were induced. For vaccinated mice increased serum IFNγ levels and a reduced Plasmodium 
liver burden were detected, which was associated with superior protection upon sporozoite 
challenge (Draper et al., 2009).  
Even though CD4+ T-cells seem to play a role in controlling Plasmodium blood stages (Perlmann and 
Troye-Blomberg, 2000; Quakyi et al., 1994; Riley et al., 1992b; Troye-Blomberg et al., 1994), CD8+ T-
cells are considered as the key players against Plasmodium liver stages and crucial for protection 
against malaria. For example, depletion of CD8+ but not CD4+ T-cells in vivo reverses RAS-induced 
sterile protection in mice (Schofield et al., 1987; Weiss et al., 1988) and primates (Weiss and Jiang, 
2012). Furthermore, RAS-immunized mice with a defect HLA-I receptor are not protected against 
parasite challenge (White et al., 1996). Interestingly, naïve recipient mice could be protected against 
parasite infection by transfer of CD8+ T-cells from immune mice (Imai et al., 2010; Lewis et al., 2015; 
Schofield et al., 1987). Thus, CD8+ T-cells appear to be crucially required for sterile protection against 
malaria infection while CD4+ T-cells may contribute to protective immunity e.g. by inducing B-cells to 
produce protective antibodies (Brando et al., 2014). 
Importantly, CD8+ T-cell epitopes for the HLA haplotype A0201 have been identified in full-length 
MSP-1D (Carralot, 2008; Idler, 2004). Peptide 291 dominated the CD8+ T-cell response in HHD mice 
immunized with MSP-1D while peptide 674 was identified under physiological conditions by mass 
spectrometry (details in 5.3.1). Both CD8+ T-cell epitopes, 291 and 674, are located in dimorphic 
regions within MSP-138 and MSP-183, respectively. Thus, they were not included in previous studies 
reported so far.  
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6.2.2. HLA-A0201 restricted MSP-1 specific CD8+ T-cell response 
In this work, peripheral blood mononuclear cells (PBMCs) from semi-immune African and malaria-
naïve European individuals were used to analyze the MSP-1 specific CD8+ T-cell response. Thus, 
monocytes, B-cells and dendritic cells present in peripheral blood were employed as antigen-
presenting cells. If MSP-1 derived epitopes are presented by these cells via their HLA-I receptors to 
cytotoxic CD8+ T-cells leading to production of IFNγ, it will be most likely that MSP-1 can also induce 
a CD8+ T-cell response in the liver. Recently, it was even reported that in RAS-immunized mice 
memory CD8+ T-cells, which are essential for protection against sporozoite challenge, remain 
constantly in the liver (Fernandez-Ruiz et al., 2016). Interestingly, in nonhuman primates immunized 
with RAS, P. falciparum-specific CD8+ T-cells secreting IFNγ showed an approximately 100 fold higher 
frequency in the liver compared to blood (Ishizuka et al., 2016). Thus, we can assume that if we 
detect a MSP-1 specific T-cell response using human blood samples, the actual immune reaction in 
the liver of these individuals might be much higher.  
Since Plasmodium-specific CD8+ T-cells are known to be present at very low frequency in peripheral 
blood from individuals with naturally acquired immunity (Lalvani et al., 1996; Plebanski et al., 1997), 
we had to choose a highly sensitive detection method – the IFNγ ELISPOT assay. The latter shows the 
lowest detection limit regarding all in vitro assays available so far to measure cytokine producing T-
cells, such as lymphoproliferation, cytotoxicity assays or intracellular cytokine staining combined with 
flow cytometry. Strikingly, its sensitivity is about 400 fold higher compared to conventional ELISA. 
Since the ELISPOT method is quite robust without using radioactivity, it probably can be also used in 
tropical regions for field studies.  
In this part, HLA-A0201 restricted CD8+ T-cell epitopes located within the complete MSP-1D protein 
(Figure 5.21) and identified previously in the laboratory of Prof. Bujard (Carralot et al., 2008; Idler, 
2004) were used for stimulation of PBMCs from semi-immune African adults from Burkina Faso and 
from malaria-naïve European controls. Importantly, PBMCs from all African individuals, which were 
available in sufficient quantity and quality and thus, could be tested via IFNγ ELISPOT assay, reacted 
against the MSP-1 epitopes 291, 674 and 374 and/or 437 (Figure 5.22 A). In contrast, PBMCs from 
only one out of four tested malaria-naïve individuals cross-reacted against peptide 291. The amino 
acid sequence of 291 was examined by blast-p analysis indicating that this peptide is not only present 
in P. falciparum MSP-1 but also in certain bacteria such as Streptomyces, Kribella or Enterococcus 
faecium (see Appendix 7.7), which may explain the observed cross-reaction. However, despite the 
limited sample size a significant difference could be detected for the CD8+ T-cell response of semi-
immune compared to malaria-naïve individuals to the MSP-1 specific peptide 674 and to a peptide 
pool consisting of 291+374+437 (Figure 5.22 C/D).  
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Interestingly, a ChAd63-MVA-vectored MSP-1 vaccine construct - consisting of conserved regions and 
MSP-142 - could induce a T-cell response in vaccinated volunteers but no protection against mosquito 
bite challenge (Sheehy et al., 2012). However, their vaccine construct did not contain the potentially 
protective CD8+ T-cell epitopes 291, 374 and 674 which are all located in dimorphic regions.  
There are several limitations of the results obtained using HLA-A0201 restricted CD8+ T-cell epitopes 
and the PBMCs tested: (i) the sample size was quite small - PBMCs with sufficient quality were 
available from 3 semi-immune and 4 malaria-naïve individuals, (ii) the quality of the African PBMC 
preparations was poor due to interruptions of the cold chain in Burkina Faso or during 
transportation, thus the quite fragile monocyte and dendritic cell populations were missing in the 
PBMCs from semi-immune individuals (see Appendix 7.5) and a high cell death rate was observed 
during cultivation. We can assume that the T-cell response might be even higher with intact PBMC 
preparations. (iii) We do not know if individuals with different – possibly even closely related – HLA 
subtypes can present the identified HLA-A0201 restricted MSP-1 specific epitopes to CD8+ T-cells 
since each HLA-type may present different antigenic epitopes (Barouch et al., 1995). (iv) The 
identified CD8+ T-cell epitopes within MSP-1D – 291, 374, 437 and 674 – are all located in dimorphic 
regions and their amino acid sequence may differ between P. falciparum parasite strains. Aligning 
the amino acid sequence of MSP-1D for the respective peptides between 3d7 and FCB1 strains 
shows, that there is one amino acid difference for 291 and 437 and two for 674; 374 differs in almost 
all amino acids (Figure 6.1). Thus, it is unknown whether these MSP-1 specific epitopes may elicit a 
CD8+ T-cell response only against the homologous strain 3d7 or also against other parasite strains. 
However, all these limitations can be overcome by analyzing a larger cohort of semi-immune African 
as well as malaria-naïve control individuals using an HLA-independent approach and including many 
potential MSP-1 specific T-cell epitopes.  
 
 
Figure 6.1: Comparison of the amino acid sequence within MSP-1 between P. falciparum 3d7 and FCB1. Both 
MSP-1 specific CD8+ T-cell epitopes 674 and 291 are located in dimorphic regions within MSP-183 (block 7) and 
MSP-138 (block 13), respectively. There are two (674) or one (291) amino acid differences detected between Pf 
3d7 or FCB1 strains. The program Clustal 2.1. was used for alignment.  
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6.2.3. HLA-independent analysis of the MSP-1 specific T-cell response 
One possibility for an HLA-independent approach to investigate the MSP-1 specific T-cell response 
would be the use of comprehensive peptide pools covering all frequent HLA-types for stimulation of 
PBMCs and following analysis via IFNγ ELISPOT assay. However, potential CD8+ T-cell epitopes within 
MSP-1D - predicted by the artifical neural networks (ANN)-algorithm (Honeyman et al., 1998) to 
several HLA-types - are distributed throughout the whole protein (Figure 5.23 A), suggesting that the 
complete MSP-1D sequence should be taken into account. Furthermore, a diverse pattern of 
frequent HLA-types can be detected in Africa and Europe e.g. in Mali (Cao et al., 2004) and Germany 
(Source: Bone marrow registry, n ≈ 40 000) (Figure 5.23 B/C). In order to cover about 80 % of HLA-
alleles in Germany, 5 peptide pools would be required but at most two of them (for HLA-A0201 and 
C0401) could be also used for individuals from Mali. Thus, separate peptide pools spanning the 
complete MSP-1 sequence would have to be synthesized in order to analyze the T-cell response from 
semi-immune African individuals as well as malaria-naïve European controls.     
Another HLA-independent approach – the use of complete proteins such as MSP-1D as stimulus for 
PBMCs – shows several advantages: (i) it is a much easier and cheaper method compared to the use 
of large peptide pools, (ii) since the complete proteins contains both CD4+ and CD8+ T-cell epitopes, 
a more comprehensive picture of the MSP-1 specific T-cell response will be obtained and (iii) the 
protocol may be adapted to test further antigens such as MSP-1F, MSP-6 or MSP-7. The application 
of protein antigens, e.g. tetanus toxoid, in IFNγ ELISPOT assay has been reported previously 
(Schmittel et al., 2001) and seems to require a pre-incubation period in presence of the protein 
stimulus as well as monocytes as antigen-presenting cells.  
In this work, the IFNγ ELISPOT assay was successfully modified for the use of complete MSP-1D 
protein. A pre-incubation period (24 h) of PBMCs in presence of MSP-1D appears to be crucial for 
protein processing and presentation, presumably by monocytes (Schmittel et al., 2001), while this 
step could be omitted using short peptides (Figure 5.24). A MSP-1D concentration of 5 µg/ml was 
found to be optimal. However, these results were obtained using PBMCs from the cross-reactive 
malaria-naïve individual. PBMCs from the semi-immune African adults from Burkina Faso were also 
tested but showed no reaction to MSP-1D protein since professional antigen-presenting cells 
(monocytes and dendritic cells), which are crucial for protein processing and presentation (Schmittel 
et al., 2001), were missing in their PBMC preparations (Appendix 7.5). The three malaria-naïve 
individuals not cross-reacting to MSP-1 specific peptides showed also no response to MSP-1D protein 
indicating that the detected T-cell response to MSP-1D may be specific. However, these results 
should be verified using intact PBMC preparations from malaria-exposed individuals.    
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Originally, we aimed to apply the HLA-independent MSP-1 protein approach to analyze the MSP-1 
specific T-cell response of 210 children from Samako, Mali, for which blood samples were taken at 
different time points before, during and after malaria transmission season and detailed health 
records were available. Thus, it would have been possible to investigate a potential correlation 
between MSP-1 specific T-cell response and protection against malaria. Unfortunately, the PBMCs 
which arrived in Heidelberg (~ 1400 cryotubes) were all dead and could not be used (Figure 5.25). 
Thus, these questions may be addressed in the future as soon as intact PBMCs from a suitable cohort 
of malaria-exposed individuals are available.  
 
6.3. TUECHMI I  
Besides the MSP-1 specific immune response in individuals with naturally acquired immunity against 
malaria, we were also interested in immune responses elicited in malaria-naïve volunteers by 
experimental P. falciparum sporozoite infection. In TUECHMI I – a controlled human malaria infection 
study performed in Tübingen in 2011/12 – thirty malaria-naïve volunteers were infected 
intravenously or intradermally with different doses of cryopreserved Pf sporozoites (NF54 strain) 
from Sanaria. Results of this dose-finding trial have already been published (Mordmuller et al., 2015) 
showing safety and tolerability of Pf sporozoite challenge and the detected parasitemia for each 
individual but not the induced immune responses. In 22 out of 30 infected malaria-naïve volunteers 
parasites could be detected in the blood by microscopy 10-15 days after infection. Importantly, in the 
highest dose group – 3200 Pf sporozoites by intravenous injection – 100 % of individuals (9/9) 
developed malaria (Figure 5.26 B) (Mordmuller et al., 2015). This finding laid the foundations for 
TUECHMI II (Mordmuller et al., 2017), in which malaria-naïve volunteers were immunized 3x 
intravenously with non-attenuated cryopreserved Pf sporozoites under chloroquine cover and 
challenged ten weeks after last immunization. In TUECHMI II, 3200 Pf sporozoites was the lowest 
dose used and protected 33 % (3/9) of vaccinated volunteers against homologous Pf sporozoite 
challenge while the highest dose, 51 200 Pf sporozoites, protected 100 % (9/9) of individuals.   
In this work, we aimed to characterize the human immune response induced by experimental non-
attenuated P. falciparum sporozoite infection. In detail, serum antibody levels against the merozoite 
surface proteins MSP-1/-6/-7 were analyzed by ELISA, and – in cooperation with Dr. Kirsten Heiss and 
Dr. Ann-Kristin Müller – the CD8+ T-cell response against LSA-1, CSP, malS and MSP-1 was examined 
via IFNγ ELISPOT assay. Antibodies to MSP-1/-6/-7 could be induced by experimental Pf sporozoite 
infection (Figure 5.27) even though infected volunteers were immediately treated with ACT 
(Lumefantrine-Arthemeter) upon detection of parasites in the thick blood smear. Since it is assumed 
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that the parasite can undergo 2 - 2.5 blood stage cycles, corresponding to 4-5 days following release 
of merozoites from liver schizonts, before it is detectable by blood film microscopy (Bejon et al., 
2005), this short exposition time of the merozoite to the human immune system seems to be enough 
to produce merozoite-specific antibodies. Strikingly, these antibodies decrease quite slowly since 
they can still be measured 84 and even 168 days after infection. Interestingly, MSP-1 is more 
immunogenic than MSP-6 or MSP-7. However, in comparison to the MSP-1 specific antibody level 
measured in semi-immune adults from Burkina Faso, the antibody titer against MSP-1 induced by 
experimental Pf sporozoite infection is approximately 100-fold lower.  
Recently, the antibody response induced by experimental intravenous injection of cryopreserved Pf 
sporozoites in 18 malaria-naïve volunteers from the UK as well as 28 malaria-exposed individuals 
from Kenya was analyzed by ELISA, GIA and ADRB assay (Hodgson et al., 2016). Interestingly, 
antibodies to MSP-119, AMA-1 and Pf schizont lysate could also be elicited by Pf sporozoite infection 
in both groups. However, since they applied a different ELISA protocol and showed antibody levels 
only for one time point after infection (day 35), a direct comparison with my data is not possible.  
Additionally, we aimed to investigate the CD8+ T-cell response against the cross-stage antigen MSP-1 
and the known pre-erythrocytic antigens CSP and LSA-1 following experimental challenge with P. 
falciparum sporozoites. Since the parasites are injected intravenously, a potential immune response 
in the skin (Mac-Daniel et al., 2014) and lymph nodes – such as priming of naïve CD8+ T-cells by 
lymph node-resident dendritic cells (Cockburn and Zavala, 2016) – is omitted. However, T-cell 
priming is also possible in the liver (Balam et al., 2012; Cockburn and Zavala, 2016; Jobe et al., 2009) 
and, according to numerous whole sporozoite vaccine approaches administered intravenously 
(reviewed in (Hollingdale and Sedegah, 2017)), can induce sterile immunity against malaria.  
CSP and LSA-1 are both known targets of IFNγ producing T-cells - not only in individuals with naturally 
acquired immunity against malaria (Jagannathan et al., 2015; Luty et al., 1999; Lyke et al., 2005) but 
also in RAS-immunized volunteers (Krzych et al., 1995). Furthermore, it was shown in mice that 
hepatocytes can present CSP-derived peptides to CD8+ T-cells resulting in protection against 
Plasmodium infection (Balam et al., 2012). Importantly, we detected a MSP-1 specific CD8+ T-cell 
response comparable to LSA-1 and CSP by analyzing PBMCs before and at several time points after Pf 
sporozoite infection via IFNγ ELISPOT assay (Figure 5.28). Interestingly, the highest MSP-1 and LSA-1 
specific CD8+ T-cell stimulation was detected on day 10-12 post infection while the highest response 
against CSP was observed on day 7 – according to their expression in late or early liver stages, 
respectively. However, compared to the MSP-1 specific CD8+ T-cell response of semi-immune adults 
from Burkina Faso, the activation of MSP-1 / LSA-1 / CSP-specific CD8+ T-cells after a single Pf 
sporozoite infection is much lower (~2200 versus maximum 300 net SFUs per 106 PBMCs, 
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respectively). Furthermore, levels of several cytokines were determined in sera from malaria-positive 
individuals by cytokine bead array (performed by Dr. Michael Pritsch in Munich, Appendix 7.6). 
However, the concentration of IFNγ was below the detection limit while the levels of IL-4, IL-6, IL-10 
and TNFα showed no significant differences over the course of the study.  
Interestingly, cellular immune responses against Pf sporozoites, Pf RBCs (schizont stage) and against 
several Pf proteins such as CSP or LSA-1 were also assessed in 5 malaria-naïve individuals 
experimentally infected with Pf sporozoites via mosquito bite (Teirlinck et al., 2011). By overnight 
stimulation followed by intracellular cytokine staining and flow cytometry, an IFN γ response against 
Pf sporozoites and Pf RBCs was detected 35 days after challenge and strikingly, this response did not 
decrease up to 14 month post infection. However, they could not detect a response against any of 
the proteins tested, supposedly because the cytokine concentrations were below the detection limit 
of flow cytometry analysis. According to their results, about 1 % of total lymphocytes reacted to Pf 
RBCs with IFNγ secretion at day 35 post infection while only approximately 0.05 % reacted against Pf 
sporozoites. Thus, antigens present in blood stage schizonts, such as MSP-1, might be stronger 
elicitors of lymphocyte-specific IFNγ secretion than sporozoites. T-cell responses against MSP-1 have 
– to my knowledge – not been investigated following CHMI.  
However, several factors limit the significance of the gained results regarding the T-cell response: (i) 
the HLA-types of the tested individuals are unknown and it is not allowed to determine them 
because genetic analysis was not included in the informed consent sheet of the clinical study. Thus, 
we cannot verify whether the malaria-positive volunteers showing a specific CD8+ T-cell response 
against MSP-1, LSA-1 and CSP (3 out of 9) have the compatible HLA-A0201 subtype. (ii) The T-cell 
responses are generally quite low after a single Pf infection. (iii) Since the malaria-naïve volunteers 
were only infected once, it is not possible to investigate a potential correlation between measured 
immune responses and protection against experimental malaria infection. Thus, a study with several 
parasite infections of human volunteers e.g. during CPS immunization followed by Pf challenge, 
would provide more interesting information.  
 
 
 
 
Discussion
 
118 
 
6.4. Summary & Outlook 
6.4.1. Summary 
The objective of this work was to characterize the human humoral and cellular immune response 
against the malaria vaccine candidate PfMSP-1D in semi-immune African adults as well as in malaria-
naïve individuals experimentally infected with P. falciparum wildtype sporozoites. By using sera from 
eleven individuals from Burkina Faso with naturally acquired immunity against malaria it was 
demonstrated that (i) antibodies against MSP-1 partially contribute to direct growth inhibition of P. 
falciparum blood stages in vitro, (ii) opsonizing antibodies which induce neutrophil respiratory burst 
detected via ADRB assay, correlate with antibody levels against MSP-1 and are mainly cross-reactive, 
(iii) opsonizing antibodies target MSP-1 and its fragment MSP-183 and contribute strongly to ADRB 
activity. Moreover, we show that immunization with recombinant MSP-1D elicits opsonizing 
antibodies in rhesus monkeys, suggesting that the induction of ADRB-effective antibodies may be an 
important immune mechanism for a vaccine based on MSP-1. Regarding the T-cell response after 
natural exposure to P. falciparum, we detected MSP-1-specific IFNγ-secreting CD8+ T-cells in PBMCs 
from semi-immune African adults from Burkina Faso.    
Additionally, the immune response following experimental infection of malaria-naïve volunteers with 
P. falciparum sporozoites (TUECHMI I) is investigated, indicating that (i) antibodies to MSP-1, MSP-6 
and MSP-7 are induced by Pf sporozoite challenge and (ii) the cross-stage antigen MSP-1 elicits a 
CD8+ T-cell response comparable to the known pre-erythrocytic antigens LSA-1 and CSP.    
6.4.2. Outlook 
This study is limited in its ability to examine a potential correlation between MSP-1 specific immune 
responses and protection against malaria since the sample size is quite small (eleven African 
individuals) and the degree of immunity against malaria between different samples is comparable 
(same transmission area and similar age). Furthermore, the malaria-naïve volunteers from the 
TUECHMI trial were only once experimentally infected with Pf sporozoites without prior vaccinations. 
Thus, investigating a potential correlation between detected immune responses and either naturally 
acquired immunity against malaria or protection against experimental malaria infection is not 
possible. For this aim, it would be crucial to investigate the MSP-1 specific immune response in a 
large cohort of individuals living in malaria-endemic regions with optimally different age groups and 
available health records. Additionally, it will be of prime importance for MSP-1 as vaccine candidate 
to investigate whether functional antibodies and T-cells can be induced in humans by immunizations 
during clinical trials and if these MSP-1 specific immune mechanisms can protect against malaria.    
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Regarding the humoral immune response, sera from malaria-naïve volunteers, immunized with 
recombinant PfMSP-1D and adjuvant IDRI-SE + GLA during a Phase 1 clinical study in Heidelberg, will 
be analyzed this year. Recent results indicate that antibodies against MSP-1D are considerably 
induced by immunization and the functionality of these antibodies will soon be examined via GIA and 
ADRB assay. In a potential Phase II study it can be additionally analyzed if the elicited antibodies 
contribute to protection against malaria. Moreover, it would be interesting to investigate if 
opsonizing antibodies targeting MSP-1 may also act via different mechanisms than neutrophil 
respiratory burst, such as opsonic phagocytosis (Osier et al., 2014a), complement-dependent 
inhibition (Boyle et al., 2015) or monocyte-dependent inhibition (Bouharoun-Tayoun et al., 1990).   
Regarding the cellular immune response, PBMCs with sufficient quality will be hopefully obtained 
from individuals with naturally acquired immunity against malaria – optimally from regions with 
different malaria transmission intensity or from varying age groups, thus the individuals should differ 
in their acquired immunity. The following questions will be interesting to investigate using these 
samples: (i) Can we validate the use of recombinant MSP-1D protein as stimulus for PBMCs and 
following IFNγ ELISPOT analysis? (ii) Can we detect MSP-1 specific T-cells in this cohort? (iii) Do we 
observe an age dependency in developing MSP-1 specific T-cells? (iv) Can we detect a correlation 
between MSP-1 specific T-cell responses and naturally acquired immunity against malaria? (v) Does 
the MSP-1 specific T-cell response acquired by natural exposure differ from the T-cell response 
experimentally induced by whole sporozoite vaccinations e.g. via CPS immunization during the 
TUECHMI II study? Importantly, PBMCs from several malaria-naïve volunteers – e.g. from the clinical 
phase I trial with PfMSP-1D before immunization (day 0) – should be analyzed in parallel in order to 
examine potential cross-reactions to amino acid sequences within MSP-1 (as observed for one 
malaria-naïve volunteer).  
Furthermore, by using PBMCs from the clinical Phase I study with PfMSP-1D currently running in 
Heidelberg, it will be analyzed if MSP-1 specific T-cells can be induced by immunization with 
recombinant MSP-1D. However, usually T-cell responses elicited by vaccination with proteins are 
quite low, thus viral vectors – such as MVA or adenoviruses – might be included in a potential Phase 
II trial with MSP-1 in order to stimulate T-cell responses. Indeed, high-capacity adenoviral vectors 
expressing full-length msp-1 are already available and the induction of antibodies and high levels of 
IFNγ-producing CD8+ T-cells in mice has been shown (Zong et al., 2011). Thus, it might be interesting 
to compare the MSP-1 specific T-cell response elicited by different immunization strategies during 
clinical trials. Additionally, PBMCs derived from a possible Phase II study with MSP-1 could be 
employed to investigate whether the elicited T-cell response contributes to protection against 
malaria.  
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6.4.3. MSP-1 as malaria vaccine candidate 
Although several malaria vaccine candidates have been tested in clinical trials, so far none of them 
showed protective efficacy in malaria-endemic countries. The most progressed vaccine candidate up 
to date, RTS.S/AS01, recently demonstrated no efficacy in African children within a 7 year period 
(Olotu et al., 2016). Even though whole sporozoite vaccinations are able to confer sterile immunity 
against malaria at least against the homologous strain and for a short time-period (e.g. (Mordmuller 
et al., 2017; Seder et al., 2013)), many major obstacles and difficulties have to be overcome to 
potentially realize vaccinations in malaria-endemic regions (see 1.3.2 for details). Thus, an effective 
malaria vaccine as well as robust in vitro assays measuring correlates of protective immunity are still 
urgently required.  
Although immunization with native PfMSP-1 could protect Saimiri and Aotus monkeys against a 
lethal P. falciparum infection (Etlinger et al., 1991; Perrin et al., 1984; Siddiqui et al., 1987), clinical 
vaccination trials in humans – performed with recombinant PfMSP-119 or PfMSP-142 – showed no 
protective efficacy against malaria so far (Ogutu et al., 2009; Sheehy et al., 2012). Thus, possibly 
different MSP-1 regions besides MSP-142 may be important for protection. Indeed it was shown 
recently, that MSP-1 serves as platform for several peripheral MSPs and the formation of these 
complexes on the merozoite surface can be inhibited by targeting MSP-183 resulting in reduced 
parasite growth in vitro (Lin et al., 2016). Furthermore, antibody levels against MSP-183 (Tolle et al., 
1993) or a part of it, namely MSP-1block 2 (Cavanagh et al., 2004; Conway et al., 2000), have been 
correlated with naturally acquired immunity against malaria. Importantly, antibodies against MSP-183 
seem to act via several immune mechanisms such as direct growth inhibition of Plasmodium blood 
stages (Woehlbier et al., 2006), monocyte-dependent ADCI activity (Galamo et al., 2009), 
complement-dependent parasite inhibition (Boyle et al., 2015) and by induction of neutrophil 
respiratory burst (this work). Furthermore, many potential CD8+ T-cell epitopes are distributed 
throughout the complete MSP-1D protein and for some epitopes located in dimorphic regions – 674 
within MSP-183 as well as 291 and 374 within MSP-138 – a stimulation of IFNγ-secreting CD8+ T-cells in 
PBMCs from semi-immune African individuals has been shown (this work).  
Since multiple immune mechanisms probably contribute to naturally acquired immunity against 
malaria (Murungi et al., 2016; Rono et al., 2013), it is advantageous for a malaria vaccine candidate 
to contain both CD4+ and CD8+ T-cell epitopes and to induce a variety of antibody- and cell-mediated 
immune mechanisms. A malaria vaccine providing several relevant epitopes may also impede the 
development of resistance by the parasite and may reduce the effect of genetic diversity between 
individuals, such as the HLA-subtype, for developing a protective immunity.  
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Additionally, most of the difficulties and challenges described for whole parasite vaccinations will not 
apply for a malaria vaccine based on a recombinant protein. Thus, we suggest PfMSP-1D as malaria 
vaccine candidate, possibly in combination with other Plasmodium antigens.  
This work provides useful information about the human immune response against PfMSP-1D, 
acquired by natural exposure to P. falciparum or by experimental challenge with Pf sporozoites. 
Furthermore, the immunological assays established in our laboratory can be applied to characterize 
the humoral and cellular immune response elicited by immunization with MSP-1 during clinical trials. 
Finally, our results further support the ADRB as robust in vitro assay to investigate the function of 
merozoite-specific antibodies and strengthen the candidacy of MSP-1 as promising malaria vaccine 
antigen.      
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7.  Appendices 
7.1. Protein sequence of recombinant PfMSP-1D  
MVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEEEITTKGASAQSGASAQSGASAQGASAQSGASAQSGASAQSGTSGPSGPSGTSPSS
RSNTLPRSNTSSGASPPADASDSDAKSYADLKHRVRNYLFTIKELKYPELFDLTNHMLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLRAKLND
VCANDYCQIPFNLKIRANELDVLKKLVFGYRKPLDNIKDNVGKMEDYIKKNKTTIANINELIEGSKKTIDQNKNADNEEGKKKLYQAQYDLSIYNK
QLEEAHNLISVLEKRIDTLKKNENIKKLLDKINEIKNPPPANSGNTPNTLLDKNKKIEEHEEKIKEIAKTIKFNIDSLFTDPLELEYYLREKNKKVDVTP
KSQDPTKSVQIPKVPYPNGIVYPLPLTDIHNSLAADNDKNSYGDLMNPHTKEKINEKIITDNKERKIFINNIKKKIDLEEKNINHTKEQNKKLLEDYE
KSKKDYEELLEKFYEMKFNNNFNKDVVDKIFSARYTYNVEKQRYNNKFSSSNNSVYNVQKLKKALSYLEDYSLRKGISEKDFNHYYTLKTGLEADI
KKLTEEIKSSENKILEKNFKGLTHSANGSLEVSDIVKLQVQKVLLIKKIEDLRKIELFLKNAQLKDSIHVPNIYKPQNKPEPYYLIVLKKEVDKLKEFIPK
VKDMLKKEQAVLSSITQPLVAASETTEDGGHSTHTLSQSGETEVTEETEETEETVGHTTTVTITLPPTQPSPPKEVKVVNSIEHKSNDNSQALTKT
VYLKKLDEFLTKSYICHKYLVSNSSMDQKLLEVYNLTPEEENELKSCDPLDLLFNIQNNIPAMYSLYDSMNNDLQHLFFELYQKEMIYYLHKLKEE
NHIKKLLEEQKQITGTMSSTSSPGNTTVNTAQSATHSNSQNQQSNASSTNTQNGVAVSSGPAVVEESHDPLTVLSISNDLKGIVSLLNLGNKTK
VPNPLTISTTEMEKFYENILKNNDTYFNDDIKQFVKSNSKVITGLTETQKNALNDEIKKLKDTLQLSFDLYNKYKLKLDRLFNKKKELGQDKMQIKK
LTLLKEQLESKLNSLNNPHNVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEVSIQTEDNYANLEKFRVLSKIDGKL
NDNLHLGKKKLSFLSSGLHHLITELKEVIKNKNYTGNSPSENNKKVNEALKSYENFLPEAKVTTVVTPPQPDVTPSPLSVRVSGSSGSTKEETQIPT
SGSLLTELQQVVQLQNYDEEDDSLVVLPIFGESEDNDEYLDQVVTGEAISVTMDNILSGFENEYDVIYLKPLAGVYRSLKKQIEKNIFTFNLNLNDI
LNSRLKKRKYFLDVLESDLMQFKHISSNEYIIEDSFKLLNSEQKNTLLKSYKYIKESVENDIKFAQEGISYYEKVLAKYKDDLESIKKVIKEEKEKFPSSP
PTTPPSPAKTDEQKKESKFLPFLTNIETLYNNLVNKIDDYLINLKAKINDCNVEKDEAHVKITKLSDLKAIDDKIDLFKNPYDFEAIKKLINDDTKKD
MLGKLLSTGLVQNFPNTIISKLIEGKFQDMLNISQHQCVKKQCPENSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADATC
TEEDSGSSRKKITCECTKPDSYPLFDGIFCSSSN 
Figure 7.1: Protein sequence of recombinant PfMSP-1D. The MSP-1 subunits MSP-183/30 (102 kDa, light grey) 
and MSP-138/42 (90 kDa, dark grey) are produced separately in E.coli and combined to full-length MSP-1D in 
vitro. Recombinant MSP-1D differs in small parts from the native protein: (i) no signal sequence in front of MSP-
183/30, (ii) no GST anchor behind MSP-138/42 and (iii) a Methionin (M) in front of each of the two fragments.  
 
7.2. Antibody titers against MSP-1  
 
Figure 7.2: Antibody levels to MSP-1 in semi-immune individuals and immunized rhesus monkeys. Antibody 
titers to full-length MSP-1D/F and to the four MSP-1 subunits were examined via ELISA in: (i) semi-immune 
individuals from Nouna (n=11, Nouna Pool and single donors 1-11) (ii) malaria-exposed individuals from Kenya 
(WHO Pool, NIBSC code: 10/198; (Bryan D., 2014)) and (iii) rhesus monkeys (n=5, rhesus pool, sample from d70) 
immunized 3x with recombinant MSP-1D. 
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7.3. Mass Spec analysis of Pf schizont lysate 
 
 
Figure 7.3: Mass Spec results. P. falciparum (3d7) schizont lysate was separated on a gel via SDS-PAGE and 
stained with Coomassie brilliant blue. At the MS facility in the ZMBH (Heidelberg) six bands were cut out, 
digested with Trypsin and compared to the Swiss-Prot protein sequence database. The best results for human 
and P. falciparum proteins for band 1-4 (A) and 5-6 (B) are shown. The sequence coverage for each protein is 
indicated with yellow (90-94 % probability) and green (95-100 % probability) color.  
B 
A 
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7.4. Correlations between antibody levels and GIA/ADRB activity 
 
Table 7.1: Spearman`s rank correlation coefficients between antibody levels to MSP-1 or P. falciparum blood 
stages and GIA or ADRB activity. Antibody levels to P. falciparum 3d7 schizont lysate or merozoites or the 
recombinant proteins MSP-1D/F were determined via ELISA in 11 semi-immune individuals from Burkina Faso 
and correlated to their GIA and ADRB activity against P. falciparum 3d7. All correlations are significant, the P 
value is indicated. 
 
7.5. Quality of Nouna PBMCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4: Quality control of PBMCs from a malaria-naïve donor (Heidelberg) and a semi-immune donor 
(Nouna). PBMCs were thawed, stained with CD4-PerCP and CD8-PE antibodies for 20 min, fixed with 1 % PFA 
and analyzed by flow cytometry. (A/C) FSC-SSC diagram showing different cell populations; lymphocytes were 
gated. (B/D) CD4-PerCP and CD8-PE staining of lymphocytes; percentages of stained cells from total / gated 
cells are indicated in the respective field. This experiment was performed by myself during my master thesis.  
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7.6. TUECHMI I, Cytokine analysis (Munich)  
 
Figure 7.5: Cytokine profile of 9 malaria-positive individuals after challenge with 3200 cryopreserved PfSpz. 
This experiment was done by our cooperation partner in Munich (Dr. Michael Pritsch). Sera of the indicated 
volunteers were analyzed by cytokine bead array using flow cytometry for cytokine levels to IL-4, IL-6, IL-10 and 
TNFα at different time points starting at the day before challenge (C-1) up to day 28. Mann-Whitney test was 
used for statistical analysis.  
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7.7 Taxonomy report of peptide 291 (BLAST-p search) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References
 
127 
 
8.  References 
al-Yaman, F., Genton, B., Anders, R.F., Falk, M., Triglia, T., Lewis, D., Hii, J., Beck, H.P., and Alpers, M.P. (1994). Relationship 
between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly 
endemic area of Papua New Guinea. The American journal of tropical medicine and hygiene 51, 593-602. 
al-Yaman, F., Genton, B., Kramer, K.J., Chang, S.P., Hui, G.S., Baisor, M., and Alpers, M.P. (1996). Assessment of the role of 
naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean 
children from malaria morbidity. The American journal of tropical medicine and hygiene 54, 443-448. 
Allison, A.C., and Eugui, E.M. (1983). The role of cell-mediated immune responses in resistance to malaria, with special 
reference to oxidant stress. Annual review of immunology 1, 361-392. 
Aly, A.S., Mikolajczak, S.A., Rivera, H.S., Camargo, N., Jacobs-Lorena, V., Labaied, M., Coppens, I., and Kappe, S.H. (2008). 
Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver 
infection. Molecular microbiology 69, 152-163. 
Aponte, J.J., Menendez, C., Schellenberg, D., Kahigwa, E., Mshinda, H., Vountasou, P., Tanner, M., and Alonso, P.L. (2007). 
Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. 
PLoS medicine 4, e242. 
Badiane, A.S., Bei, A.K., Ahouidi, A.D., Patel, S.D., Salinas, N., Ndiaye, D., Sarr, O., Ndir, O., Tolia, N.H., Mboup, S., and 
Duraisingh, M.T. (2013). Inhibitory humoral responses to the Plasmodium falciparum vaccine candidate EBA-175 are 
independent of the erythrocyte invasion pathway. Clinical and vaccine immunology : CVI 20, 1238-1245. 
Balam, S., Romero, J.F., Bongfen, S.E., Guillaume, P., and Corradin, G. (2012). CSP--a model for in vivo presentation of 
Plasmodium berghei sporozoite antigens by hepatocytes. PloS one 7, e51875. 
Baldwin, M.R., Li, X., Hanada, T., Liu, S.C., and Chishti, A.H. (2015). Merozoite surface protein 1 recognition of host 
glycophorin A mediates malaria parasite invasion of red blood cells. Blood 125, 2704-2711. 
Barouch, D., Friede, T., Stevanović, S., Tussey, L., Smith, K., Rowland-Jones, S., Braud, V., McMichael, A., and Rammensee, 
H.G. (1995). HLA-A2 subtypes are functionally distinct in peptide binding and presentation. The Journal of experimental 
medicine 182, 1847-1856. 
Baruch, D.I., Pasloske, B.L., Singh, H.B., Bi, X., Ma, X.C., Feldman, M., Taraschi, T.F., and Howard, R.J. (1995). Cloning the P. 
falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human 
erythrocytes. Cell 82, 77-87. 
Baum, B. (2006). Left-right asymmetry: actin-myosin through the looking glass. Curr Biol 16, R502-504. 
Beeson, J.G., Drew, D.R., Boyle, M.J., Feng, G., Fowkes, F.J., and Richards, J.S. (2016). Merozoite surface proteins in red 
blood cell invasion, immunity and vaccines against malaria. FEMS microbiology reviews 40, 343-372. 
Bejon, P., Andrews, L., Andersen, R.F., Dunachie, S., Webster, D., Walther, M., Gilbert, S.C., Peto, T., and Hill, A.V. (2005). 
Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative 
polymerase chain reaction studies of volunteers challenged with malaria sporozoites. The Journal of infectious diseases 191, 
619-626. 
Belnoue, E., Costa, F.T., Frankenberg, T., Vigario, A.M., Voza, T., Leroy, N., Rodrigues, M.M., Landau, I., Snounou, G., and 
Renia, L. (2004). Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under 
chloroquine treatment. Journal of immunology 172, 2487-2495. 
Bergmann-Leitner, E.S., Duncan, E.H., and Angov, E. (2009). MSP-1p42-specific antibodies affect growth and development 
of intra-erythrocytic parasites of Plasmodium falciparum. Malaria journal 8, 183. 
Bergmann-Leitner, E.S., Duncan, E.H., Mullen, G.E., Burge, J.R., Khan, F., Long, C.A., Angov, E., and Lyon, J.A. (2006). Critical 
evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. 
The American journal of tropical medicine and hygiene 75, 437-442. 
Bisseye, C., Yindom, L.M., Simporé, J., Morgan, W.D., Holder, A.A., and Ismaili, J. (2011). An engineered Plasmodium 
falciparum C-terminal 19-kilodalton merozoite surface protein 1 vaccine candidate induces high levels of interferon-gamma 
production associated with cellular immune responses to specific peptide sequences in Gambian adults naturally exposed 
to malaria. Clinical and experimental immunology 166, 366-373. 
Biswas, S., Choudhary, P., Elias, S.C., Miura, K., Milne, K.H., de Cassan, S.C., Collins, K.A., Halstead, F.D., Bliss, C.M., Ewer, 
K.J., et al. (2014). Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA 
immunization, controlled human malaria infection and natural exposure. PloS one 9, e107903. 
References
 
128 
 
Blackman, M.J., Heidrich, H.G., Donachie, S., McBride, J.S., and Holder, A.A. (1990). A single fragment of a malaria merozoite 
surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. The 
Journal of experimental medicine 172, 379-382. 
Blackman, M.J., and Holder, A.A. (1992). Secondary processing of the Plasmodium falciparum merozoite surface protein-1 
(MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated 
complex with other fragments of the MSP1. Molecular and biochemical parasitology 50, 307-315. 
Blackman, M.J., Scott-Finnigan, T.J., Shai, S., and Holder, A.A. (1994). Antibodies inhibit the protease-mediated processing 
of a malaria merozoite surface protein. The Journal of experimental medicine 180, 389-393. 
Borrmann, S., and Matuschewski, K. (2011). Targeting Plasmodium liver stages: better late than never. Trends Mol Med 17, 
527-536. 
Bouharoun-Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T., and Druilhe, P. (1990). Antibodies that 
protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in 
vitro, but act in cooperation with monocytes. The Journal of experimental medicine 172, 1633-1641. 
Bowman, N.M., Juliano, J.J., Snider, C.J., Kharabora, O., Meshnick, S.R., Vulule, J., John, C.C., and Moormann, A.M. (2016). 
Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan 
Children from Regions of Different Malaria Transmission Intensity. The American journal of tropical medicine and hygiene 
95, 580-587. 
Boyle, M.J., Reiling, L., Feng, G., Langer, C., Osier, F.H., Aspeling-Jones, H., Cheng, Y.S., Stubbs, J., Tetteh, K.K., Conway, D.J., 
et al. (2015). Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are 
Associated with Protection against Malaria. Immunity 42, 580-590. 
Boyle, M.J., Richards, J.S., Gilson, P.R., Chai, W., and Beeson, J.G. (2010a). Interactions with heparin-like molecules during 
erythrocyte invasion by Plasmodium falciparum merozoites. Blood 115, 4559-4568. 
Boyle, M.J., Wilson, D.W., and Beeson, J.G. (2013). New approaches to studying Plasmodium falciparum merozoite invasion 
and insights into invasion biology. International journal for parasitology 43, 1-10. 
Boyle, M.J., Wilson, D.W., Richards, J.S., Riglar, D.T., Tetteh, K.K., Conway, D.J., Ralph, S.A., Baum, J., and Beeson, J.G. 
(2010b). Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine 
and drug development. Proceedings of the National Academy of Sciences of the United States of America 107, 14378-
14383. 
Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the 
principle of protein-dye binding. Analytical biochemistry 72, 248-254. 
Brando, C., Richardson, J.H., Murphy, J., Ockenhouse, C.F., and Kamau, E. (2014). Phenotypic characterization of 
Plasmodium berghei responsive CD8+ T cells after immunization with live sporozoites under chloroquine cover. Malaria 
journal 13, 92. 
Brown, J., and Smalley, M.E. (1981). Inhibition of the in vitro growth of Plasmodium falciparum by human 
polymorphonuclear neutrophil leucocytes. Clinical and experimental immunology 46, 106-109. 
Bruhns, P. (2012). Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119, 5640-
5649. 
Bryan D, S.N., Rigsby P, Dougall T and Ho M. M    (2014). International collaborative study to evaluate and establish the 1st 
WHO Reference Reagent for anti-malaria (Plasmodium falciparum) human serum. WHO/BS/2014.2235  
Bull, P.C., and Abdi, A.I. (2016). The role of PfEMP1 as targets of naturally acquired immunity to childhood malaria: 
prospects for a vaccine. Parasitology 143, 171-186. 
Butler, N.S., Schmidt, N.W., Vaughan, A.M., Aly, A.S., Kappe, S.H., and Harty, J.T. (2011). Superior antimalarial immunity 
after vaccination with late liver stage-arresting genetically attenuated parasites. Cell host & microbe 9, 451-462. 
Cao, K., Moormann, A.M., Lyke, K.E., Masaberg, C., Sumba, O.P., Doumbo, O.K., Koech, D., Lancaster, A., Nelson, M., Meyer, 
D., et al. (2004). Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA 
class I loci. Tissue antigens 63, 293-325. 
Carralot, J.-P., Lemmel, C., Stevanovic, S., and Pascolo, S. (2008). Mass spectrometric identification of an HLA-A*0201 
epitope from Plasmodium falciparum MSP-1. International immunology 20, 1451-1456. 
Caulfield, T.W.T.M.J. (2004). Identification of T-Cell Epitopes Using ELISpot and Peptide Pool Arrays. In Molecular Diagnosis 
of Infectious Diseases, pp. pp 121-132. 
Cavanagh, D.R., Dodoo, D., Hviid, L., Kurtzhals, J.A.L., Theander, T.G., Akanmori, B.D., Polley, S., Conway, D.J., Koram, K., and 
McBride, J.S. (2004). Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are 
associated with protection against clinical malaria. Infection and immunity 72, 6492-6502. 
References
 
129 
 
Cavanagh, D.R., Kocken, C.H., White, J.H., Cowan, G.J., Samuel, K., Dubbeld, M.A., Voorberg-van der Wel, A., Thomas, A.W., 
McBride, J.S., and Arnot, D.E. (2014). Antibody responses to a novel Plasmodium falciparum merozoite surface protein 
vaccine correlate with protection against experimental malaria infection in Aotus monkeys. PloS one 9, e83704. 
Chang, S.P., Case, S.E., Gosnell, W.L., Hashimoto, A., Kramer, K.J., Tam, L.Q., Hashiro, C.Q., Nikaido, C.M., Gibson, H.L., Lee-
Ng, C.T., et al. (1996). A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite 
surface protein 1 protects Aotus monkeys against malaria. Infection and immunity 64, 253-261. 
Chelimo, K., Embury, P.B., Sumba, P.O., Vulule, J., Ofulla, A.V., Long, C., Kazura, J.W., and Moormann, A.M. (2011). Age-
related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1. PloS one 6, 
e24852. 
Chelimo, K., Sumba, P.O., Kazura, J.W., Ofula, A.V., and John, C.C. (2003). Interferon-gamma responses to Plasmodium 
falciparum liver-stage antigen-1 and merozoite-surface protein-1 increase with age in children in a malaria holoendemic 
area of western Kenya. Malaria journal 2, 37. 
Cherif, M.K., Sanou, G.S., Bougouma, E.C., Diarra, A., Ouedraogo, A., Dolo, A., Troye-Blomberg, M., Cavanagh, D.R., Theisen, 
M., Modiano, D., et al. (2015). Is Fc gamma receptor IIA (FcgammaRIIA) polymorphism associated with clinical malaria and 
Plasmodium falciparum specific antibody levels in children from Burkina Faso? Acta tropica 142, 41-46. 
Chiu, C.Y., Hodder, A.N., Lin, C.S., Hill, D.L., Li Wai Suen, C.S., Schofield, L., Siba, P.M., Mueller, I., Cowman, A.F., and Hansen, 
D.S. (2015). Antibodies to the Plasmodium falciparum Proteins MSPDBL1 and MSPDBL2 Opsonize Merozoites, Inhibit 
Parasite Growth, and Predict Protection From Clinical Malaria. The Journal of infectious diseases. 
Clark, I.A. (1987). Monokines and lymphokines in malarial pathology. Annals of tropical medicine and parasitology 81, 577-
585. 
Clark, I.A., and Hunt, N.H. (1983). Evidence for reactive oxygen intermediates causing hemolysis and parasite death in 
malaria. Infection and immunity 39, 1-6. 
Clyde, D.F., Most, H., McCarthy, V.C., and Vanderberg, J.P. (1973). Immunization of man against sporozite-induced 
falciparum malaria. The American journal of the medical sciences 266, 169-177. 
Cockburn, I.A., Amino, R., Kelemen, R.K., Kuo, S.C., Tse, S.W., Radtke, A., Mac-Daniel, L., Ganusov, V.V., Zavala, F., and 
Menard, R. (2013). In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages. Proceedings of the National 
Academy of Sciences of the United States of America 110, 9090-9095. 
Cockburn, I.A., Tse, S.W., and Zavala, F. (2014). CD8+ T Cells Eliminate Liver-Stage Plasmodium berghei Parasites without 
Detectable Bystander Effect. Infection and immunity 82, 1460-1464. 
Cockburn, I.A., and Zavala, F. (2016). Dendritic cell function and antigen presentation in malaria. Current opinion in 
immunology 40, 1-6. 
Cohen, J., Benns, S., Vekemans, J., and Leach, A. (2010). [The malaria vaccine candidate RTS,S/AS is in phase III clinical 
trials]. Ann Pharm Fr 68, 370-379. 
Cohen, S., McGregor, I.A., and Carrington, S. (1961). Gamma-globulin and acquired immunity to human malaria. Nature 
192, 733-737. 
Conway, D.J., Cavanagh, D.R., Tanabe, K., Roper, C., Mikes, Z.S., Sakihama, N., Bojang, K.A., Oduola, A.M., Kremsner, P.G., 
Arnot, D.E., et al. (2000). A principal target of human immunity to malaria identified by molecular population genetic and 
immunological analyses. Nature medicine 6, 689-692. 
Cooke, G.S., Aucan, C., Walley, A.J., Segal, S., Greenwood, B.M., Kwiatkowski, D.P., and Hill, A.V. (2003). Association of 
Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa. The American journal of tropical medicine 
and hygiene 69, 565-568. 
Courtin, D., Oesterholt, M., Huismans, H., Kusi, K., Milet, J., Badaut, C., Gaye, O., Roeffen, W., Remarque, E.J., Sauerwein, R., 
et al. (2009). The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection 
against Plasmodium falciparum malaria. PloS one 4, e7590. 
Cowan, G.J., Creasey, A.M., Dhanasarnsombut, K., Thomas, A.W., Remarque, E.J., and Cavanagh, D.R. (2011). A malaria 
vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. PloS 
one 6, e26616. 
Cowman, A.F., and Crabb, B.S. (2006). Invasion of red blood cells by malaria parasites. Cell 124, 755-766. 
Crompton, P.D., Kayala, M.A., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G.E., Molina, D.M., Burk, C.R., Waisberg, M., 
Jasinskas, A., et al. (2010a). A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria 
season by protein microarray. Proceedings of the National Academy of Sciences of the United States of America 107, 6958-
6963. 
References
 
130 
 
Crompton, P.D., Miura, K., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G., Doumbo, S., Doumtabe, D., Kone, Y., Huang, C.-
Y., et al. (2010b). In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infection and immunity 78, 
737-745. 
Cyrklaff, M., Srismith, S., Nyboer, B., Burda, K., Hoffmann, A., Lasitschka, F., Adjalley, S., Bisseye, C., Simpore, J., Mueller, 
A.K., et al. (2016). Oxidative insult can induce malaria-protective trait of sickle and fetal erythrocytes. Nature 
communications 7, 13401. 
Dahlgren, C., and Karlsson, A. (1999). Respiratory burst in human neutrophils. Journal of immunological methods 232, 3-14. 
Daly, T.M., and Long, C.A. (1995). Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays 
a predominant role in controlling blood-stage infection in rodent malaria. Journal of immunology (Baltimore, Md. : 1950) 
155, 236-243. 
Das, S., Hertrich, N., Perrin, A.J., Withers-Martinez, C., Collins, C.R., Jones, M.L., Watermeyer, J.M., Fobes, E.T., Martin, S.R., 
Saibil, H.R., et al. (2015). Processing of Plasmodium falciparum Merozoite Surface Protein MSP1 Activates a Spectrin-Binding 
Function Enabling Parasite Egress from RBCs. Cell host & microbe 18, 433-444. 
Dent, A.E., Bergmann-Leitner, E.S., Wilson, D.W., Tisch, D.J., Kimmel, R., Vulule, J., Sumba, P.O., Beeson, J.G., Angov, E., 
Moormann, A.M., and Kazura, J.W. (2008). Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to 
age and protection from parasitemia in Kenyan children and adults. PloS one 3, e3557. 
Dent, A.E., Chelimo, K., Sumba, P.O., Spring, M.D., Crabb, B.S., Moormann, A.M., Tisch, D.J., and Kazura, J.W. (2009). 
Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults. Malaria journal 8, 162. 
Dicko, A., Sagara, I., Ellis, R.D., Miura, K., Guindo, O., Kamate, B., Sogoba, M., Niambele, M.B., Sissoko, M., Baby, M., et al. 
(2008). Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PloS one 3, e1563. 
Doolan, D.L., and Hoffman, S.L. (2000). The complexity of protective immunity against liver-stage malaria. Journal of 
immunology (Baltimore, Md. : 1950) 165, 1453-1462. 
Doolan, D.L., Wizel, B., and Hoffman, S.L. (1996). Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--
elucidation on the basis of HLA peptide binding motifs. Immunologic research 15, 280-305. 
Douglas, A.D., de Cassan, S.C., Dicks, M.D., Gilbert, S.C., Hill, A.V., and Draper, S.J. (2010). Tailoring subunit vaccine 
immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-
adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28, 7167-7178. 
Douglas, A.D., Williams, A.R., Knuepfer, E., Illingworth, J.J., Furze, J.M., Crosnier, C., Choudhary, P., Bustamante, L.Y., 
Zakutansky, S.E., Awuah, D.K., et al. (2014). Neutralization of Plasmodium falciparum merozoites by antibodies against 
PfRH5. Journal of immunology 192, 245-258. 
Drakeley, C.J., Corran, P.H., Coleman, P.G., Tongren, J.E., McDonald, S.L., Carneiro, I., Malima, R., Lusingu, J., Manjurano, A., 
Nkya, W.M., et al. (2005). Estimating medium- and long-term trends in malaria transmission by using serological markers of 
malaria exposure. Proceedings of the National Academy of Sciences of the United States of America 102, 5108-5113. 
Draper, S.J., Goodman, A.L., Biswas, S., Forbes, E.K., Moore, A.C., Gilbert, S.C., and Hill, A.V. (2009). Recombinant viral 
vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against 
malaria. Cell host & microbe 5, 95-105. 
Druilhe, P., Spertini, F., Soesoe, D., Corradin, G., Mejia, P., Singh, S., Audran, R., Bouzidi, A., Oeuvray, C., and Roussilhon, C. 
(2005). A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS medicine 2, e344. 
Duncan, C.J., Hill, A.V., and Ellis, R.D. (2012). Can growth inhibition assays (GIA) predict blood-stage malaria vaccine 
efficacy? Human vaccines & immunotherapeutics 8, 706-714. 
Duncan, C.J.A., Sheehy, S.H., Ewer, K.J., Douglas, A.D., Collins, K.A., Halstead, F.D., Elias, S.C., Lillie, P.J., Rausch, K., Aebig, J., 
et al. (2011). Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine 
AMA1-C1/Alhydrogel+CPG 7909. PloS one 6, e22271. 
Dups, J.N., Pepper, M., and Cockburn, I.A. (2014). Antibody and B cell responses to Plasmodium sporozoites. Frontiers in 
microbiology 5, 625. 
Dutta, S., Haynes, J.D., Moch, J.K., Barbosa, A., and Lanar, D.E. (2003). Invasion-inhibitory antibodies inhibit proteolytic 
processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proceedings of the National Academy of 
Sciences of the United States of America 100, 12295-12300. 
Egan, A., Waterfall, M., Pinder, M., Holder, A., and Riley, E. (1997). Characterization of human T- and B-cell epitopes in the C 
terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with 
numerous disulfide bonds. Infection and immunity 65, 3024-3031. 
References
 
131 
 
Egan, A.F., Burghaus, P., Druilhe, P., Holder, A.A., and Riley, E.M. (1999). Human antibodies to the 19kDa C-terminal 
fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite immunology 21, 
133-139. 
Egan, A.F., Morris, J., Barnish, G., Allen, S., Greenwood, B.M., Kaslow, D.C., Holder, A.A., and Riley, E.M. (1996). Clinical 
immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the 
merozoite surface antigen, PfMSP-1. The Journal of infectious diseases 173, 765-769. 
Eisenhut, M. (2007). Immunity to blood stages of Plasmodium falciparum is dependent on a specific pattern of 
immunoglobulin subclass responses to multiple blood stage antigens. Med Hypotheses 69, 804-808. 
Epp, C., Kauth, C.W., Bujard, H., and Lutz, R. (2003). Expression and purification of Plasmodium falciparum MSP-1(42): A 
malaria vaccine candidate. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 786, 
61-72. 
Epstein, J.E., Paolino, K.M., Richie, T.L., Sedegah, M., Singer, A., Ruben, A.J., Chakravarty, S., Stafford, A., Ruck, R.C., Eappen, 
A.G., et al. (2017). Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI insight 2, e89154. 
Epstein, J.E., and Richie, T.L. (2013). The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a 
review. Current opinion in infectious diseases 26, 420-428. 
Epstein, J.E., Tewari, K., Lyke, K.E., Sim, B.K., Billingsley, P.F., Laurens, M.B., Gunasekera, A., Chakravarty, S., James, E.R., 
Sedegah, M., et al. (2011). Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. 
Science 334, 475-480. 
Etlinger, H.M., Caspers, P., Matile, H., Schoenfeld, H.J., Stueber, D., and Takacs, B. (1991). Ability of recombinant or native 
proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infection and immunity 59, 3498-
3503. 
Farrow, R.E., Green, J., Katsimitsoulia, Z., Taylor, W.R., Holder, A.A., and Molloy, J.E. (2011). The mechanism of erythrocyte 
invasion by the malarial parasite, Plasmodium falciparum. Seminars in cell & developmental biology 22, 953-960. 
Fenton, B., Clark, J.T., Khan, C.M., Robinson, J.V., Walliker, D., Ridley, R., Scaife, J.G., and McBride, J.S. (1991). Structural and 
antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium 
falciparum. Mol Cell Biol 11, 963-971. 
Fernandez-Ruiz, D., Ng, W.Y., Holz, L.E., Ma, J.Z., Zaid, A., Wong, Y.C., Lau, L.S., Mollard, V., Cozijnsen, A., Collins, N., et al. 
(2016). Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection. Immunity 45, 
889-902. 
Ferreira, A., Schofield, L., Enea, V., Schellekens, H., van der Meide, P., Collins, W.E., Nussenzweig, R.S., and Nussenzweig, V. 
(1986). Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232, 881-
884. 
Fowkes, F.J.I., Richards, J.S., Simpson, J.A., and Beeson, J.G. (2010). The relationship between anti-merozoite antibodies and 
incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS medicine 7, e1000218. 
Frevert, U., and Krzych, U. (2015). Plasmodium cellular effector mechanisms and the hepatic microenvironment. Frontiers in 
microbiology 6, 482. 
Fried, M., and Duffy, P.E. (2015). Designing a VAR2CSA-based vaccine to prevent placental malaria. Vaccine 33, 7483-7488. 
Friedman, M.J. (1979). Oxidant damage mediates variant red cell resistance to malaria. Nature 280, 245-247. 
Friesen, J., Silvie, O., Putrianti, E.D., Hafalla, J.C., Matuschewski, K., and Borrmann, S. (2010). Natural immunization against 
malaria: causal prophylaxis with antibiotics. Science translational medicine 2, 40ra49. 
Frischknecht, F., Baldacci, P., Martin, B., Zimmer, C., Thiberge, S., Olivo-Marin, J.C., Shorte, S.L., and Menard, R. (2004). 
Imaging movement of malaria parasites during transmission by Anopheles mosquitoes. Cellular microbiology 6, 687-694. 
Früh, K., Doumbo, O., Müller, H.M., Koita, O., McBride, J., Crisanti, A., Touré, Y., and Bujard, H. (1991). Human antibody 
response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived. Infection and 
immunity 59, 1319-1324. 
Galamo, C.D., Jafarshad, A., Blanc, C., and Druilhe, P. (2009). Anti-MSP1 block 2 antibodies are effective at parasite killing in 
an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition. The Journal of infectious diseases 
199, 1151-1154. 
Gbedande, K., Fievet, N., Viwami, F., Ezinmegnon, S., Issifou, S., Chippaux, J.P., Dossou, Y., Moutairou, K., Massougbodji, A., 
Ndam, N., et al. (2017). Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine 
antigen-specific memory B & T cell activity in Beninese primigravidae. Vaccine 35, 3474-3481. 
References
 
132 
 
Genton, B., Al-Yaman, F., Betuela, I., Anders, R.F., Saul, A., Baea, K., Mellombo, M., Taraika, J., Brown, G.V., Pye, D., et al. 
(2003). Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against 
Plasmodium falciparum in Papua New Guinean children. Vaccine 22, 30-41. 
Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R.F., Saul, A., Rare, L., Baisor, M., Lorry, K., Brown, G.V., et al. (2002). 
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on 
parasite populations in a phase 1-2b trial in Papua New Guinea. The Journal of infectious diseases 185, 820-827. 
Gilson, P.R., and Crabb, B.S. (2009). Morphology and kinetics of the three distinct phases of red blood cell invasion by 
Plasmodium falciparum merozoites. International journal for parasitology 39, 91-96. 
Gilson, P.R., Nebl, T., Vukcevic, D., Moritz, R.L., Sargeant, T., Speed, T.P., Schofield, L., and Crabb, B.S. (2006). Identification 
and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium 
falciparum. Molecular & cellular proteomics : MCP 5, 1286-1299. 
Goel, V.K., Li, X., Chen, H., Liu, S.-C., Chishti, A.H., and Oh, S.S. (2003). Band 3 is a host receptor binding merozoite surface 
protein 1 during the Plasmodium falciparum invasion of erythrocytes. Proceedings of the National Academy of Sciences of 
the United States of America 100, 5164-5169. 
Golenser, J., Kamyl, M., Tsafack, A., Marva, E., Cohen, A., Kitrossky, N., and Chevion, M. (1992). Correlation between 
destruction of malarial parasites by polymorphonuclear leucocytes and oxidative stress. Free radical research 
communications 17, 249-262. 
Gomez-Perez, G.P., Legarda, A., Munoz, J., Sim, B.K., Ballester, M.R., Dobano, C., Moncunill, G., Campo, J.J., Cistero, P., 
Jimenez, A., et al. (2015). Controlled human malaria infection by intramuscular and direct venous inoculation of 
cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on 
infectivity rates. Malaria journal 14, 306. 
Gopalakrishnan, A.M., and Kumar, N. (2015). Antimalarial action of artesunate involves DNA damage mediated by reactive 
oxygen species. Antimicrobial agents and chemotherapy 59, 317-325. 
Greve, B., Kremsner, P.G., Lell, B., Luckner, D., and Schmid, D. (2000). Malarial anaemia in African children associated with 
high oxygen-radical production. Lancet 355, 40-41. 
Greve, B., Lehman, L.G., Lell, B., Luckner, D., Schmidt-Ott, R., and Kremsner, P.G. (1999). High oxygen radical production is 
associated with fast parasite clearance in children with Plasmodium falciparum malaria. The Journal of infectious diseases 
179, 1584-1586. 
Gunjan, S., Singh, S.K., Sharma, T., Dwivedi, H., Chauhan, B.S., Imran Siddiqi, M., and Tripathi, R. (2016). Mefloquine induces 
ROS mediated programmed cell death in malaria parasite: Plasmodium. Apoptosis : an international journal on 
programmed cell death 21, 955-964. 
Gupta, S., Snow, R.W., Donnelly, C.A., Marsh, K., and Newbold, C. (1999). Immunity to non-cerebral severe malaria is 
acquired after one or two infections. Nature medicine 5, 340-343. 
Hafalla, J.C., Silvie, O., and Matuschewski, K. (2011). Cell biology and immunology of malaria. Immunological reviews 240, 
297-316. 
Halbroth, B.R., and Draper, S.J. (2015). Recent developments in malaria vaccinology. Advances in parasitology 88, 1-49. 
Haldar, K., Murphy, S.C., Milner, D.A., and Taylor, T.E. (2007). Malaria: mechanisms of erythrocytic infection and 
pathological correlates of severe disease. Annu Rev Pathol 2, 217-249. 
Haussig, J.M., Matuschewski, K., and Kooij, T.W. (2011). Inactivation of a Plasmodium apicoplast protein attenuates 
formation of liver merozoites. Molecular microbiology 81, 1511-1525. 
Herrera, S., Herrera, M.A., Perlaza, B.L., Burki, Y., Caspers, P., Dobeli, H., Rotmann, D., and Certa, U. (1990). Immunization of 
Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins. Proceedings of the National Academy of 
Sciences of the United States of America 87, 4017-4021. 
Herrera, S., Rudin, W., Herrera, M., Clavijo, P., Mancilla, L., Plata, C., Matile, H., and Certa, U. (1993). A conserved region of 
the MSP-1 surface protein of Plasmodium falciparum contains a recognition sequence for erythrocyte spectrin. The EMBO 
journal 12, 1607-1614. 
Hill, D.L., Eriksson, E.M., Li Wai Suen, C.S., Chiu, C.Y., Ryg-Cornejo, V., Robinson, L.J., Siba, P.M., Mueller, I., Hansen, D.S., and 
Schofield, L. (2013). Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PloS 
one 8, e74627. 
Hill, D.L., Wilson, D.W., Sampaio, N.G., Eriksson, E.M., Ryg-Cornejo, V., Harrison, G.L., Uboldi, A.D., Robinson, L.J., Beeson, 
J.G., Siba, P., et al. (2016). Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. 
Infection and immunity 84, 2175-2184. 
References
 
133 
 
Hirunpetcharat, C., Tian, J.H., Kaslow, D.C., van Rooijen, N., Kumar, S., Berzofsky, J.A., Miller, L.H., and Good, M.F. (1997). 
Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the 
merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of 
protection with antigen-specific antibody titer, but not with effector CD4+ T cells. Journal of immunology (Baltimore, Md. : 
1950) 159, 3400-3411. 
Hodgson, S.H., Llewellyn, D., Silk, S.E., Milne, K.H., Elias, S.C., Miura, K., Kamuyu, G., Juma, E.A., Magiri, C., Muia, A., et al. 
(2016). Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection. 
Frontiers in microbiology 7, 1604. 
Hoffman, S.L., Goh, L.M., Luke, T.C., Schneider, I., Le, T.P., Doolan, D.L., Sacci, J., de la Vega, P., Dowler, M., Paul, C. , et al. 
(2002). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum 
sporozoites. The Journal of infectious diseases 185, 1155-1164. 
Hoffman, S.L., Oster, C.N., Plowe, C.V., Woollett, G.R., Beier, J.C., Chulay, J.D., Wirtz, R.A., Hollingdale, M.R., and Mugambi, 
M. (1987). Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 
(New York, N.Y.) 237, 639-642. 
Holder, A.A. (2009). The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to 
malaria. Parasitology 136, 1445-1456. 
Holder, A.A., and Freeman, R.R. (1981). Immunization against blood-stage rodent malaria using purified parasite antigens. 
Nature 294, 361-364. 
Holder, A.A., and Freeman, R.R. (1982). Biosynthesis and processing of a Plasmodium falciparum schizont antigen 
recognized by immune serum and a monoclonal antibody. The Journal of experimental medicine 156, 1528-1538. 
Holder, A.A., Lockyer, M.J., Odink, K.G., Sandhu, J.S., Riveros-Moreno, V., Nicholls, S.C., Hillman, Y., Davey, L.S., Tizard, M.L., 
Schwarz, R.T., and Freeman, R.R. (1985). Primary structure of the precursor to the three major surface antigens of 
Plasmodium falciparum merozoites. Nature 317, 270-273. 
Hollingdale, M.R., and Sedegah, M. (2017). Development of whole sporozoite malaria vaccines. Expert review of vaccines 
16, 45-54. 
Honeyman, M.C., Brusic, V., Stone, N.L., and Harrison, L.C. (1998). Neural network-based prediction of candidate T-cell 
epitopes. Nature biotechnology 16, 966-969. 
Huang, J., Li, X., Coelho-dos-Reis, J.G., Zhang, M., Mitchell, R., Nogueira, R.T., Tsao, T., Noe, A.R., Ayala, R., Sahi, V., et al. 
(2015). Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective 
human humoral immunity against malaria. Journal of immunological methods 427, 42-50. 
Huizinga, T.W., van Kemenade, F., Koenderman, L., Dolman, K.M., von dem Borne, A.E., Tetteroo, P.A., and Roos, D. (1989). 
The 40-kDa Fc gamma receptor (FcRII) on human neutrophils is essential for the IgG-induced respiratory burst and IgG-
induced phagocytosis. Journal of immunology 142, 2365-2369. 
Idler, I. (2004). Untersuchungen zur zellulären und humoralen Immunantwort gegen das Merozoitenoberflächenprotein-1 
des Malariaerregers Plasmodium falciparum.  (Heidelberg). 
Imai, T., Shen, J., Chou, B., Duan, X., Tu, L., Tetsutani, K., Moriya, C., Ishida, H., Hamano, S., Shimokawa, C., et al. (2010). 
Involvement of CD8+ T cells in protective immunity against murine blood-stage infection with Plasmodium yoelii 17XL 
strain. European journal of immunology 40, 1053-1061. 
Ishizuka, A.S., Lyke, K.E., DeZure, A., Berry, A.A., Richie, T.L., Mendoza, F.H., Enama, M.E., Gordon, I.J., Chang, L.J., Sarwar, 
U.N., et al. (2016). Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature medicine 
22, 614-623. 
Jagannathan, P., Nankya, F., Stoyanov, C., Eccles-James, I., Sikyomu, E., Naluwu, K., Wamala, S., Nalubega, M., Briggs, J., 
Bowen, K., et al. (2015). IFNgamma Responses to Pre-erythrocytic and Blood-stage Malaria Antigens Exhibit Differential 
Associations With Past Exposure and Subsequent Protection. The Journal of infectious diseases 211, 1987-1996. 
Jäschke, A. (2012). Analysis of the human immune response against the Merozoite Surface Protein 1 (MSP-1) from 
Plasmodium falciparum. In Center for Infectious Diseases - Parasitology (University of Heidelberg). 
Jäschke A., Coulibaly B., Remarque E.J., Bujard H., Epp C. (2017). Merozoite surface protein-1 from P. falciparum is a major 
target of opsonizing antibodies in individuals with acquired immunity against malaria (submitted to Clinical and Vaccine 
Immunology (CVI)). 
Jepsen, M.P., Jogdand, P.S., Singh, S.K., Esen, M., Christiansen, M., Issifou, S., Hounkpatin, A.B., Ateba-Ngoa, U., Kremsner, 
P.G., Dziegiel, M.H., et al. (2013). The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from 
malaria endemic and non-endemic areas. The Journal of infectious diseases 208, 479-488. 
References
 
134 
 
Jobe, O., Donofrio, G., Sun, G., Liepinsh, D., Schwenk, R., and Krzych, U. (2009). Immunization with radiation-attenuated 
Plasmodium berghei sporozoites induces liver cCD8alpha+DC that activate CD8+T cells against liver-stage malaria. PloS one 
4, e5075. 
Jobe, O., Lumsden, J., Mueller, A.K., Williams, J., Silva-Rivera, H., Kappe, S.H., Schwenk, R.J., Matuschewski, K., and Krzych, 
U. (2007). Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by 
major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. The Journal of infectious 
diseases 196, 599-607. 
Joos, C., Marrama, L., Polson, H.E.J., Corre, S., Diatta, A.-M., Diouf, B., Trape, J.-F., Tall, A., Longacre, S., and Perraut, R. 
(2010). Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites 
opsonized with human serum antibodies. PloS one 5, e9871. 
Joos, C., Varela, M.L., Mbengue, B., Mansourou, A., Marrama, L., Sokhna, C., Tall, A., Trape, J.F., Toure, A., Mercereau-
Puijalon, O., and Perraut, R. (2015). Antibodies to Plasmodium falciparum merozoite surface protein-1p19 malaria vaccine 
candidate induce antibody-dependent respiratory burst in human neutrophils. Malaria journal 14, 409. 
Kapulu, M.C., Da, D.F., Miura, K., Li, Y., Blagborough, A.M., Churcher, T.S., Nikolaeva, D., Williams, A.R., Goodman, A.L., 
Sangare, I., et al. (2015). Comparative assessment of transmission-blocking vaccine candidates against Plasmodium 
falciparum. Scientific reports 5, 11193. 
Kauth, C.W., Epp, C., Bujard, H., and Lutz, R. (2003). The merozoite surface protein 1 complex of human malaria parasite 
Plasmodium falciparum: interactions and arrangements of subunits. The Journal of biological chemistry 278, 22257-22264. 
Kauth, C.W., Woehlbier, U., Kern, M., Mekonnen, Z., Lutz, R., Mücke, N., Langowski, J., and Bujard, H. (2006). Interactions 
between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. The Journal of biological 
chemistry 281, 31517-31527. 
Koussis, K., Withers-Martinez, C., Yeoh, S., Child, M., Hackett, F., Knuepfer, E., Juliano, L., Woehlbier, U., Bujard, H., and 
Blackman, M.J. (2009). A multifunctional serine protease primes the malaria parasite for red blood cell invasion. The EMBO 
journal 28, 725-735. 
Krzych, U., Lyon, J.A., Jareed, T., Schneider, I., Hollingdale, M.R., Gordon, D.M., and Ballou, W.R. (1995). T lymphocytes from 
volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. 
Journal of immunology (Baltimore, Md. : 1950) 155, 4072-4077. 
Krzych, U., Zarling, S., and Pichugin, A. (2014). Memory T cells maintain protracted protection against malaria. Immunology 
letters 161, 189-195. 
Kublin, J.G., Mikolajczak, S.A., Sack, B.K., Fishbaugher, M.E., Seilie, A., Shelton, L., VonGoedert, T., Firat, M., Magee, S., 
Fritzen, E., et al. (2017). Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human 
subjects. Science translational medicine 9. 
Kumar, S., Yadava, A., Keister, D.B., Tian, J.H., Ohl, M., Perdue-Greenfield, K.A., Miller, L.H., and Kaslow, D.C. (1995). 
Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. 
Molecular medicine (Cambridge, Mass.) 1, 325-332. 
Kumaratilake, L.M., Ferrante, A., Jaeger, T., and Rzepczyk, C.M. (1992). Effects of cytokines, complement, and antibody on 
the neutrophil respiratory burst and phagocytic response to Plasmodium falciparum merozoites. Infection and immunity 60, 
3731-3738. 
Lalvani, A., Hurt, N., Aidoo, M., Kibatala, P., Tanner, M., and Hill, A.V. (1996). Cytotoxic T lymphocytes to Plasmodium 
falciparum epitopes in an area of intense and perennial transmission in Tanzania. European journal of immunology 26, 773-
779. 
Lewis, M.D., Behrends, J., Sa, E.C.C., Mendes, A.M., Lasitschka, F., Sattler, J.M., Heiss, K., Kooij, T.W., Prudencio, M., 
Bringmann, G., et al. (2015). Chemical attenuation of Plasmodium in the liver modulates severe malaria disease 
progression. Journal of immunology 194, 4860-4870. 
Li, X., Chen, H., Oo, T.H., Daly, T.M., Bergman, L.W., Liu, S.C., Chishti, A.H., and Oh, S.S. (2004). A co-ligand complex anchors 
Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3. The Journal of biological chemistry 279, 
5765-5771. 
Lin, C.S., Uboldi, A.D., Epp, C., Bujard, H., Tsuboi, T., Czabotar, P.E., and Cowman, A.F. (2016). Multiple Plasmodium 
falciparum Merozoite Surface Protein 1 Complexes Mediate Merozoite Binding to Human Erythrocytes. The Journal of 
biological chemistry 291, 7703-7715. 
Llewellyn, D., de Cassan, S.C., Williams, A.R., Douglas, A.D., Forbes, E.K., Adame-Gallegos, J.R., Shi, J., Pleass, R.J., and 
Draper, S.J. (2014). Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium 
yoelii malaria challenge outcome. Journal of leukocyte biology 95, 369-382. 
References
 
135 
 
Llewellyn, D., Miura, K., Fay, M.P., Williams, A.R., Murungi, L.M., Shi, J., Hodgson, S.H., Douglas, A.D., Osier, F.H., Fairhurst, 
R.M., et al. (2015). Standardization of the antibody-dependent respiratory burst assay with human neutrophils and 
Plasmodium falciparum malaria. Scientific reports 5, 14081. 
Lundquist, R., Nielsen, L.K., Jafarshad, A., Soesoe, D., Christensen, L.H., Druilhe, P., and Dziegiel, M.H. (2006). Human 
recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood 
leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infection and immunity 74, 3222-
3231. 
Luty, A.J., Lell, B., Schmidt-Ott, R., Lehman, L.G., Luckner, D., Greve, B., Matousek, P., Herbich, K., Schmid, D., Migot-Nabias, 
F., et al. (1999). Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in 
young African children. The Journal of infectious diseases 179, 980-988. 
Lyke, K.E., Burges, R.B., Cissoko, Y., Sangare, L., Kone, A., Dao, M., Diarra, I., Fernandez-Vina, M.A., Plowe, C.V., Doumbo, 
O.K., and Sztein, M.B. (2005). HLA-A2 supertype-restricted cell-mediated immunity by peripheral blood mononuclear cells 
derived from Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. Infection 
and immunity 73, 5799-5808. 
Lyke, K.E., Ishizuka, A.S., Berry, A.A., Chakravarty, S., DeZure, A., Enama, M.E., James, E.R., Billingsley, P.F., Gunasekera, A., 
Manoj, A., et al. (2017). Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against 
heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of 
America 114, 2711-2716. 
Mac-Daniel, L., Buckwalter, M.R., Berthet, M., Virk, Y., Yui, K., Albert, M.L., Gueirard, P., and Menard, R. (2014). Local 
immune response to injection of Plasmodium sporozoites into the skin. Journal of immunology 193, 1246-1257. 
Mahdi Abdel Hamid, M., Remarque, E.J., van Duivenvoorde, L.M., van der Werff, N., Walraven, V., Faber, B.W., Kocken, 
C.H., and Thomas, A.W. (2011). Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine 
HT protects against blood-stage challenge in rhesus macaques. PloS one 6, e20547. 
Malkin, E., Long, C.A., Stowers, A.W., Zou, L., Singh, S., MacDonald, N.J., Narum, D.L., Miles, A.P., Orcutt, A.C., Muratova, O., 
et al. (2007). Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. 
PLoS clinical trials 2, e12. 
Malkin, E.M., Diemert, D.J., McArthur, J.H., Perreault, J.R., Miles, A.P., Giersing, B.K., Mullen, G.E., Orcutt, A., Muratova, O., 
Awkal, M., et al. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium 
falciparum malaria. Infection and immunity 73, 3677-3685. 
Marsh, K., and Kinyanjui, S. (2006). Immune effector mechanisms in malaria. Parasite immunology 28, 51-60. 
Matuschewski, K. (2017). Vaccines against malaria-still a long way to go. The FEBS journal. 
McCallum, F.J., Persson, K.E., Mugyenyi, C.K., Fowkes, F.J., Simpson, J.A., Richards, J.S., Williams, T.N., Marsh, K., and 
Beeson, J.G. (2008). Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PloS one 3, 
e3571. 
McCarthy, J.S., Marjason, J., Elliott, S., Fahey, P., Bang, G., Malkin, E., Tierney, E., Aked-Hurditch, H., Adda, C., Cross, N., et 
al. (2011). A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with 
Montanide(R) ISA 720. PloS one 6, e24413. 
Mellouk, S., Maheshwari, R.K., Rhodes-Feuillette, A., Beaudoin, R.L., Berbiguier, N., Matile, H., Miltgen, F., Landau, I., Pied, 
S., and Chigot, J.P. (1987). Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum 
in human hepatocyte cultures. Journal of immunology (Baltimore, Md. : 1950) 139, 4192-4195. 
Ménard, R. (2005). Medicine: knockout malaria vaccine? Nature 433, 113-114. 
Mensah, V.A., Gueye, A., Ndiaye, M., Edwards, N.J., Wright, D., Anagnostou, N.A., Syll, M., Ndaw, A., Abiola, A., Bliss, C., et 
al. (2016). Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP 
against Plasmodium falciparum Infection in Adults in Senegal. PloS one 11, e0167951. 
Michalakis, Y., and Renaud, F. (2009). Malaria: Evolution in vector control. Nature 462, 298-300. 
Miller, L.H., Roberts, T., Shahabuddin, M., and McCutchan, T.F. (1993). Analysis of sequence diversity in the Plasmodium 
falciparum merozoite surface protein-1 (MSP-1). Molecular and biochemical parasitology 59, 1-14. 
Mitchell, M.A., Huang, M.M., Chien, P., Indik, Z.K., Pan, X.Q., and Schreiber, A.D. (1994). Substitutions and deletions in the 
cytoplasmic domain of the phagocytic receptor Fc gamma RIIA: effect on receptor tyrosine phosphorylation and 
phagocytosis. Blood 84, 1753-1759. 
Moormann, A.M., Sumba, P.O., Chelimo, K., Fang, H., Tisch, D.J., Dent, A.E., John, C.C., Long, C.A., Vulule, J., and Kazura, J.W. 
(2013). Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from 
infection with blood-stage parasites. The Journal of infectious diseases 208, 149-158. 
References
 
136 
 
Moorthy, V.S., Newman, R.D., and Okwo-Bele, J.M. (2013). Malaria vaccine technology roadmap. Lancet 382, 1700-1701. 
Mordmuller, B., Supan, C., Sim, K.L., Gomez-Perez, G.P., Ospina Salazar, C.L., Held, J., Bolte, S., Esen, M., Tschan, S., Joanny, 
F., et al. (2015). Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a 
dose-finding trial in two centres. Malaria journal 14, 117. 
Mordmuller, B., Surat, G., Lagler, H., Chakravarty, S., Ishizuka, A.S., Lalremruata, A., Gmeiner, M., Campo, J.J., Esen, M., 
Ruben, A.J., et al. (2017). Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445-
449. 
Morgan, W.D., Birdsall, B., Frenkiel, T.A., Gradwell, M.G., Burghaus, P.A., Syed, S.E., Uthaipibull, C., Holder, A.A., and 
Feeney, J. (1999). Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. 
Journal of molecular biology 289, 113-122. 
Mueller, A.-K., Camargo, N., Kaiser, K., Andorfer, C., Frevert, U., Matuschewski, K., and Kappe, S.H.I. (2005a). Plasmodium 
liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proceedings of the National 
Academy of Sciences of the United States of America 102, 3022-3027. 
Mueller, A.K., Deckert, M., Heiss, K., Goetz, K., Matuschewski, K., and Schluter, D. (2007). Genetically attenuated 
Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. The American journal of 
pathology 171, 107-115. 
Mueller, A.K., Labaied, M., Kappe, S.H., and Matuschewski, K. (2005b). Genetically modified Plasmodium parasites as a 
protective experimental malaria vaccine. Nature 433, 164-167. 
Mullen, G.E., Ellis, R.D., Miura, K., Malkin, E., Nolan, C., Hay, M., Fay, M.P., Saul, A., Zhu, D., Rausch, K., et al. (2008). Phase 1 
trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PloS one 3, 
e2940. 
Müller, H.M., Früh, K., Brunn, A., Esposito, F., Lombardi, S., Crisanti, A., and Bujard, H. (1989). Development of the human 
immune response against the major surface protein (gp190) of Plasmodium falciparum. Infection and immunity 57, 3765-
3769. 
Muller, H.M., Fruh, K., Doumbo, O., Lyon, J.A., and Bujard, H. (1991). The human antibody response against the major 
merozoite surface antigen of P. falciparum is mainly directed against non-conserved sequences. Behring Inst Mitt, 157-160. 
Murphy, K.M. (2014). Janeway`s Immunobiology, 8th edition edn. 
Murungi, L.M., Kamuyu, G., Lowe, B., Bejon, P., Theisen, M., Kinyanjui, S.M., Marsh, K., and Osier, F.H. (2013). A threshold 
concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine 31, 3936-
3942. 
Murungi, L.M., Sonden, K., Llewellyn, D., Rono, J., Guleid, F., Williams, A.R., Ogada, E., Thairu, A., Farnert, A., Marsh, K., et 
al. (2016). Targets and Mechanisms Associated with Protection from Severe Plasmodium falciparum Malaria in Kenyan 
Children. Infection and immunity 84, 950-963. 
Murungi, L.M., Sonden, K., Odera, D., Oduor, L.B., Guleid, F., Nkumama, I.N., Otiende, M., Kangoye, D.T., Fegan, G., Farnert, 
A., et al. (2017). Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life. International 
journal for parasitology 47, 153-162. 
Nganou-Makamdop, K., van Gemert, G.J., Arens, T., Hermsen, C.C., and Sauerwein, R.W. (2012). Long term protection after 
immunization with P. berghei sporozoites correlates with sustained IFNgamma responses of hepatic CD8+ memory T cells. 
PloS one 7, e36508. 
Nussenzweig, R.S., Vanderberg, J., Most, H., and Orton, C. (1967). Protective immunity produced by the injection of x-
irradiated sporozoites of plasmodium berghei. Nature 216, 160-162. 
O'Donnell, R.A., Koning-Ward, T.F., Burt, R.A., Bockarie, M., Reeder, J.C., Cowman, A.F., and Crabb, B.S. (2001). Antibodies 
against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals 
immune to malaria. The Journal of experimental medicine 193, 1403-1412. 
O'Donnell, R.A., Saul, A., Cowman, A.F., and Crabb, B.S. (2000). Functional conservation of the malaria vaccine antigen MSP-
119across distantly related Plasmodium species. Nature medicine 6, 91-95. 
Oeuvray, C., Bouharoun-Tayoun, H., Gras-Masse, H., Bottius, E., Kaidoh, T., Aikawa, M., Filgueira, M.C., Tartar, A., and 
Druilhe, P. (1994). Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum 
killing by cooperation with blood monocytes. Blood 84, 1594-1602. 
Ogutu, B.R., Apollo, O.J., McKinney, D., Okoth, W., Siangla, J., Dubovsky, F., Tucker, K., Waitumbi, J.N., Diggs, C., Wittes, J., et 
al. (2009). Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to 
young children in Western Kenya. PloS one 4, e4708. 
References
 
137 
 
Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Leach, A., Lievens, M., Kaslow, D.C., Njuguna, P., Marsh, K., and Bejon, P. 
(2016). Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. The New England journal of 
medicine 374, 2519-2529. 
Omi, K., Ohashi, J., Patarapotikul, J., Hananantachai, H., Naka, I., Looareesuwan, S., and Tokunaga, K. (2002). Fcgamma 
receptor IIA and IIIB polymorphisms are associated with susceptibility to cerebral malaria. Parasitology international 51, 
361-366. 
Osier, F.H., Fegan, G., Polley, S.D., Murungi, L., Verra, F., Tetteh, K.K., Lowe, B., Mwangi, T., Bull, P.C., Thomas, A.W., et al. 
(2008). Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are 
associated with protection from clinical malaria. Infection and immunity 76, 2240-2248. 
Osier, F.H., Feng, G., Boyle, M.J., Langer, C., Zhou, J., Richards, J.S., McCallum, F.J., Reiling, L., Jaworowski, A., Anders, R.F., et 
al. (2014a). Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of 
protection against malaria. BMC medicine 12, 108. 
Osier, F.H., Mackinnon, M.J., Crosnier, C., Fegan, G., Kamuyu, G., Wanaguru, M., Ogada, E., McDade, B., Rayner, J.C., Wright, 
G.J., and Marsh, K. (2014b). New antigens for a multicomponent blood-stage malaria vaccine. Science translational 
medicine 6, 247ra102. 
Ouattara, A., Mu, J., Takala-Harrison, S., Saye, R., Sagara, I., Dicko, A., Niangaly, A., Duan, J., Ellis, R.D., Miller, L.H., et al. 
(2010). Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malaria journal 9, 175. 
Ouma, C., Davenport, G.C., Garcia, S., Kempaiah, P., Chaudhary, A., Were, T., Anyona, S.B., Raballah, E., Konah, S.N., Hittner, 
J.B., et al. (2012). Functional haplotypes of Fc gamma (Fcgamma) receptor (FcgammaRIIA and FcgammaRIIIB) predict risk to 
repeated episodes of severe malarial anemia and mortality in Kenyan children. Hum Genet 131, 289-299. 
Pachebat, J.A., Kadekoppala, M., Grainger, M., Dluzewski, A.R., Gunaratne, R.S., Scott-Finnigan, T.J., Ogun, S.A., Ling, I.T., 
Bannister, L.H., Taylor, H.M., et al. (2007). Extensive proteolytic processing of the malaria parasite merozoite surface 
protein 7 during biosynthesis and parasite release from erythrocytes. Molecular and biochemical parasitology 151, 59-69. 
Palacpac, N.M., Ntege, E., Yeka, A., Balikagala, B., Suzuki, N., Shirai, H., Yagi, M., Ito, K., Fukushima, W., Hirota, Y., et al. 
(2013). Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. 
PloS one 8, e64073. 
Pan, W., Ravot, E., Tolle, R., Frank, R., Mosbach, R., Türbachova, I., and Bujard, H. (1999). Vaccine candidate MSP-1 from 
Plasmodium falciparum: a redesigned 4917 bp polynucleotide enables synthesis and isolation of full-length protein from 
Escherichia coli and mammalian cells. Nucleic acids research 27, 1094-1103. 
Pantaleo, A., Giribaldi, G., Mannu, F., Arese, P., and Turrini, F. (2008). Naturally occurring anti-band 3 antibodies and red 
blood cell removal under physiological and pathological conditions. Autoimmunity reviews 7, 457-462. 
Perkins, M.E., and Rocco, L.J. (1988). Sialic acid-dependent binding of Plasmodium falciparum merozoite surface antigen, 
Pf200, to human erythrocytes. Journal of immunology (Baltimore, Md. : 1950) 141, 3190-3196. 
Perlmann, P., and Troye-Blomberg, M. (2000). Malaria blood-stage infection and its control by the immune system. Folia 
Biol (Praha) 46, 210-218. 
Perraut, R., Joos, C., Sokhna, C., Polson, H.E., Trape, J.F., Tall, A., Marrama, L., Mercereau-Puijalon, O., Richard, V., and 
Longacre, S. (2014). Association of Antibody Responses to the Conserved Plasmodium falciparum Merozoite Surface Protein 
5 with Protection against Clinical Malaria. PloS one 9, e101737. 
Perrin, L.H., Merkli, B., Loche, M., Chizzolini, C., Smart, J., and Richle, R. (1984). Antimalarial immunity in Saimiri monkeys. 
Immunization with surface components of asexual blood stages. The Journal of experimental medicine 160, 441-451. 
Plebanski, M., Aidoo, M., Whittle, H.C., and Hill, A.V. (1997). Precursor frequency analysis of cytotoxic T lymphocytes to pre-
erythrocytic antigens of Plasmodium falciparum in West Africa. Journal of immunology (Baltimore, Md. : 1950) 158, 2849-
2855. 
Pratt-Riccio, L.R., Bianco, C., Totino, P.R.R., Perce-Da-Silva, D.S., Silva, L.A., Riccio, E.K.P., Ennes-Vidal, V., Neves-Ferreira, 
A.G.C., Perales, J., Da Rocha, S.L.G., et al. (2011). Antibodies against the Plasmodium falciparum glutamate-rich protein from 
naturally exposed individuals living in a Brazilian malaria-endemic area can inhibit in vitro parasite growth. Memorias do 
Instituto Oswaldo Cruz 106 Suppl 1, 34-43. 
Putrianti, E.D., Silvie, O., Kordes, M., Borrmann, S., and Matuschewski, K. (2009). Vaccine-like immunity against malaria by 
repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. The Journal of infectious diseases 199, 899-
903. 
Quakyi, I.A., Currier, J., Fell, A., Taylor, D.W., Roberts, T., Houghten, R.A., England, R.D., Berzofsky, J.A., Miller, L.H., and 
Good, M.F. (1994). Analysis of human T cell clones specific for conserved peptide sequences within malaria proteins. 
Paucity of clones responsive to intact parasites. Journal of immunology 153, 2082-2092. 
References
 
138 
 
Quintana Mdel, P., Angeletti, D., Moll, K., Chen, Q., and Wahlgren, M. (2016). Phagocytosis-inducing antibodies to 
Plasmodium falciparum upon immunization with a recombinant PfEMP1 NTS-DBL1alpha domain. Malaria journal 15, 416. 
Radtke, A.J., Kastenmuller, W., Espinosa, D.A., Gerner, M.Y., Tse, S.W., Sinnis, P., Germain, R.N., Zavala, F.P., and Cockburn, 
I.A. (2015). Lymph-node resident CD8alpha+ dendritic cells capture antigens from migratory malaria sporozoites and induce 
CD8+ T cell responses. PLoS pathogens 11, e1004637. 
Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., and Stevanović, S. (1999). SYFPEITHI: database for MHC 
ligands and peptide motifs. Immunogenetics 50, 213-219. 
Reiling, L., Richards, J.S., Fowkes, F.J., Barry, A.E., Triglia, T., Chokejindachai, W., Michon, P., Tavul, L., Siba, P.M., Cowman, 
A.F., et al. (2010). Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against 
Plasmodium falciparum malaria. J Immunol 185, 6157-6167. 
Richards, J.S., Arumugam, T.U., Reiling, L., Healer, J., Hodder, A.N., Fowkes, F.J., Cross, N., Langer, C., Takeo, S., Uboldi, A.D., 
et al. (2013). Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium 
falciparum malaria for vaccine and biomarker development. Journal of immunology 191, 795-809. 
Richards, J.S., Stanisic, D.I., Fowkes, F.J., Tavul, L., Dabod, E., Thompson, J.K., Kumar, S., Chitnis, C.E., Narum, D.L., Michon, 
P., et al. (2010). Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium 
falciparum and protection from malaria and high-density parasitemia. Clinical infectious diseases : an official publication of 
the Infectious Diseases Society of America 51, e50-60. 
Richie, T.L., and Saul, A. (2002). Progress and challenges for malaria vaccines. Nature 415, 694-701. 
Riley, E.M., Allen, S.J., Wheeler, J.G., Blackman, M.J., Bennett, S., Takacs, B., Schonfeld, H.J., Holder, A.A., and Greenwood, 
B.M. (1992a). Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) 
of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite immunology 14, 321-337. 
Riley, E.M., Allen, S.J., Wheeler, J.G., Blackman, M.J., Bennett, S., Takacs, B., Schönfeld, H.J., Holder, A.A., and Greenwood, 
B.M. (1992b). Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) 
of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite immunology 14, 321-337. 
Roestenberg, M., McCall, M., Hopman, J., Wiersma, J., Luty, A.J., van Gemert, G.J., van de Vegte-Bolmer, M., van Schaijk, B., 
Teelen, K., Arens, T., et al. (2009). Protection against a malaria challenge by sporozoite inoculation. The New England 
journal of medicine 361, 468-477. 
Roestenberg, M., Teirlinck, A.C., McCall, M.B., Teelen, K., Makamdop, K.N., Wiersma, J., Arens, T., Beckers, P., van Gemert, 
G., van de Vegte-Bolmer, M., et al. (2011). Long-term protection against malaria after experimental sporozoite inoculation: 
an open-label follow-up study. Lancet 377, 1770-1776. 
Rono, J., Osier, F.H., Olsson, D., Montgomery, S., Mhoja, L., Rooth, I., Marsh, K., and Farnert, A. (2013). Breadth of anti-
merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections 
and protection against clinical malaria. Clinical infectious diseases : an official publication of the Infectious Diseases Society 
of America 57, 1409-1416. 
Sack, B.K., Keitany, G.J., Vaughan, A.M., Miller, J.L., Wang, R., and Kappe, S.H. (2015). Mechanisms of stage-transcending 
protection following immunization of mice with late liver stage-arresting genetically attenuated malaria parasites. PLoS 
pathogens 11, e1004855. 
Sakamoto, H., Takeo, S., Maier, A.G., Sattabongkot, J., Cowman, A.F., and Tsuboi, T. (2012). Antibodies against a 
Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. Vaccine 30, 1972-1980. 
Salmon, D., Vilde, J.L., Andrieu, B., Simonovic, R., and Lebras, J. (1986). Role of immune serum and complement in 
stimulation of the metabolic burst of human neutrophils by Plasmodium falciparum. Infection and immunity 51, 801-806. 
Schats, R., Bijker, E.M., van Gemert, G.J., Graumans, W., van de Vegte-Bolmer, M., van Lieshout, L., Haks, M.C., Hermsen, 
C.C., Scholzen, A., Visser, L.G., and Sauerwein, R.W. (2015). Heterologous Protection against Malaria after Immunization 
with Plasmodium falciparum Sporozoites. PloS one 10, e0124243. 
Schmittel, A., Keilholz, U., Bauer, S., Kuhne, U., Stevanovic, S., Thiel, E., and Scheibenbogen, C. (2001). Application of the 
IFN-gamma ELISPOT assay to quantify T cell responses against proteins. Journal of immunological methods 247, 17-24. 
Schofield, L., Villaquiran, J., Ferreira, A., Schellekens, H., Nussenzweig, R., and Nussenzweig, V. (1987). Gamma interferon, 
CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330, 664-666. 
Seder, R.A., Chang, L.J., Enama, M.E., Zephir, K.L., Sarwar, U.N., Gordon, I.J., Holman, L.A., James, E.R., Billingsley, P.F., 
Gunasekera, A., et al. (2013). Protection against malaria by intravenous immunization with a nonreplicating sporozoite 
vaccine. Science 341, 1359-1365. 
 
References
 
139 
 
Sheehy, S.H., Duncan, C.J., Elias, S.C., Choudhary, P., Biswas, S., Halstead, F.D., Collins, K.A., Edwards, N.J., Douglas, A.D., 
Anagnostou, N.A., et al. (2012). ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: 
assessment of efficacy against mosquito bite challenge in humans. Molecular therapy : the journal of the American Society 
of Gene Therapy 20, 2355-2368. 
Shi, J., McIntosh, R.S., Adame-Gallegos, J., Dehal, P.K., van Egmond, M., van de Winkel, J., Draper, S.J., Forbes, E.K., Corran, 
P.H., Holder, A.A., et al. (2011). The generation and evaluation of recombinant human IgA specific for Plasmodium 
falciparum merozoite surface protein 1-19 (PfMSP1 19). BMC Biotechnol 11, 77. 
Shi, Y.P., Nahlen, B.L., Kariuki, S., Urdahl, K.B., McElroy, P.D., Roberts, J.M., and Lal, A.A. (2001). Fcgamma receptor IIa 
(CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. 
Asembo Bay Cohort Project. The Journal of infectious diseases 184, 107-111. 
Siddiqui, W.A., Tam, L.Q., Kramer, K.J., Hui, G.S., Case, S.E., Yamaga, K.M., Chang, S.P., Chan, E.B., and Kan, S.C. (1987). 
Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. 
Proceedings of the National Academy of Sciences of the United States of America 84, 3014-3018. 
Sim, B.K., Carter, J.M., Deal, C.D., Holland, C., Haynes, J.D., and Gross, M. (1994). Plasmodium falciparum: further 
characterization of a functionally active region of the merozoite invasion ligand EBA-175. Experimental parasitology 78, 
259-268. 
Singh, B., and Daneshvar, C. (2013). Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 26, 165-
184. 
Singh, S., Miura, K., Zhou, H., Muratova, O., Keegan, B., Miles, A., Martin, L.B., Saul, A.J., Miller, L.H., and Long, C.A. (2006). 
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai 
monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infection and immunity 
74, 4573-4580. 
Singh, S., Soe, S., Roussilhon, C., Corradin, G., and Druilhe, P. (2005). Plasmodium falciparum merozoite surface protein 6 
displays multiple targets for naturally occurring antibodies that mediate monocyte-dependent parasite killing. Infection and 
immunity 73, 1235-1238. 
Singh, S., Soe, S., Weisman, S., Barnwell, J.W., Perignon, J.L., and Druilhe, P. (2009). A conserved multi-gene family induces 
cross-reactive antibodies effective in defense against Plasmodium falciparum. PloS one 4, e5410. 
Sirima, S.B., Cousens, S., and Druilhe, P. (2011). Protection against malaria by MSP3 candidate vaccine. The New England 
journal of medicine 365, 1062-1064. 
Sirima, S.B., Mordmuller, B., Milligan, P., Ngoa, U.A., Kironde, F., Atuguba, F., Tiono, A.B., Issifou, S., Kaddumukasa, M., 
Bangre, O., et al. (2016). A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African 
children. Vaccine 34, 4536-4542. 
Snow, R.W., Omumbo, J.A., Lowe, B., Molyneux, C.S., Obiero, J.O., Palmer, A., Weber, M.W., Pinder, M., Nahlen, B., Obonyo, 
C., et al. (1997). Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in 
Africa. Lancet 349, 1650-1654. 
Stafford, W.H., Günder, B., Harris, A., Heidrich, H.G., Holder, A.A., and Blackman, M.J. (1996). A 22 kDa protein associated 
with the Plasmodium falciparum merozoite surface protein-1 complex. Molecular and biochemical parasitology 80, 159-
169. 
Stanisic, D.I., Richards, J.S., McCallum, F.J., Michon, P., King, C.L., Schoepflin, S., Gilson, P.R., Murphy, V.J., Anders, R.F., 
Mueller, I., and Beeson, J.G. (2009). Immunoglobulin G subclass-specific responses against Plasmodium falciparum 
merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infection and 
immunity 77, 1165-1174. 
Szarfman, A., Walliker, D., McBride, J.S., Lyon, J.A., Quakyi, I.A., and Carter, R. (1988). Allelic forms of gp195, a major blood-
stage antigen of Plasmodium falciparum, are expressed in liver stages. The Journal of experimental medicine 167, 231-236. 
Tanabe, K., Mackay, M., Goman, M., and Scaife, J.G. (1987). Allelic dimorphism in a surface antigen gene of the malaria 
parasite Plasmodium falciparum. Journal of molecular biology 195, 273-287. 
Tarun, A.S., Dumpit, R.F., Camargo, N., Labaied, M., Liu, P., Takagi, A., Wang, R., and Kappe, S.H. (2007). Protracted sterile 
protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of 
significant liver-stage persistence and is mediated by CD8+ T cells. The Journal of infectious diseases 196, 608-616. 
Teirlinck, A.C., McCall, M.B., Roestenberg, M., Scholzen, A., Woestenenk, R., de Mast, Q., van der Ven, A.J., Hermsen, C.C., 
Luty, A.J., and Sauerwein, R.W. (2011). Longevity and composition of cellular immune responses following experimental 
Plasmodium falciparum malaria infection in humans. PLoS pathogens 7, e1002389. 
Teneza-Mora, N., Lumsden, J., and Villasante, E. (2015). A malaria vaccine for travelers and military personnel: 
Requirements and top candidates. Vaccine 33, 7551-7558. 
References
 
140 
 
Teo, A., Feng, G., Brown, G.V., Beeson, J.G., and Rogerson, S.J. (2016). Functional Antibodies and Protection against Blood-
stage Malaria. Trends in parasitology. 
Tetteh, K.K., Osier, F.H., Salanti, A., Kamuyu, G., Drought, L., Failly, M., Martin, C., Marsh, K., and Conway, D.J. (2013). 
Analysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted 
target of naturally acquired immunity. Infection and immunity 81, 3835-3842. 
Theisen, M., Soe, S., Jessing, S.G., Okkels, L.M., Danielsen, S., Oeuvray, C., Druilhe, P., and Jepsen, S. (2000). Identification of 
a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies 
mediating parasite killing. Vaccine 19, 204-212. 
Tian, J.H., Kumar, S., Kaslow, D.C., and Miller, L.H. (1997). Comparison of protection induced by immunization with 
recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infection and immunity 
65, 3032-3036. 
Tiendrebeogo, R.W., Adu, B., Singh, S.K., Dziegiel, M.H., Nebie, I., Sirima, S.B., Christiansen, M., Dodoo, D., and Theisen, M. 
(2015). Antibody-Dependent Cellular Inhibition Is Associated With Reduced Risk Against Febrile Malaria in a Longitudinal 
Cohort Study Involving Ghanaian Children. Open forum infectious diseases 2, ofv044. 
Tolle, R., Früh, K., Doumbo, O., Koita, O., N'Diaye, M., Fischer, A., Dietz, K., and Bujard, H. (1993). A prospective study of the 
association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and 
control of malarial infections. Infection and immunity 61, 40-47. 
Tongren, J.E., Drakeley, C.J., McDonald, S.L., Reyburn, H.G., Manjurano, A., Nkya, W.M., Lemnge, M.M., Gowda, C.D., Todd, 
J.E., Corran, P.H., and Riley, E.M. (2006). Target antigen, age, and duration of antigen exposure independently regulate 
immunoglobulin G subclass switching in malaria. Infection and immunity 74, 257-264. 
Troye-Blomberg, M., Berzins, K., and Perlmann, P. (1994). T-cell control of immunity to the asexual blood stages of the 
malaria parasite. Critical reviews in immunology 14, 131-155. 
Trucco, C., Fernandez-Reyes, D., Howell, S., Stafford, W.H., Scott-Finnigan, T.J., Grainger, M., Ogun, S.A., Taylor, W.R., and 
Holder, A.A. (2001). The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium 
falciparum merozoite surface protein-1 complex. Molecular and biochemical parasitology 112, 91-101. 
Tuteja, R. (2007). Malaria - an overview. The FEBS journal 274, 4670-4679. 
Weatherall, D. (2006). The use of non-human primates in research.  (London: Academy of Medical Sciences). 
Weiss, W.R., and Jiang, C.G. (2012). Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PloS 
one 7, e31247. 
Weiss, W.R., Sedegah, M., Beaudoin, R.L., Miller, L.H., and Good, M.F. (1988). CD8+ T cells (cytotoxic/suppressors) are 
required for protection in mice immunized with malaria sporozoites. Proceedings of the National Academy of Sciences of 
the United States of America 85, 573-576. 
White, K.L., Snyder, H.L., and Krzych, U. (1996). MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T 
lymphocytes is required for protective immunity against Plasmodium berghei. Journal of immunology 156, 3374-3381. 
WHO, W.H.O. (2016). World malaria report 2016.  (Geneva). 
Wilson, D.W., Fowkes, F.J., Gilson, P.R., Elliott, S.R., Tavul, L., Michon, P., Dabod, E., Siba, P.M., Mueller, I., Crabb, B.S., and 
Beeson, J.G. (2011). Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies 
against Plasmodium falciparum in humans. PloS one 6, e27705. 
Woehlbier, U., Epp, C., Hackett, F., Blackman, M.J., and Bujard, H. (2010). Antibodies against multiple merozoite surface 
antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion. 
Malaria journal 9, 77. 
Woehlbier, U., Epp, C., Kauth, C.W., Lutz, R., Long, C.A., Coulibaly, B., Kouyaté, B., Arevalo-Herrera, M., Herrera, S., and 
Bujard, H. (2006). Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite 
Plasmodium falciparum. Infection and immunity 74, 1313-1322. 
Wu, Y., Sinden, R.E., Churcher, T.S., Tsuboi, T., and Yusibov, V. (2015). Development of malaria transmission-blocking 
vaccines: from concept to product. Advances in parasitology 89, 109-152. 
Yap, A., Azevedo, M.F., Gilson, P.R., Weiss, G.E., O'Neill, M.T., Wilson, D.W., Crabb, B.S., and Cowman, A.F. (2014). 
Conditional expression of apical membrane antigen 1 in Plasmodium falciparum shows it is required for erythrocyte 
invasion by merozoites. Cellular microbiology 16, 642-656. 
Yeoh, S., O'Donnell, R.A., Koussis, K., Dluzewski, A.R., Ansell, K.H., Osborne, S.A., Hackett, F., Withers-Martinez, C., Mitchell, 
G.H., Bannister, L.H., et al. (2007). Subcellular discharge of a serine protease mediates release of invasive malaria parasites 
from host erythrocytes. Cell 131, 1072-1083. 
References
 
141 
 
Zong, S., Kron, M.W., Epp, C., Engler, T., Bujard, H., Kochanek, S., and Kreppel, F. (2011). ΔE1 and high-capacity adenoviral 
vectors expressing full-length codon-optimized merozoite surface protein 1 for vaccination against Plasmodium falciparum. 
The journal of gene medicine. 
 
